

EASL Clinical Practice Guidelines: Management of chronic hepatitis C

Journal of Hepatology

50, 227-242

DOI: [10.1016/j.jhep.2008.10.001](https://doi.org/10.1016/j.jhep.2008.10.001)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The effect of oral contraceptives on vitamin B12 metabolism. American Journal of Obstetrics and Gynecology, 1979, 135, 129-134.	0.7	27
2	Surgical and medical experience with 734 premature infants with patent ductus arteriosus. Journal of Thoracic and Cardiovascular Surgery, 1982, 83, 349-357.	0.4	56
4	Flares on and off therapy during chronic HBV infection: Pathogenesis, significance and management. Hepatitis B Annual, 2008, 5, 12.	0.0	3
5	Pretreatment with Pegylated Interferon Prevents Emergence of Lamivudine Mutants in Lamivudine-Naive Patients: A Pilot Study. Antiviral Therapy, 2009, 14, 1081-1087.	0.6	8
6	A randomized controlled trial of pegylated interferon- α 2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antiviral Therapy, 2009, 14, 1165-1174.	0.6	83
7	A review of the use of telbivudine in the treatment of chronic hepatitis B. Clinical Medicine Therapeutics, 2009, 1, CMT.S2321.	0.1	2
8	Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Therapeutics and Clinical Risk Management, 2009, 5, 789.	0.9	12
9	Patterns of viral load in chronic hepatitis B patients in Brazil and their association with ALT levels and HBeAg status. Annals of Hepatology, 2009, 8, 339-345.	0.6	4
10	Treatment of HBV-related cirrhosis. Expert Review of Anti-Infective Therapy, 2009, 7, 527-535.	2.0	10
11	Hepatitis B therapies and antiviral resistance detection and management. Expert Review of Gastroenterology and Hepatology, 2009, 3, 693-699.	1.4	2
12	Reactivation of Hepatitis B Viral Infection in Inactive HBsAg Carriers Following Anti-Tumor Necrosis Factor- α Therapy. Journal of Rheumatology, 2009, 36, 2416-2420.	1.0	109
13	Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis. Journal of Antimicrobial Chemotherapy, 2009, 64, 877-878.	1.3	21
14	Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries. Expert Opinion on Pharmacotherapy, 2009, 10, 1605-1614.	0.9	11
15	Treatment of chronic hepatitis B: focus on telbivudine. Expert Review of Anti-Infective Therapy, 2009, 7, 259-268.	2.0	13
16	Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy, 2009, 1, 1053-1061.	1.0	14
19	Chronic hepatitis B and C: update on therapy. Future Virology, 2009, 4, 437-452.	0.9	3
20	Comparison of different Hepatitis B guidelines. Hepatitis B Annual, 2009, 6, 55.	0.0	3
21	HBV and HCV Therapy. Viruses, 2009, 1, 484-509.	1.5	7

#	ARTICLE	IF	CITATIONS
22	Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 875-877.	1.3	3
23	Biologic Agents in the Treatment of Rheumatic Diseases with Chronic Viral Infection. <i>Where Are We?</i> . <i>Journal of Rheumatology</i> , 2009, 36, 1107-1108.	1.0	6
24	Antiviral therapy for chronic hepatitis B: are we doing any good to patients?. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 223-226.	1.3	2
25	Liver and inflammatory bowel disease. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, 370-381.	0.9	17
26	Inflammatory bowel disease and hepatitis B and C. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, 1082-1093.	0.9	20
30	Maladies inflammatoires chroniques intestinales et hépatites B et C. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, e1-e14.	0.9	1
31	Anaes practice guidelines for vaccination against hepatitis B virus: Impact on general practitioners. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, 1166-1170.	0.9	4
32	Antiviral resistance and hepatitis B therapy. <i>Hepatology</i> , 2009, 49, S174-S184.	3.6	189
33	Benefits and risks of combination therapy for hepatitis B. <i>Hepatology</i> , 2009, 49, S122-S128.	3.6	47
34	Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. <i>Hepatology</i> , 2009, 50, 1064-1071.	3.6	59
35	Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. <i>Hepatology</i> , 2009, 50, 2001-2006.	3.6	228
36	Response to antiviral treatment in patients infected with hepatitis B virus genotypes E and H. <i>Journal of Medical Virology</i> , 2009, 81, 1716-1720.	2.5	33
38	The saga of entecavir. <i>Hepatology International</i> , 2009, 3, 421-424.	1.9	2
39	Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand. <i>Hepatology International</i> , 2009, 3, 453-460.	1.9	9
40	HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. <i>Hepatology International</i> , 2009, 3, 425-433.	1.9	128
41	On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. <i>Hepatology International</i> , 2009, 3, 16-23.	1.9	7
42	The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. <i>Hepatology International</i> , 2009, 3, 5-15.	1.9	47
43	Current treatment of chronic HBV infection: A European perspective. <i>Current Hepatitis Reports</i> , 2009, 8, 141-147.	0.3	1

#	ARTICLE	IF	CITATIONS
44	Current treatment of chronic HBV infection: An Asian-Pacific perspective. <i>Current Hepatitis Reports</i> , 2009, 8, 154-160.	0.3	2
45	Society guidelines, US treatment algorithm, and NIH consensus: Similarities and differences in management of hepatitis B. <i>Current Hepatitis Reports</i> , 2009, 8, 161-168.	0.3	0
46	Quantitative HBsAg titer as predictor of response to therapy. <i>Current Hepatitis Reports</i> , 2009, 8, 169-172.	0.3	2
47	Hepatitis B: Management of suboptimal response to oral antiviral therapy. <i>Current Hepatitis Reports</i> , 2009, 8, 173-180.	0.3	0
51	How to compare antivirals in the treatment of chronic hepatitis B?. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2009, 8, 6.	1.7	2
52	Hepatitis B treatment in resource poor settings: time for action. <i>Tropical Medicine and International Health</i> , 2009, 15, 2-4.	1.0	15
53	Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 240-246.	1.9	50
54	Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. <i>Journal of Viral Hepatitis</i> , 2009, 17, 493-500.	1.0	30
55	HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. <i>Journal of Viral Hepatitis</i> , 2009, 17, 631-9.	1.0	9
56	The role of entecavir in preventing hepatitis B recurrence after liver transplantation. <i>Journal of Digestive Diseases</i> , 2009, 10, 321-327.	0.7	57
57	Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. <i>Liver International</i> , 2009, 29, 789-796.	1.9	125
58	Current management of hepatitis B virus infection before and after liver transplantation. <i>Liver International</i> , 2009, 29, 1294-1305.	1.9	65
59	Analogs and fibrosis regression in hepatitis B. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, 923-929.	0.9	6
60	Interacting with HBsAg compromises resistance of jumping translocation breakpoint protein to ultraviolet radiation-induced apoptosis in 293FT cells. <i>Cancer Letters</i> , 2009, 285, 151-156.	3.2	11
62	Partial virological response to nucleos(t)ide analogues in na ^À -ve patients with chronic hepatitis B: From guidelines to field practice. <i>Journal of Hepatology</i> , 2009, 50, 644-647.	1.8	22
63	Prevention of hepatocellular carcinoma: The holy grail of hepatitis B treatment. <i>Journal of Hepatology</i> , 2009, 50, 854-856.	1.8	1
64	EASL clinical practice guidelines on the management of chronic hepatitis B: The need for liver biopsy. <i>Journal of Hepatology</i> , 2009, 51, 226-227.	1.8	25
65	Treatment with nucleos(t)ide analogues in chronic hepatitis B: Where does the road map lead us?. <i>Journal of Hepatology</i> , 2009, 51, 1-3.	1.8	9

#	ARTICLE	IF	CITATIONS
66	Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2009, 51, 640-646.	1.8	76
67	EASL clinical practice guidelines. <i>Journal of Hepatology</i> , 2009, 51, 821-822.	1.8	26
68	How reproducible are rat steatosis models using high-fat diets?. <i>Journal of Hepatology</i> , 2009, 51, 822-823.	1.8	6
69	Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. <i>Journal of Hepatology</i> , 2009, 51, 468-474.	1.8	91
70	Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. <i>Journal of Hepatology</i> , 2009, 51, 1091-1096.	1.8	34
71	Cost-effectiveness of oral treatments for chronic hepatitis B. <i>Journal of Hepatology</i> , 2009, 51, 623-625.	1.8	6
72	The controversial role of lamivudine prophylaxis in occult HBV carriers treated with chemo-immune therapy. <i>Digestive and Liver Disease</i> , 2009, 41, 839-840.	0.4	1
73	Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a. <i>Gastroenterology</i> , 2009, 136, 2169-2179.e4.	0.6	288
74	Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa. <i>Gastroenterology</i> , 2009, 137, 2002-2009.	0.6	349
75	Hepatitis B Virus Resistance to Nucleos(t)ide Analogues. <i>Gastroenterology</i> , 2009, 137, 1593-1608.e2.	0.6	614
76	Entecavir. <i>Drugs</i> , 2009, 69, 1003-1033.	4.9	38
77	Tenofovir Disoproxil Fumarate. <i>Drugs</i> , 2009, 69, 2245-2256.	4.9	25
78	Peginterferon-2a (40µg). <i>Drugs</i> , 2009, 69, 2633-2660.	4.9	17
79	Predictors of Treatment Response in Chronic Hepatitis B. <i>Drugs</i> , 2009, 69, 2167-2177.	4.9	40
80	Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. <i>Virology Journal</i> , 2009, 6, 163.	1.4	47
81	Chronic hepatitis B: who to treat and which choice of treatment?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 281-291.	2.0	9
82	Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 1487-1490.	0.6	55
83	Monitoring drug therapy for hepatitis B—a global challenge?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 565-567.	8.2	15

#	ARTICLE	IF	CITATIONS
84	Entecavir for the long-term treatment of chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 1053-1062.	2.0	10
85	Monotherapy versus combination therapy for the treatment of chronic hepatitis B. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1655-1666.	1.9	38
86	Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. <i>Haematologica</i> , 2009, 94, 998-1005.	1.7	71
87	Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2009, 49, 651-681.	2.9	392
88	Pathobiology of HBV mutants and clinical impact for treatment monitoring. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 309-320.	2.0	17
89	Chronic hepatitis B: back to the future with HBsAg. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 633-636.	2.0	18
91	Chronic hepatitis B: Do we know everything or is there still something to learn?. <i>Digestive and Liver Disease Supplements</i> , 2009, 3, 61-66.	0.2	1
92	New therapeutic approaches for long-term control of chronic hepatitis B. <i>Digestive and Liver Disease Supplements</i> , 2009, 3, 67-70.	0.2	0
93	Prevention of HBV recurrence after liver transplant: The role of combination therapy. <i>Digestive and Liver Disease Supplements</i> , 2009, 3, 98-103.	0.2	0
94	Chronic Hepatitis B: Pathophysiology, Diagnosis and Treatment Options. <i>Frontiers of Gastrointestinal Research</i> , 2009, , 32-41.	0.1	1
95	Hepatitis B and Liver Transplantation. <i>Current Drug Therapy</i> , 2009, 4, 194-201.	0.2	0
96	Implications of Hepatitis B Virus Genomic Variations on Treatment Outcomes. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2010, 8, 280-288.	0.2	4
98	High prevalence of HBV genotype D in Syria and the clinical characteristics of hepatitis B e antigen-negative chronic hepatitis B. <i>Epidemiology and Infection</i> , 2010, 138, 40-44.	1.0	16
99	Change in Serum Hepatitis B Surface Antigen Level and Its Clinical Significance in Treatment-naïve, Hepatitis B e Antigen-positive Patients Receiving Entecavir. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 653-657.	1.1	42
100	Rheumatic manifestations of hepatitis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 91-96.	2.0	18
102	Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 494-499.	0.8	36
103	Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 952-960.	0.8	13
104	The A, B, Cs of viral hepatitis in the biologic era. <i>Current Opinion in Rheumatology</i> , 2010, 22, 443-450.	2.0	33

#	ARTICLE	IF	CITATIONS
105	Management of Hepatitis B Virus Infection. <i>Gastroenterology Nursing</i> , 2010, 33, 120-126.	0.2	4
106	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , 2010, 15, 145-155.	0.6	38
107	Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. <i>Antiviral Therapy</i> , 2010, 15, 929-932.	0.6	17
108	Molecular genesis of drug-resistant and vaccine-escape HBV mutants. <i>Antiviral Therapy</i> , 2010, 15, 451-461.	0.6	91
109	New approaches to optimize treatment responses in chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 61-68.	0.6	7
110	Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 1185-1190.	0.6	33
111	Effect of newer oral antiviral agents on future therapy of chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 13-22.	0.6	7
112	Liver Transient Elastography (Fibroscan®): A Place in the Management Algorithms of Chronic Viral Hepatitis. <i>Antiviral Therapy</i> , 2010, 15, 1-11.	0.6	29
113	A personalized approach to optimize hepatitis B treatment in treatment-naive patients. <i>Antiviral Therapy</i> , 2010, 15, 53-59.	0.6	11
114	Antiviral therapy for hepatitis B in special populations. <i>Antiviral Therapy</i> , 2010, 15, 1067-1075.	0.6	1
115	Patient Management and Clinical Decision Making in HBV – Aims of Therapy and What we can Achieve. <i>Antiviral Therapy</i> , 2010, 15, 45-51.	0.6	5
116	Comparing Hepatic Resection and Transarterial Chemoembolization for Barcelona Clinic Liver Cancer (BCLC) Stage B Hepatocellular Carcinoma: Change for Treatment of Choice?. <i>World Journal of Surgery</i> , 2010, 34, 2155-2161.	0.8	86
118	Interferon and nucleoside analog combination therapy for hepatitis B. <i>Clinical Journal of Gastroenterology</i> , 2010, 3, 69-72.	0.4	0
119	Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. <i>Hepatology International</i> , 2010, 4, 386-395.	1.9	47
120	Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. <i>Hepatology International</i> , 2010, 4, 594-600.	1.9	12
121	Baseline and On-Treatment Predictors for Outcome of Chronic Hepatitis B Treatment. <i>Current Hepatitis Reports</i> , 2010, 9, 53-59.	0.3	1
122	A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2010, 9, 75-90.	0.3	29
123	Histologic Disease in Patients with Chronic Hepatitis B, High HBV DNA, and Normal Alanine Aminotransferase Levels. <i>Current Hepatitis Reports</i> , 2010, 9, 65-74.	0.3	3

#	ARTICLE	IF	CITATIONS
124	Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2010, 9, 91-98.	0.3	26
125	Chemoprevention of Patients with Hepatitis B Receiving Chemotherapy or Bone Marrow Transplant. <i>Current Hepatitis Reports</i> , 2010, 9, 178-186.	0.3	1
126	Hepatitis B Biomarkers: Clinical Significance of the Old and the New. <i>Current Hepatitis Reports</i> , 2010, 9, 187-196.	0.3	1
127	The Role of Interferon in Hepatitis B Therapy. <i>Current Hepatitis Reports</i> , 2010, 9, 231-238.	0.3	37
128	Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2727-2734.	1.1	83
129	Antiviral Therapy for Acute-on-Chronic Liver Failure in Chronic Hepatitis B: Is It Too Late?. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2126-2128.	1.1	8
131	Suivi virologique des h�patites B chroniques : les recommandations de lâ�EASL 2009. <i>Option/Bio</i> , 2010, 21, 18-19.	0.0	0
132	Efficacy compared between entecavir and adefovir dipivoxil on HBeAg-positive nucleos(t)ide-naive patients with chronic hepatitis B at week 12 and week 48. <i>Journal of Medical Colleges of PLA</i> , 2010, 25, 298-306.	0.1	0
133	Tocilizumab: Therapy and safety management. <i>Joint Bone Spine</i> , 2010, 77, S3-S100.	0.8	52
136	Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the Northern Netherlands between 2000 and 2006. <i>Clinical Therapeutics</i> , 2010, 32, 133-144.	1.1	3
137	Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. <i>Hepatology</i> , 2010, 51, 1185-1189.	3.6	45
138	Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase?. <i>Hepatology</i> , 2010, 51, 1107-1109.	3.6	2
139	Routine hepatitis B virus DNA testing in patients with human immunodeficiency virus. <i>Hepatology</i> , 2010, 52, 397-397.	3.6	0
140	Think twice if you consider entecavir treatment in cases with lamivudine refractoriness. <i>Hepatology</i> , 2010, 52, 397-398.	3.6	2
141	Hemochromatosis protein HFE C282Y conformational considerations. <i>Hepatology</i> , 2010, 52, 398-399.	3.6	1
142	Natural approach against lipotoxic traffic in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 399-399.	3.6	1
143	Genetic variations in heme oxygenase-1 and chronic hepatitis. <i>Hepatology</i> , 2010, 52, 400-401.	3.6	12
144	Quantification of genotype 4 serum samples: Impact of hepatitis C virus genetic variability. <i>Hepatology</i> , 2010, 52, 401-401.	3.6	12

#	ARTICLE	IF	CITATIONS
145	Transient elastography in the early prediction of progressive recurrent hepatitis C following liver transplantation. <i>Hepatology</i> , 2010, 52, 800-801.	3.6	11
146	Targeting heme oxygenase/adiponectin axis for chronic hepatitis C treatment. <i>Hepatology</i> , 2010, 52, 801-801.	3.6	3
147	Hepatitis B in refugees, guessing the prevalence. <i>Hepatology</i> , 2010, 52, 802-803.	3.6	1
148	Is cigarette smoking an independent risk factor or a cofactor for nonalcoholic fatty liver disease?. <i>Hepatology</i> , 2010, 52, 803-804.	3.6	6
149	Histological subclassification of cirrhosis. <i>Hepatology</i> , 2010, 52, 805-805.	3.6	12
150	Diagnostic utility of chromosome 17 and p16 abnormalities in fluorescence in situ hybridization tests in primary sclerosing cholangitis. <i>Hepatology</i> , 2010, 52, 393-394.	3.6	0
151	Cigarette smoking is not associated with specific histological features or severity of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 391-391.	3.6	14
152	Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. <i>Hepatology</i> , 2010, 52, 454-461.	3.6	215
153	Ferritin and liver allocation? Impact on mortality not only on the waiting list but also after orthotopic liver transplantation should be considered. <i>Hepatology</i> , 2010, 52, 392-393.	3.6	5
154	Reply: Cigarette Smoking Is Not Associated with Specific Histological Features or Severity of Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2010, 52, 391-392.	3.6	1
155	Reply: Ferritin and Liver Allocation? Impact on Mortality Not Only on the Waiting List But Also After Orthotopic Liver Transplantation Should Be Considered. <i>Hepatology</i> , 2010, 52, 393-393.	3.6	0
156	Reply: Diagnostic Utility of Chromosome 17 and p16 Abnormalities in Fluorescence In Situ Hybridization Tests in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2010, 52, 394-395.	3.6	0
157	Methodological issues in a meta-analysis. <i>Hepatology</i> , 2010, 52, 395-396.	3.6	4
158	Reply: Methodological issues in a meta-analysis. <i>Hepatology</i> , 2010, 52, 396-397.	3.6	0
159	Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. <i>Hepatology</i> , 2010, 52, 886-893.	3.6	840
160	Drug Therapy: Tenofovir. <i>Hepatology</i> , 2010, 52, 743-747.	3.6	18
161	“Nonalcoholic fatty liver disease” in a developing country: A different perspective. <i>Hepatology</i> , 2010, 52, 797-797.	3.6	2
162	Antituberculosis therapy drug-induced liver injury and acute liver failure. <i>Hepatology</i> , 2010, 52, 798-799.	3.6	25

#	ARTICLE	IF	CITATIONS
163	Reply:. Hepatology, 2010, 52, 797-798.	3.6	0
164	Reply:. Hepatology, 2010, 52, 799-800.	3.6	0
165	Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology, 2010, 52, 1251-1257.	3.6	259
166	Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology, 2010, 52, 1611-1620.	3.6	184
167	Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options. Hepatology, 2010, 52, 2192-2205.	3.6	129
168	Entecavir treatment for chronic hepatitis B infection in end-stage renal disease and kidney transplantation. Dialysis and Transplantation, 2010, 39, 397-400.	0.2	11
169	Prediction of the response to peginterferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. Journal of Medical Virology, 2010, 82, 1135-1142.	2.5	39
170	Clinical use of liver biopsy for the diagnosis and management of inactive and asymptomatic hepatitis B virus carriers in Bangladesh. Journal of Medical Virology, 2010, 82, 1350-1354.	2.5	19
171	Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. Journal of Medical Virology, 2010, 82, 1494-1500.	2.5	54
172	Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterology, 2010, 10, 100.	0.8	67
173	British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Medicine, 2010, 11, 1-30.	1.0	73
174	Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver International, 2010, 30, 512-520.	1.9	22
175	Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver International, 2010, 30, 657-668.	1.9	7
176	Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver International, 2010, 30, 1033-1042.	1.9	36
177	Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis. Value in Health, 2010, 13, 592-600.	0.1	54
178	Mixed Treatment Comparison Meta-Analysis Evaluating the Relative Efficacy of Nucleos(t)ides for Treatment of Nucleos(t)ide-Naïve Patients with Chronic Hepatitis B. Value in Health, 2010, 13, 934-945.	0.1	34
179	Cost-Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B. Value in Health, 2010, 13, 922-933.	0.1	35
180	Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2010, 31, 1095-1103.	1.9	110

#	ARTICLE	IF	CITATIONS
181	Main mutations in the hepatitis B virus basic core promoter (A1762T/G1764A) before HBeAg loss are markers that identify patients who will require long-term treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 97-104.	1.9	6
182	Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1323-1331.	1.9	98
183	Naturally occurring amino acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2010, 17, 23-27.	1.0	28
184	The prevalence and clinical correlates of elevated ALT levels in an urban Chinatown community. <i>Journal of Viral Hepatitis</i> , 2010, 17, 148-152.	1.0	12
185	Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. <i>Journal of Viral Hepatitis</i> , 2010, 17, 178-184.	1.0	14
186	Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. <i>Journal of Viral Hepatitis</i> , 2010, 17, 887-895.	1.0	82
187	Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2010, 17, 24-33.	1.0	16
188	Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naïve Chinese chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2010, 17, 51-58.	1.0	19
189	A survey of chronic hepatitis B patient management practices in the European Union. <i>Journal of Viral Hepatitis</i> , 2010, 17, no-no.	1.0	7
190	Do we need to determine viral genotype in treating chronic hepatitis B?. <i>Journal of Viral Hepatitis</i> , 2010, 17, no-no.	1.0	37
191	Endpoints of hepatitis B treatment. <i>Journal of Viral Hepatitis</i> , 2010, 17, 675-684.	1.0	17
192	Safety of antitumour necrosis factor- α therapy in psoriatic patients with hepatitis B virus infection. <i>British Journal of Dermatology</i> , 2010, 162, 1408-1410.	1.4	23
193	Thymalfasin in the treatment of hepatitis B and C. <i>Annals of the New York Academy of Sciences</i> , 2010, 1194, 141-146.	1.8	13
194	Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 892-898.	1.4	13
195	Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 657-663.	1.4	134
196	Transmission of antiviral drug resistant hepatitis B virus: Implications for public health and patient management. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 649-651.	1.4	11
197	Peginterferon for chronic hepatitis B: Predicting success with on-treatment benchmarks. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1474-1475.	1.4	7
198	New developments in antiviral therapy for chronic hepatitis B. <i>Vox Sanguinis</i> , 2010, 98, 481-494.	0.7	14

#	ARTICLE	IF	CITATIONS
199	Interferon gamma for chronic hepatitis B. The Cochrane Library, 0, , .	1.5	0
200	Telbivudine for chronic hepatitis B. The Cochrane Library, 0, , .	1.5	6
201	Genotype f prevails in Venezuelan urban patients with chronic hepatitis B. <i>Annals of Hepatology</i> , 2010, 9, 172-176.	0.6	5
202	Short and long term outcome of kidney transplanted patients with chronic viral hepatitis B and C. <i>Annals of Hepatology</i> , 2010, 9, 271-277.	0.6	18
204	Response predictors to treatment with pegylated interferon in chronic hepatitis B. <i>Brazilian Journal of Infectious Diseases</i> , 2010, 14, 519-525.	0.3	7
205	Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Na ⁺ ve Patients with HBeAg Positive Chronic Hepatitis B. <i>Journal of Korean Medical Science</i> , 2010, 25, 738.	1.1	6
206	Performance of Version 2.0 of the Cobas AmpliPrep/Cobas TaqMan Real-Time PCR Assay for Hepatitis B Virus DNA Quantification. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3641-3647.	1.8	58
207	Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. The Cochrane Library, 2010, , CD006005.	1.5	15
208	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. <i>Clinical Chemistry</i> , 2010, 56, e1-e48.	1.5	184
209	Differential Impact of Immune Escape Mutations G145R and P120T on the Replication of Lamivudine-Resistant Hepatitis B Virus e Antigen-Positive and -Negative Strains. <i>Journal of Virology</i> , 2010, 84, 1026-1033.	1.5	40
210	Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 548-555.	1.3	51
211	The role of anti-core antibody response in the detection of occult hepatitis B virus infection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 23-29.	1.4	49
212	Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 554-557.	0.6	2
213	Managing HBV in patients with impaired immunity. <i>Gut</i> , 2010, 59, 1430-1445.	6.1	63
214	Safety evaluation of telbivudine. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 821-829.	1.0	25
215	HEPATITIS B AND PREGNANCY, THE SCIENTIFIC BASIS FOR PERINATAL PREVENTION. <i>Fetal and Maternal Medicine Review</i> , 2010, 21, 89-113.	0.3	4
216	Tocilizumab for Rheumatoid Arthritis with Chronic Hepatitis B Virus Infection without Antiviral Therapy. <i>Journal of Rheumatology</i> , 2010, 37, 1066-1066.	1.0	4
217	How to Overcome Antiviral-Resistant Hepatitis B Virus?. <i>Intervirolgy</i> , 2010, 53, 29-38.	1.2	4

#	ARTICLE	IF	CITATIONS
218	Response to Adefovir Depends on Mutation Patterns in Precore Region, Basal Core Promoter and Reverse Transcriptase, and On-Treatment Responses in Lamivudine-Resistant Chronic Hepatitis B Patients. <i>Intervirology</i> , 2010, 53, 203-210.	1.2	6
219	European guideline for the management of hepatitis B and C virus infections, 2010. <i>International Journal of STD and AIDS</i> , 2010, 21, 669-678.	0.5	19
220	Hepatitis B Virus (HBV) Subgenotypes C2 and B2 Differ in Lamivudine- and Adefovir-Resistance-Associated Mutational Patterns in HBV-Infected Chinese Patients. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4363-4369.	1.8	36
221	Liver biopsy for histological assessment - the case against. <i>Saudi Journal of Gastroenterology</i> , 2010, 16, 124.	0.5	68
222	Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B. <i>North American Journal of Medical Sciences</i> , 2010, 2, 365-370.	1.7	2
223	Rituximab Administration and Reactivation of HBV. <i>Hepatitis Research and Treatment</i> , 2010, 2010, 1-8.	2.0	21
224	Treatment of viral hepatitis B in children. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 889-903.	0.9	9
225	A Randomized Trial of Peginterferon α -2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2010, 105, 1762-1769.	0.2	83
226	Viral load predicts HBV recurrence after liver transplant. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 657-658.	8.2	1
227	Peginterferon Therapy for HBeAg-Negative Chronic Hepatitis B: Less Than Meets the Eye. <i>American Journal of Gastroenterology</i> , 2010, 105, 1770-1772.	0.2	1
228	Relative Roles of HBsAg Seroclearance and Mortality in the Decline of HBsAg Prevalence With Increasing Age. <i>American Journal of Gastroenterology</i> , 2010, 105, 1102-1109.	0.2	41
229	Is HMGB1 a New Indirect Marker for Revealing Fibrosis in Chronic Hepatitis and a New Therapeutic Target in Treatment?. <i>Viral Immunology</i> , 2010, 23, 633-638.	0.6	67
230	Establishment of a Novel Quantitative Hepatitis D Virus (HDV) RNA Assay Using the Cobas TaqMan Platform To Study HDV RNA Kinetics. <i>Journal of Clinical Microbiology</i> , 2010, 48, 2022-2029.	1.8	84
231	Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Oncology</i> , 2010, 28, 2437-2444.	0.8	249
232	HBsAg Profiles in Patients Receiving Peginterferon Alfa α -2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. <i>Journal of Infectious Diseases</i> , 2010, 202, 86-92.	1.9	46
233	Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1352-1355.	0.5	133
234	Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. <i>Viruses</i> , 2010, 2, 1279-1305.	1.5	56
235	Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. <i>International Journal of STD and AIDS</i> , 2010, 21, 553-557.	0.5	21

#	ARTICLE	IF	CITATIONS
236	Liver dysfunction in patients with IBD under immunosuppressive treatment: do we need to fear?. Gut, 2010, 59, 1310-1311.	6.1	7
239	Management of Chronic Hepatitis B: Status and Challenges beyond Treatment Guidelines. Seminars in Liver Disease, 2010, 30, 361-377.	1.8	40
241	Microarray for Hepatitis B Virus Genotyping and Detection of 994 Mutations along the Genome. Journal of Clinical Microbiology, 2010, 48, 4207-4215.	1.8	20
242	End points of therapy in chronic hepatitis B. Expert Review of Gastroenterology and Hepatology, 2010, 4, 37-49.	1.4	3
243	Treatment of HBV/HCV coinfection. Expert Opinion on Pharmacotherapy, 2010, 11, 919-928.	0.9	38
244	Résultats des essais thérapeutiques dans l'hépatite chronique B. Antibiotiques, 2010, 12, 42-54.	0.1	0
246	Hepatitis B Virus Load in Serum Does Not Reflect Histologic Activity in Patients With Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology, 2010, 8, 60-65.	2.4	9
247	Chronic Hepatitis B: Past, Present, and Future. Clinics in Liver Disease, 2010, 14, 531-546.	1.0	27
248	Sexually Transmitted Infections in Men. Primary Care - Clinics in Office Practice, 2010, 37, 509-525.	0.7	3
249	Thrombocytopenia With Abnormal Liver Function Tests. Clinical Gastroenterology and Hepatology, 2010, 8, 920-923.	2.4	0
250	Management of Chronic Hepatitis B in Pregnancy. Clinics in Liver Disease, 2010, 14, 495-504.	1.0	43
251	Antiviral Therapy for Chronic Hepatitis B. Clinics in Liver Disease, 2010, 14, 425-438.	1.0	33
252	Drug Resistance in Antiviral Therapy. Clinics in Liver Disease, 2010, 14, 439-459.	1.0	27
253	Management of End-Stage Liver Disease in Chronic Hepatitis B. Clinics in Liver Disease, 2010, 14, 477-493.	1.0	3
254	Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. Expert Review of Anti-Infective Therapy, 2010, 8, 717-726.	2.0	19
255	Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 31-40.	8.2	342
256	Interferon beta for chronic hepatitis B. The Cochrane Library, 2010, , .	1.5	1
257	Bile salts and cholestasis. Digestive and Liver Disease, 2010, 42, 409-418.	0.4	131

#	ARTICLE	IF	CITATIONS
258	Antiviral activity of 5â€²-O-carbonate-2â€²,3â€²-dideoxy-3â€²-thiacytidine prodrugs against hepatitis B virus in HepG2 2.2.15 cells. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 566-569.	1.1	7
259	Are TNF blockers safe for patients with hepatitis B virus infection?. <i>Nature Reviews Rheumatology</i> , 2010, 6, 618-620.	3.5	6
260	Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy. <i>Virology Journal</i> , 2010, 7, 324.	1.4	27
261	Telbivudine. <i>Drugs</i> , 2010, 70, 1857-1883.	4.9	17
262	Does chemotherapy prevent HBV-related hepatocellular carcinoma? <i>Cons. Digestive and Liver Disease</i> , 2010, 42, S298-S301.	0.4	4
265	Screening and Early Treatment of Migrants for Chronic Hepatitis B Virus Infection Is Cost-Effective. <i>Gastroenterology</i> , 2010, 138, 522-530.	0.6	110
266	Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2010, 139, 491-498.	0.6	180
267	Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses. <i>Gastroenterology</i> , 2010, 139, 1218-1229.e5.	0.6	227
268	Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection. <i>Gastroenterology</i> , 2010, 139, 1207-1217.e3.	0.6	133
269	Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus. <i>Gastroenterology</i> , 2010, 139, 1934-1941.	0.6	123
270	Review of Hepatitis B Therapeutics. <i>Clinical Infectious Diseases</i> , 2010, 51, 1201-1208.	2.9	69
271	Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. <i>Human Immunology</i> , 2010, 71, 950-956.	1.2	33
272	Entecavir in decompensated HBV cirrhosis: The future is looking brighter. <i>Journal of Hepatology</i> , 2010, 52, 147-149.	1.8	19
273	Mechanisms of HBV-related hepatocarcinogenesis. <i>Journal of Hepatology</i> , 2010, 52, 594-604.	1.8	371
274	Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. <i>Journal of Hepatology</i> , 2010, 52, 176-182.	1.8	244
275	Reactivation of hepatitis B virus after transarterial chemo-embolization for hepatocellular carcinoma in one patient with negative hepatitis B surface antigen. <i>Journal of Hepatology</i> , 2010, 52, 463-465.	1.8	11
276	Is response to antiviral treatment influenced by hepatitis B virus genotype?. <i>Journal of Hepatology</i> , 2010, 52, 441-449.	1.8	62
277	Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. <i>Journal of Hepatology</i> , 2010, 52, 778.	1.8	23

#	ARTICLE	IF	CITATIONS
278	Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia. <i>Journal of Hepatology</i> , 2010, 52, 508-513.	1.8	319
279	Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. <i>Journal of Hepatology</i> , 2010, 52, 514-522.	1.8	355
280	Re-emerging interest in hepatitis delta: New insights into the dynamic interplay between HBV and HDV. <i>Journal of Hepatology</i> , 2010, 52, 627-629.	1.8	49
281	Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. <i>Journal of Hepatology</i> , 2010, 53, 348-356.	1.8	397
282	Clinical, biochemical, and pathological characteristics of clevidine-associated myopathy. <i>Journal of Hepatology</i> , 2010, 53, 261-266.	1.8	33
283	Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. <i>Journal of Hepatology</i> , 2010, 53, 449-454.	1.8	45
284	Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study. <i>Journal of Hepatology</i> , 2010, 53, 1006-1012.	1.8	46
285	Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). <i>Journal of Hepatology</i> , 2010, 53, 1013-1021.	1.8	386
287	Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. <i>Journal of Clinical Virology</i> , 2010, 47, 193-195.	1.6	15
288	Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2010, 47, 243-247.	1.6	39
289	On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. <i>Journal of Clinical Virology</i> , 2010, 48, 22-26.	1.6	77
290	HBs seroconversion in a patient with acute hepatitis B treated with entecavir during immunosuppression against severe bronchiolitis obliterans in the course of chronic graft versus host disease. <i>Journal of Clinical Virology</i> , 2010, 48, 218-219.	1.6	7
291	Acute hepatitis B infection associated with drug-resistant hepatitis B virus. <i>Journal of Clinical Virology</i> , 2010, 48, 270-274.	1.6	45
295	Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 809-817.	2.0	41
296	Liver Transplantation in Bearers of Hepatitis B Associated or Not With Delta Hepatitis in the Age of the New Antiviral Drugs: Is Hyperimmune Globulin Still Necessary?. <i>Transplantation Proceedings</i> , 2010, 42, 496-497.	0.3	8
297	Efficacy and Safety of Entecavir and/or Tenofovir for Prophylaxis and Treatment of Hepatitis B Recurrence Post-Liver Transplant. <i>Transplantation Proceedings</i> , 2010, 42, 3167-3168.	0.3	63
298	Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. <i>Hepatology Research</i> , 2010, 40, 853-861.	1.8	51
299	The curative efficiency of tenofovir for patients with chronic hepatitis B after failure of nucleoside/nucleotide analogues. <i>Hepatology</i> , 2010, 52, 802-802.	3.6	0

#	ARTICLE	IF	CITATIONS
300	Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B. <i>International Journal of Infectious Diseases</i> , 2010, 14, e136-e141.	1.5	34
301	Hepatitis B virus genotyping: current methods and clinical implications. <i>International Journal of Infectious Diseases</i> , 2010, 14, e941-e953.	1.5	73
302	Time for universal HIV and HBV screening for patients with cancer. <i>Lancet Oncology</i> , The, 2010, 11, 916-918.	5.1	2
303	Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?. <i>Gut</i> , 2010, 59, 861-866.	6.1	182
304	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. <i>Blood</i> , 2010, 116, 2875-2883.	0.6	79
305	Response predictors to treatment with pegylated interferon in chronic hepatitis B. <i>Brazilian Journal of Infectious Diseases</i> , 2010, 14, 519-525.	0.3	0
306	Level of Hepatitis B Virus DNA in Inactive Carriers With Persistently Normal Levels of Alanine Aminotransferase. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 535-540.	2.4	23
307	Detection of Bacteria, Viruses, Parasites and Fungi. <i>NATO Science for Peace and Security Series A: Chemistry and Biology</i> , 2010, , .	0.5	3
308	Epidemiology and Diagnosis of Hepatitis B in the Mediterranean Region and Elsewhere. <i>NATO Science for Peace and Security Series A: Chemistry and Biology</i> , 2010, , 239-260.	0.5	0
309	Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 1678-1685.	0.6	12
310	Mathematical modeling based on lamivudine switching to adefovir dipivoxil and to entecavir anti-hepatitis B infection treatment. , 2010, , .		0
311	Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. <i>Leukemia and Lymphoma</i> , 2010, 51, 1592-1595.	0.6	8
312	Treatment of special populations with chronic hepatitis B infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 323-339.	1.4	12
313	Effectiveness of entecavir in the management of acute hepatitis B developing in a patient with Hodgkin's lymphoma: A case report. <i>Scandinavian Journal of Infectious Diseases</i> , 2011, 43, 750-752.	1.5	5
314	Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 285-295.	8.2	26
317	Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. <i>Gut</i> , 2011, 60, 1109-1116.	6.1	159
318	Recent advances in the treatment of chronic hepatitis B. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2025-2040.	0.9	26
320	Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 274-276.e1.	2.4	159

#	ARTICLE	IF	CITATIONS
321	Emerging pipeline drugs for hepatitis B infection. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 713-729.	1.0	23
322	Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2011, 43, S40-S48.	0.4	34
323	HBV therapy: Guidelines and open issues. <i>Digestive and Liver Disease</i> , 2011, 43, S57-S63.	0.4	18
324	Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. <i>Gastroenterology</i> , 2011, 141, 517-525.e2.	0.6	184
325	Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 455-464.	0.7	4
326	HBV-carriers: When is monitoring and surveillance sufficient? (point of view). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 813-818.	0.7	7
327	Predictors of Histologic Severity in Chronic Hepatitis B-infected Patients. <i>Journal of Experimental and Clinical Medicine</i> , 2011, 3, 300-303.	0.2	0
328	Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). <i>Digestive and Liver Disease</i> , 2011, 43, 589-595.	0.4	44
329	Interferon alpha for chronic hepatitis D. <i>The Cochrane Library</i> , 2011, , CD006002.	1.5	29
330	VIRAL hepatitis in solid organ transplantation other than liver. <i>Journal of Hepatology</i> , 2011, 55, 474-482.	1.8	44
331	Entecavir. <i>Drugs</i> , 2011, 71, 2511-2529.	4.9	19
332	Hepatitis B: Modern End Points of Treatment and the Specter of Viral Resistance. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 495-505.	1.0	15
333	Antiviral drugs for HBV liver disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 285-300.	1.4	21
334	Hepatitis B prevention, diagnosis, treatment and care: a review. <i>Occupational Medicine</i> , 2011, 61, 531-540.	0.8	117
335	Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 891-899.	2.0	14
336	Autoimmune Diseases. , 2011, , .		1
337	Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective. <i>Pharmacoeconomics</i> , 2011, 29, 1075-1091.	1.7	8
338	The impact of biologic response modifiers on hepatitis B virus infection. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 533-544.	1.4	24

#	ARTICLE	IF	CITATIONS
340	The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B. <i>Auris Nasus Larynx</i> , 2011, 38, 312-318.	0.5	3
344	Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 1287-1298.	1.3	133
345	Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. <i>European Journal of Internal Medicine</i> , 2011, 22, 572-575.	1.0	20
346	Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO. <i>European Journal of Internal Medicine</i> , 2011, 22, 576-581.	1.0	5
347	Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. <i>Journal of Clinical Virology</i> , 2011, 50, 292-296.	1.6	76
348	Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy. <i>Journal of Clinical Virology</i> , 2011, 51, 241-245.	1.6	17
349	Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: A clinical survey of 5 cases in Catania, Italy. <i>Journal of Clinical Virology</i> , 2011, 52, 284-287.	1.6	6
350	CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase. <i>International Immunopharmacology</i> , 2011, 11, 406-411.	1.7	13
353	Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy. <i>Journal of Hepatology</i> , 2011, 54, 195-200.	1.8	29
354	Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. <i>Journal of Hepatology</i> , 2011, 54, 236-242.	1.8	122
355	Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2011, 54, 209-218.	1.8	171
356	Study of adherence comes to the treatment of chronic hepatitis B. <i>Journal of Hepatology</i> , 2011, 54, 6-8.	1.8	34
357	Focus. <i>Journal of Hepatology</i> , 2011, 54, 189-190.	1.8	0
358	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. <i>Journal of Hepatology</i> , 2011, 55, 522-528.	1.8	33
359	Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries. <i>Journal of Hepatology</i> , 2011, 55, 183-191.	1.8	138
360	Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. <i>Journal of Hepatology</i> , 2011, 55, 587-593.	1.8	78
361	Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2011, 55, 1235-1240.	1.8	75
362	Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. <i>Journal of Hepatology</i> , 2011, 55, 1121-1131.	1.8	280

#	ARTICLE	IF	CITATIONS
364	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology</i> , The, 2011, 12, 568-574.	5.1	541
365	Hepatitis B therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 275-284.	8.2	232
366	Acute hepatitis B in Japan: Incidence, clinical practices and health policy. <i>Hepatology Research</i> , 2011, 41, 39-45.	1.8	30
367	Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. <i>Hepatology Research</i> , 2011, 41, 405-416.	1.8	39
368	Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. <i>Hepatology Research</i> , 2011, 41, 553-563.	1.8	42
369	Recommendation of lamivudine to entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial. <i>Hepatology Research</i> , 2011, 41, 505-511.	1.8	4
370	Management of hepatitis B virus infection in the pre-transplant setting. <i>Digestive and Liver Disease Supplements</i> , 2011, 5, 10-14.	0.2	0
371	Elevación crónica de las transaminasas: hipertransaminasemia crónica. <i>EMC - Tratado De Medicina</i> , 2011, 15, 1-8.	0.0	0
372	Complications of thalassemia major and their treatment. <i>Expert Review of Hematology</i> , 2011, 4, 353-366.	1.0	111
373	Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B. <i>International Journal of Infectious Diseases</i> , 2011, 15, e722-e726.	1.5	15
374	Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with real-time PCR. <i>Clinica Chimica Acta</i> , 2011, 412, 1905-1911.	0.5	33
375	Tratamiento de las hepatitis virales. <i>Medicine</i> , 2011, 10, 6249-6254.	0.0	0
376	Increasing burden of liver disease in patients with HIV infection. <i>Lancet</i> , The, 2011, 377, 1198-1209.	6.3	258
377	Recent advances in the management of viral hepatitis. <i>Journal of the Royal College of Physicians of Edinburgh</i> , The, 2011, 41, 59-66.	0.2	1
378	Impact of Fibroscan® on management of chronic viral hepatitis in clinical practice. <i>Annals of Hepatology</i> , 2011, 10, 469-476.	0.6	19
379	Effectiveness of add-on Pegylated interferon alfa-2a therapy in a Lamivudine-treated patient with chronic hepatitis B. <i>Annals of Hepatology</i> , 2011, 10, 84-87.	0.6	7
381	Glycyrrhizin for chronic hepatitis B virus infection. <i>The Cochrane Library</i> , 2011, , .	1.5	0
382	HBV DNA Loss within 24 Weeks Predicts Late Viral Breakthrough in Chronic Hepatitis B. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi</i> , The, 2011, 58, 25.	0.2	0

#	ARTICLE	IF	CITATIONS
384	A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. ClinicoEconomics and Outcomes Research, 2011, 3, 37.	0.7	22
385	Management of liver cirrhosis between primary care and specialists. World Journal of Gastroenterology, 2011, 17, 2273.	1.4	45
386	Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy. Frontiers in Bioscience - Landmark, 2011, 16, 225.	3.0	26
387	Hepatitis B and Deltavirus Infections. , 2011, , 433-440.		0
388	Canadian Patients with Chronic Hepatitis B Cannot Access Appropriate Drug Treatments: A Call for Change. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 538-541.	1.8	2
389	Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia. Case Reports in Hepatology, 2011, 2011, 1-3.	0.4	2
390	Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infection and Drug Resistance, 2011, 4, 55.	1.1	24
391	Liver Stiffness Measurement and Biochemical Markers in Senegalese Chronic Hepatitis B Patients with Normal ALT and High Viral Load. PLoS ONE, 2011, 6, e22291.	1.1	23
392	Reactivated hepatitis B due to medical interventions: the clinical spectrum expands. Antiviral Therapy, 2011, 16, 947-949.	0.6	2
393	Entecavir plus Adefovir Combination Treatment for Chronic Hepatitis B Patients after Failure of Nucleoside/Nucleotide Analogues. Antiviral Therapy, 2012, 17, 53-60.	0.6	21
394	Phyllanthus species for chronic hepatitis B virus infection. The Cochrane Library, 2011, , CD008960.	1.5	13
395	High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure. Journal of Clinical Gastroenterology, 2011, 45, 900-905.	1.1	11
396	Hepatitis delta in HIV-infected individuals in Europe. Aids, 2011, 25, 1987-1992.	1.0	79
397	A Proposed, Evidence-based Approach to the Treatment of Chronic Hepatitis B. Journal of Clinical Gastroenterology, 2011, 45, 259-266.	1.1	8
398	Comparison of Clevudine and Entecavir for Treatment-naive Patients With Chronic Hepatitis B Virus Infection. Journal of Clinical Gastroenterology, 2011, 45, 893-899.	1.1	19
399	Comparative Analysis of Noninvasive Models to Predict Early Liver Fibrosis in Hepatitis B e Antigen-negative Chronic Hepatitis B. Journal of Clinical Gastroenterology, 2011, 45, 278-285.	1.1	28
400	Fatal hepatitis B virus reactivation due to a lamivudine mutant despite undetectable initial viral load. European Journal of Gastroenterology and Hepatology, 2011, 23, 109.	0.8	3
401	Management of chronic hepatitis B. European Journal of Gastroenterology and Hepatology, 2011, 23, 642-650.	0.8	13

#	ARTICLE	IF	CITATIONS
402	Tenofovir Therapy in Hepatitis B Virus-Positive Solid-Organ Transplant Recipients. <i>Transplantation</i> , 2011, 91, 916-920.	0.5	44
403	Glycyrrhizin versus antiviral drugs for chronic hepatitis B virus infection. <i>The Cochrane Library</i> , 0, , .	1.5	0
404	HBsAg Seroclearance in Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 64-68.	1.1	35
405	Hepatitis B Virus Acquisition and Pathogenesis in Childhood: Host Genetic Determinants. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 52, 3-8.	0.9	10
406	Resistance Patterns and Response to Entecavir Intensification Among HIV-HBV Coinfected Adults With Persistent HBV Viremia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, e96-e99.	0.9	7
409	Sophorus species for chronic hepatitis B virus infection. <i>The Cochrane Library</i> , 2011, , .	1.5	3
410	Entecavir treatment in HBV-related decompensated cirrhosis. <i>Future Virology</i> , 2011, 6, 1275-1281.	0.9	0
411	Quasispecies Analysis and <i>In Vitro</i> Susceptibility of HBV Strains Isolated from HIV-HBV-Coinfected Patients with Delayed Response to Tenofovir. <i>Antiviral Therapy</i> , 2012, 17, 61-70.	0.6	15
412	Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon- α 2B: Relation to Response and HBV Genotype. <i>Antiviral Therapy</i> , 2012, 17, 9-17.	0.6	63
413	Risk of HBV Reactivation According to Viral Status and Treatment Intensity in Patients with Hepatocellular Carcinoma. <i>Antiviral Therapy</i> , 2011, 16, 969-977.	0.6	62
414	On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients. <i>Antiviral Therapy</i> , 2011, 16, 165-172.	0.6	82
415	Prediction of off-Treatment Response to Lamivudine by Serum Hepatitis B Surface Antigen Quantification in Hepatitis B E Antigen-Negative Patients. <i>Antiviral Therapy</i> , 2011, 16, 1249-1257.	0.6	100
416	Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2011, 16, 469-477.	0.6	20
417	Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide Analogues. <i>Antiviral Therapy</i> , 2011, 16, 915-924.	0.6	76
418	Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. <i>Antiviral Therapy</i> , 2011, 16, 199-205.	0.6	21
419	Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon- α 2A Therapy. <i>Antiviral Therapy</i> , 2011, 16, 629-637.	0.6	91
420	High-Resolution Melting and Real-Time Pcr for Quantification and Detection of Drug-Resistant HBV Mutants in a Single Amplicon. <i>Antiviral Therapy</i> , 2012, 17, 291-303.	0.6	9
421	Entecavir versus Lamivudine in the Treatment of Chronic Hepatitis B Patients with Hepatic Decompensation. <i>Antiviral Therapy</i> , 2012, 17, 605-612.	0.6	15

#	ARTICLE	IF	CITATIONS
422	The Role of Adherence in Virological Suppression in Patients Receiving Anti-HBV Analogues. <i>Antiviral Therapy</i> , 2012, 17, 395-400.	0.6	31
423	Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy. <i>Antiviral Therapy</i> , 2011, 16, 505-514.	0.6	6
424	Lamivudine-Resistant HBV Infection in HIV-Positive Patients Receiving Antiretroviral Therapy in a Public Routine Clinic in Cameroon. <i>Antiviral Therapy</i> , 2012, 17, 321-326.	0.6	31
426	Poor durability of lamivudine effectiveness despite stringent cessation criteria: A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 456-460.	1.4	78
427	Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 300-305.	1.4	127
428	The clinical implications of hepatitis B virus genotype: Recent advances. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 123-130.	1.4	312
429	Chronic hepatitis B in Asia—new insights from the past decade. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 131-137.	1.4	68
430	Treatment of chronic hepatitis B: Evolution over two decades. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 138-143.	1.4	143
431	Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 987-995.	1.4	15
432	To stop or not to stop: The quest for long-term viral suppression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 420-422.	1.4	2
433	Evaluation of current treatment recommendations for chronic hepatitis B: A 2011 update. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 829-835.	1.4	28
434	Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1527-1535.	1.4	36
435	Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, no-no.	1.4	23
436	Management of chronic Hepatitis B infection in the remote primary health care setting: The search for a suitable guideline. <i>Australian Journal of Rural Health</i> , 2011, 19, 95-100.	0.7	7
437	Morbilliform drug eruption due to pegylated interferon can show complete regression after switching to non-pegylated interferon. <i>Journal of Dermatology</i> , 2011, 38, 479-481.	0.6	7
438	Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 455-465.	1.9	71
439	Review article: chronic hepatitis B—anti-viral or immunomodulatory therapy?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 501-513.	1.9	34
440	Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1104-1112.	1.9	159

#	ARTICLE	IF	CITATIONS
441	Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 353-362.	1.9	66
442	Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 344-352.	1.9	107
443	Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 424-431.	1.9	20
444	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1202-1216.	1.9	111
445	Review article: current antiviral therapy of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1145-1158.	1.9	71
446	British Association of Dermatologists's™ guidelines for the safe and effective prescribing of azathioprine 2011. <i>British Journal of Dermatology</i> , 2011, 165, 711-734.	1.4	107
447	Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2011, 18, 61-69.	1.0	51
448	Clinical, epidemiological characteristics and indications for liver biopsy and treatment in immigrants with chronic hepatitis B at a referral hospital in Madrid. <i>Journal of Viral Hepatitis</i> , 2011, 18, 294-299.	1.0	10
449	Single-step real-time PCR to quantify hepatitis B virus and distinguish genotype D from non-D genotypes. <i>Journal of Viral Hepatitis</i> , 2011, 18, 300-304.	1.0	19
450	Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients. <i>Journal of Viral Hepatitis</i> , 2011, 18, 580-586.	1.0	38
451	Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. <i>Journal of Viral Hepatitis</i> , 2011, 18, e29-39.	1.0	52
452	Characteristics of chronic hepatitis B patients who underwent liver biopsies. <i>Journal of Viral Hepatitis</i> , 2011, 18, 792-803.	1.0	8
453	Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains. <i>Journal of Viral Hepatitis</i> , 2011, 18, 804-814.	1.0	7
454	Adefovir serum levels do not differ between responders and nonresponders. <i>Journal of Viral Hepatitis</i> , 2011, 18, e175-8.	1.0	1
455	Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. <i>Journal of Viral Hepatitis</i> , 2011, 18, 892-896.	1.0	33
456	Development of a protocol for the quantitative determination of HBeAg using the Elecsys® HBeAg immunoassay. <i>Journal of Viral Hepatitis</i> , 2011, 18, e179-83.	1.0	17
457	Unawareness of HBV infection among inpatients in a Southern Italian hospital. <i>Journal of Viral Hepatitis</i> , 2011, 18, e206-11.	1.0	6
458	Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011, 18, e217-25.	1.0	28

#	ARTICLE	IF	CITATIONS
459	There were no differences in serum HBV DNA level between HBeAg-positive and HBeAg-negative chronic hepatitis B with same liver histological necroinflammation grade but differences among grades 1, 2, 3 and 4 apportioned by the same hepatic parenchyma cell. <i>Journal of Viral Hepatitis</i> , 2011, 18, 637-645.	1.0	11
460	Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011, 18, e252-7.	1.0	16
461	Hepatitis B surface antigen monitoring and management of chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011, 18, 449-457.	1.0	48
462	Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients. <i>Journal of Viral Hepatitis</i> , 2011, 18, e468-e474.	1.0	25
463	Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. <i>Journal of Viral Hepatitis</i> , 2011, 18, e475-e481.	1.0	15
464	High levels of serum hepatitis B virus DNA in patients with anti-HBc alone™: role of HBsAg mutants. <i>Journal of Viral Hepatitis</i> , 2011, 18, 721-729.	1.0	31
466	Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. <i>Liver International</i> , 2011, 31, 330-339.	1.9	37
467	Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?. <i>Liver International</i> , 2011, 31, 78-84.	1.9	38
468	Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon. <i>Liver International</i> , 2011, 31, 90-94.	1.9	9
469	Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. <i>Liver International</i> , 2011, 31, 122-128.	1.9	33
470	Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. <i>Liver International</i> , 2011, 31, 95-103.	1.9	13
471	The difficulties of managing severe hepatitis B virus reactivation. <i>Liver International</i> , 2011, 31, 104-110.	1.9	55
472	Hepatitis B virus resistance to antiviral drugs: where are we going?. <i>Liver International</i> , 2011, 31, 111-116.	1.9	118
473	Milestones and perspectives in viral hepatitis B. <i>Liver International</i> , 2011, 31, 129-134.	1.9	25
474	Hepatitis D revival. <i>Liver International</i> , 2011, 31, 140-144.	1.9	37
475	Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited. <i>Liver International</i> , 2011, 31, 589-591.	1.9	5
476	Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. <i>Liver International</i> , 2011, 31, 277-279.	1.9	6
477	Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. <i>Liver International</i> , 2011, 31, 676-684.	1.9	43

#	ARTICLE	IF	CITATIONS
478	Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B. <i>Liver International</i> , 2011, 31, 824-830.	1.9	40
479	The change of the quantitative HBsAg level during the natural course of chronic hepatitis B. <i>Liver International</i> , 2011, 31, 817-823.	1.9	38
480	Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels. <i>Liver International</i> , 2011, 31, 1352-1358.	1.9	33
481	Dilemma of recurrence of hepatitis B infection after liver transplantation. <i>Liver International</i> , 2011, 31, 1422-1423.	1.9	1
482	Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. <i>Liver International</i> , 2011, 31, 1525-1532.	1.9	13
483	Viral infections associated with the clinical use of monoclonal antibodies. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1769-1775.	2.8	15
484	Effectiveness of entecavir in chronic hepatitis B NUC-naïve patients in routine clinical practice. <i>International Journal of Clinical Practice</i> , 2011, 65, 866-870.	0.8	21
485	Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2011, 46, 125-131.	1.3	84
487	Nosocomial outbreak of hepatitis B virus infection involving two hospitals in the Republic of Ireland. <i>Journal of Hospital Infection</i> , 2011, 78, 279-283.	1.4	13
488	Development and validation of a hepatitis B virus DNA sequencing assay for assessment of antiviral resistance, viral genotype and surface antigen mutation status. <i>Journal of Virological Methods</i> , 2011, 177, 31-37.	1.0	29
489	TNF alpha antagonist therapy and safety monitoring. <i>Joint Bone Spine</i> , 2011, 78, 15-185.	0.8	65
490	Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient. <i>Virology Journal</i> , 2011, 8, 518.	1.4	1
491	Polymorphisms of interferon-inducible genes OAS associated with interferon- α treatment response in chronic HBV infection. <i>Antiviral Research</i> , 2011, 89, 232-237.	1.9	32
492	Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study. <i>Antiviral Research</i> , 2011, 92, 90-95.	1.9	22
493	Drug safety evaluation of adefovir in HBV infection. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 809-818.	1.0	33
494	Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 619-633.	1.9	101
495	Long-Term Effect of Interferon Therapy in Patients with HBeAg Positive Chronic Hepatitis B Infection. <i>Digestive Diseases and Sciences</i> , 2011, 56, 208-212.	1.1	12
496	Defining Virologic Relapse in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2432-2438.	1.1	4

#	ARTICLE	IF	CITATIONS
497	The Management of Chronic Hepatitis B in Asian Americans. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3143-3162.	1.1	69
498	Access to Care and Optimal Treatment of Chronic Hepatitis B in Asian Americans: An Evolving Agenda. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3106-3108.	1.1	0
499	Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. <i>Journal of Gastroenterology</i> , 2011, 46, 391-400.	2.3	62
500	Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration. <i>Journal of Gastroenterology</i> , 2011, 46, 717-723.	2.3	8
501	Chronic hepatitis B infection in pregnancy illustrated by a case of successful treatment with entecavir. <i>Archives of Gynecology and Obstetrics</i> , 2011, 284, 1595-1596.	0.8	8
502	Role of HLA Allele Polymorphism in Chronic Hepatitis B Virus Infection and HBV Vaccine Sensitivity in Patients from Eastern Turkey. <i>Biochemical Genetics</i> , 2011, 49, 258-269.	0.8	24
503	Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 291-303.	1.0	119
504	Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. <i>Infection</i> , 2011, 39, 367-370.	2.3	1
505	A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B. <i>Hepatology International</i> , 2011, 5, 664-670.	1.9	19
506	HBV life cycle and novel drug targets. <i>Hepatology International</i> , 2011, 5, 644-653.	1.9	97
510	Adherence to Chronic Hepatitis B Treatment Guideline Recommendations for Laboratory Monitoring of Patients Who Are Not Receiving Antiviral Treatment. <i>Journal of General Internal Medicine</i> , 2011, 26, 239-244.	1.3	37
511	Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection. <i>Journal of General Internal Medicine</i> , 2011, 26, 326-339.	1.3	14
512	Hepatitis B Vaccination: Current and Evolving Recommendations. <i>Current Hepatitis Reports</i> , 2011, 10, 128-133.	0.3	0
513	Current Management of HBV Antiviral Drug Resistance. <i>Current Hepatitis Reports</i> , 2011, 10, 120-127.	0.3	0
514	Combination Therapy for Chronic Hepatitis B: Current Indications. <i>Current Hepatitis Reports</i> , 2011, 10, 98-105.	0.3	7
515	Hepatitis B Genotypes: Role of Testing in Clinical Practice. <i>Current Hepatitis Reports</i> , 2011, 10, 79-86.	0.3	0
516	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. <i>Current Hepatitis Reports</i> , 2011, 10, 235-243.	0.3	25
517	Update on Diagnosis and Treatment within the Four Clinical Phases of Chronic Hepatitis B Infection. <i>Current Hepatitis Reports</i> , 2011, 10, 229-234.	0.3	0

#	ARTICLE	IF	CITATIONS
518	Hepatitis B virus Resistance to Antivirals : Diagnosis and Management. <i>Current Hepatitis Reports</i> , 2011, 10, 244-254.	0.3	0
519	Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. <i>BMC Infectious Diseases</i> , 2011, 11, 165.	1.3	29
520	Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil. <i>BMC Infectious Diseases</i> , 2011, 11, 247.	1.3	9
521	Virologic and clinical characteristics of HBV genotypes/subgenotypes in 487 Chinese pediatric patients with CHB. <i>BMC Infectious Diseases</i> , 2011, 11, 262.	1.3	18
522	Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment. <i>Virology Journal</i> , 2011, 8, 388.	1.4	4
524	Nouveaux outils pour le diagnostic et le suivi des hépatites virales chroniques. <i>Revue Francophone Des Laboratoires</i> , 2011, 2011, 48-50.	0.0	0
525	Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: A systematic review. <i>Liver Transplantation</i> , 2011, 17, 1176-1190.	1.3	105
526	Lymphoproliferative disorders in individuals with chronic hepatitis b and C in the Turkish population. <i>Journal of Medical Virology</i> , 2011, 83, 974-980.	2.5	2
527	Serum HBsAg levels during peginterferon α 2a treatment with or without thymosin α 1 in HBeAg-positive chronic hepatitis B patients. <i>Journal of Medical Virology</i> , 2011, 83, 88-94.	2.5	11
528	High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe. <i>Journal of Medical Virology</i> , 2011, 83, 968-973.	2.5	41
529	Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. <i>Journal of Medical Virology</i> , 2011, 83, 1909-1916.	2.5	64
530	HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo. <i>Journal of Medical Virology</i> , 2011, 83, 1917-1923.	2.5	3
531	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. <i>Hepatology</i> , 2011, 53, 62-72.	3.6	274
532	Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. <i>Hepatology</i> , 2011, 53, 1494-1503.	3.6	283
533	Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. <i>Hepatology</i> , 2011, 54, 91-100.	3.6	188
534	Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. <i>Hepatology</i> , 2011, 54, 101-108.	3.6	34
535	Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , 2011, 54, 443-451.	3.6	150
536	Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. <i>Hepatology</i> , 2011, 54, 1591-1599.	3.6	183

#	ARTICLE	IF	CITATIONS
537	Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2037-2041.	0.4	14
539	Severe Agranulocytosis as a Rare Side Effect of Pegylated Interferon Therapy for Chronic Hepatitis B. <i>Zeitschrift Fur Gastroenterologie</i> , 2011, 49, 596-598.	0.2	5
540	Quantification of HBsAg and HBV-DNA during Therapy with Peginterferon alpha-2b plus Lamivudine and Peginterferon alpha-2b Alone in a German Chronic Hepatitis B Cohort. <i>Zeitschrift Fur Gastroenterologie</i> , 2011, 49, 1463-1469.	0.2	3
541	Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety. <i>American Journal of Gastroenterology</i> , 2011, 106, 1264-1271.	0.2	145
542	Risk Assessment of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis by a Liver Stiffness Measurement-Based Model. <i>American Journal of Gastroenterology</i> , 2011, 106, 1654-1662.	0.2	56
543	Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment. <i>American Journal of Gastroenterology</i> , 2011, 106, 1766-1773.	0.2	62
544	Vitamins in the treatment of chronic viral hepatitis. <i>British Journal of Nutrition</i> , 2011, 105, 982-989.	1.2	10
545	Performance Characteristics and Comparison of Abbott and artus Real-Time Systems for Hepatitis B Virus DNA Quantification. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3215-3221.	1.8	29
546	Chromatin Dynamics of Gene Activation and Repression in Response to Interferon $\hat{\pm}$ (IFN $\hat{\pm}$) Reveal New Roles for Phosphorylated and Unphosphorylated Forms of the Transcription Factor STAT2. <i>Journal of Biological Chemistry</i> , 2011, 286, 20217-20227.	1.6	51
547	Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy. <i>Medicine (United States)</i> , 2011, 90, 359-371.	0.4	247
548	Successful clearance of hepatitis C virus with pegylated interferon $\hat{\text{A}}$ -2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1343-1344.	0.5	11
549	Republished paper: Managing HBV in patients with impaired immunity. <i>Postgraduate Medical Journal</i> , 2011, 87, 223-238.	0.9	3
550	Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 3270-3277.	0.8	60
551	Assessment of Clinical Utility of Low and High Normal Alanine Aminotransferase Values in Patients with Chronic Hepatitis B Virus Infection in Bangladesh. <i>Digestion</i> , 2011, 83, 60-64.	1.2	4
552	Treatment of Hepatitis B Virus-Associated Nephropathy. <i>Nephron Clinical Practice</i> , 2011, 119, c41-c49.	2.3	41
553	Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients. <i>Digestion</i> , 2011, 84, 23-28.	1.2	13
554	Tenofovir salvage for nucleoside experienced patients: muddy waters?. <i>Gut</i> , 2011, 60, 148-150.	6.1	2
555	Managing the public health risk of a 'sex worker' with hepatitis B infection: legal and ethical considerations. <i>Journal of Medical Ethics</i> , 2011, 37, 623-626.	1.0	0

#	ARTICLE	IF	CITATIONS
556	Diagnosis and management of chronic liver disease in older people. <i>Reviews in Clinical Gerontology</i> , 2011, 21, 1-15.	0.5	10
557	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2715-2725.	1.3	168
558	An Argument for the Universal Prophylaxis of Hepatitis B Infection in Patients Receiving Rituximab: A 7-Year Institutional Experience of Hepatitis Screening. <i>Oncologist</i> , 2011, 16, 579-584.	1.9	24
559	Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 13-32.	1.4	23
560	HLA-DRB1*010101 Allele Is Closely Associated with Poor Virological Response to Lamivudine Therapy in Patients with Chronic Hepatitis B. <i>Digestion</i> , 2011, 84, 35-42.	1.2	4
561	Multilaboratory Evaluation of Real-Time PCR Tests for Hepatitis B Virus DNA Quantification. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2854-2858.	1.8	51
562	Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2648-2656.	0.4	13
563	Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay. <i>Vaccine Journal</i> , 2011, 18, 1943-1950.	3.2	35
564	Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen-“Negative” Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , 2011, 204, 408-414.	1.9	110
565	Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 641-652.	2.0	13
566	Hepatitis B Virus Reactivation by Immunosuppressive Therapy in Patients with Autoimmune Diseases: Risk Analysis in Hepatitis B Surface Antigen-negative Cases. <i>Journal of Rheumatology</i> , 2011, 38, 2209-2214.	1.0	50
567	Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1719-1725.	0.5	159
568	Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. <i>Gut</i> , 2011, 60, 1269-1277.	6.1	69
569	Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta. <i>New England Journal of Medicine</i> , 2011, 364, 322-331.	13.9	401
570	Severe Acute Hepatitis B Treated with Entecavir. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011010.	0.5	16
571	Therapy for chronic viral hepatitis: current indications, optimal therapies and delivery of care. <i>Clinical Medicine</i> , 2011, 11, 184-189.	0.8	2
572	Frequency and Mutation Patterns of Resistance in Patients with Chronic Hepatitis B Infection Treated with Nucleos(t)ide Analogues in Add-On and Switch Strategies. <i>Hepatitis Monthly</i> , 2011, 11, 835-842.	0.1	13
573	The Role of Liver Fibrosis Assessment in the Management of Patients with Chronic Hepatitis B Infection: Lessons Learned from a Single Centre Experience. <i>Hepatitis Research and Treatment</i> , 2011, 2011, 1-5.	2.0	2

#	ARTICLE	IF	CITATIONS
574	Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD. Bone Marrow Transplantation, 2011, 46, 1274-1275.	1.3	12
576	Recent Advances in the Management of Chronic Hepatitis B. Hepatitis Monthly, 2011, 11, 601-11.	0.1	8
577	Hepatitis B viral breakthrough associated with inappropriate preservation of entecavir. Indian Journal of Pharmacology, 2012, 44, 136.	0.4	1
578	Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. Journal of Infectious Diseases, 2012, 206, 1521-1531.	1.9	47
579	Efficacy of thymosin $\hat{\alpha}$ -1 plus peginterferon $\hat{\alpha}$ -2a combination therapy compared with peginterferon $\hat{\alpha}$ -2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study. Scandinavian Journal of Gastroenterology, 2012, 47, 1048-1055.	0.6	19
580	High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B. The Korean Journal of Hepatology, 2012, 18, 75.	1.5	13
582	Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro. Hepatitis Monthly, 2012, 12, 357-360.	0.1	4
583	Treatment of Hepatitis B Virus Cirrhosis. Hepatitis Monthly, 2012, 12, 309-311.	0.1	6
584	Serum angiotensin-converting enzyme level as a marker of fibrosis in patients with chronic hepatitis B. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 244-249.	1.0	13
585	Reasons to consider earlier treatment of chronic HBV infections. Gut, 2012, 61, 333-336.	6.1	98
586	ARHAI: antiviral resistance. Journal of Antimicrobial Chemotherapy, 2012, 67, i65-i68.	1.3	2
587	Old and New Antirheumatic Drugs and the Risk of Hepatotoxicity. Therapeutic Drug Monitoring, 2012, 34, 622-628.	1.0	28
588	Diagnosis and personalized management of hepatitis B including significance of genotypes. Current Opinion in Infectious Diseases, 2012, 25, 570-577.	1.3	15
589	Randomized Trial of Entecavir plus Adefovir in Patients with Lamivudine-Resistant Chronic Hepatitis B Who Show Suboptimal Response to Lamivudine plus Adefovir. Antimicrobial Agents and Chemotherapy, 2012, 56, 2941-2947.	1.4	26
590	Is ultrasound elastography of the liver ready to replace biopsy? A critical review of the current techniques. Ultrasound, 2012, 20, 24-32.	0.3	12
591	Hepatitis B Virus and HIV Infection. Seminars in Liver Disease, 2012, 32, 114-119.	1.8	19
592	Hepatitis Delta and HIV Infection. Seminars in Liver Disease, 2012, 32, 120-129.	1.8	23
594	Challenges and Priorities in the Management of HIV/HBV and HIV/HCV Coinfection in Resource-Limited Settings. Seminars in Liver Disease, 2012, 32, 147-157.	1.8	34

#	ARTICLE	IF	CITATIONS
595	Chronic Viral and Autoimmune Hepatitis. , 2012, , 973-979.		2
597	Epidemiology, Responses, and Way Forward. Journal of the International Association of Providers of AIDS Care, 2012, 11, 311-320.	1.2	20
598	Assessment of the Quality of Evidence Underlying International Guidelines in Liver Disease. American Journal of Gastroenterology, 2012, 107, 1276-1282.	0.2	17
600	Management of HBV- and HCV-induced end stage liver disease. Gut, 2012, 61, i59-i67.	6.1	38
601	Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Expert Review of Gastroenterology and Hepatology, 2012, 6, 187-198.	1.4	29
602	Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opinion on Drug Safety, 2012, 11, 361-368.	1.0	53
603	New perspectives in the therapy of chronic hepatitis B. Gut, 2012, 61, i18-i24.	6.1	51
604	Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scandinavian Journal of Gastroenterology, 2012, 47, 475-481.	0.6	30
605	Risk Assessment of Development of Hepatic Decompensation in Histologically Proven Hepatitis B Viral Cirrhosis Using Liver Stiffness Measurement. Digestion, 2012, 85, 219-227.	1.2	20
606	Biochemical, Virological, Immunological and Histopathological Features of 702 Incidentally Detected Chronic Hepatitis B Virus Carriers in Bangladesh. Digestion, 2012, 86, 1-5.	1.2	9
607	Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. Digestion, 2012, 86, 264-272.	1.2	2
608	Clinical implications of HBsAg quantification in patients with chronic hepatitis B. Saudi Journal of Gastroenterology, 2012, 18, 81.	0.5	24
609	Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: A case report and literature review. Saudi Journal of Gastroenterology, 2012, 18, 277.	0.5	13
610	Occult hepatitis B reactivation following rituximab treatment in a patient with Waldenström macroglobulinemia. Journal of Clinical and Experimental Investigations, 2012, 3, .	0.1	0
611	Serum biomarkers for the non-invasive diagnosis of liver fibrosis: the importance of being validated. Clinical Chemistry and Laboratory Medicine, 2012, 50, 595-7.	1.4	6
612	Update on entecavir in the management of severe forms of Hepatitis B. Hepatic Medicine: Evidence and Research, 2012, 4, 39.	0.9	1
613	Viral Hepatitis Infections in Chronic Kidney Disease Patients and Renal Transplant Recipients. Kidney and Blood Pressure Research, 2012, 35, 454-467.	0.9	14
614	Health-Related Quality of Life in Chinese Patients with Chronic Liver Disease. Gastroenterology Research and Practice, 2012, 2012, 1-7.	0.7	19

#	ARTICLE	IF	CITATIONS
615	Infectious Complications of Acute and Chronic Liver Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 80-95.	0.8	86
616	Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters. <i>Journal of Infectious Diseases</i> , 2012, 205, 54-63.	1.9	51
617	Comparison between Elecsys HBsAg II and Architect HBsAg QT Assays for Quantification of Hepatitis B Surface Antigen among Patients Coinfected with HIV and Hepatitis B Virus. <i>Vaccine Journal</i> , 2012, 19, 242-248.	3.2	17
619	The treatment of severe hepatitis B virus reactivation after chemotherapy. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 350-350.	12.5	3
620	Virologic Responses to Addition of Adefovir Dipivoxil Treatment Versus Entecavir Monotherapy in Children With Lamivudine-Resistant Chronic Hepatitis B. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 648-652.	0.9	18
621	Age versus clinical virological characteristics in chronic hepatitis B virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1.	0.8	9
622	Clonal Analysis of the Quasispecies of Antiviral-Resistant HBV Genomes in Patients with Entecavir Resistance during Rescue Treatment and Successful Treatment of Entecavir Resistance with Tenofovir. <i>Antiviral Therapy</i> , 2013, 18, 77-85.	0.6	12
623	Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants. <i>Antiviral Therapy</i> , 2012, 17, 701-709.	0.6	11
625	High Frequency of Recurrent Viremia After Hepatitis B e Antigen Seroconversion and Consolidation Therapy. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 865-870.	1.1	63
626	Outcome of Lamivudine-Resistant Chronic Hepatitis B after up to 5 Years of Combination Therapy with Adefovir. <i>Antiviral Therapy</i> , 2012, 17, 1255-1262.	0.6	18
627	Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. <i>Aids</i> , 2012, 26, 939-949.	1.0	45
628	Hepatitis B. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 541-549.	0.6	7
629	Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 535-542.	0.8	25
630	The safety of anti-TNF therapy in patients with hepatitis B and C virus infection. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 191-196.	0.3	1
631	Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 243-250.	1.1	4
632	Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α -2a. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1012-1019.	0.8	11
633	Chronic Hepatitis B Infection and Pregnancy. <i>Obstetrical and Gynecological Survey</i> , 2012, 67, 37-44.	0.2	27
634	Pegylated Interferon Results in Higher Serological, but Not Virological, Response Rates When Compared to Continuous Entecavir. <i>Antiviral Therapy</i> , 2012, 17, 1605-1608.	0.6	15

#	ARTICLE	IF	CITATIONS
636	Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy. <i>Antiviral Therapy</i> , 2012, 17, 1049-1058.	0.6	15
637	Challenges to the effective delivery of health care to people with chronic hepatitis B in Australia. <i>Sexual Health</i> , 2012, 9, 131.	0.4	19
638	Lamivudine plus Adefovir or Telbivudine plus Adefovir for Chronic Hepatitis B Patients with Suboptimal Response to Adefovir. <i>Antiviral Therapy</i> , 2012, 17, 973-979.	0.6	11
639	Chronic HBV infection outside treatment guidelines: is treatment needed?. <i>Antiviral Therapy</i> , 2012, 18, 229-235.	0.6	17
640	A 96-Week Randomized Trial of Switching to Entecavir in Chronic Hepatitis B Patients with a Partial Virological Response to Lamivudine. <i>Antiviral Therapy</i> , 2012, 17, 1563-1570.	0.6	12
641	A Randomized Controlled Trial of Sequential Pegylated Interferon- α and Telbivudine or Vice Versa for 48 Weeks in Hepatitis B E Antigen-Negative Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2013, 18, 57-64.	0.6	18
643	A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. <i>Modern Rheumatology</i> , 0, , 1.	0.9	1
645	Manifestaciones hepáticas de las enfermedades sistémicas no infecciosas. <i>Medicine</i> , 2012, 11, 549-556.	0.0	0
647	Management of treatment failure in chronic hepatitis B. <i>Journal of Hepatology</i> , 2012, 56, S112-S122.	1.8	116
648	Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis?. <i>Lancet</i> , The, 2012, 379, 2019-2021.	6.3	24
649	Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. <i>Journal of Viral Hepatitis</i> , 2012, 19, 724-731.	1.0	26
650	Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2012, 19, 732-743.	1.0	86
651	Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine resistance. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1454-1460.	1.4	5
652	Efficacy and tolerability of pegylated interferon- α 2a in chronic hepatitis B: A multicenter clinical experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1447-1453.	1.4	15
653	Prevention and management of drug resistant hepatitis B virus infections. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1432-1440.	1.4	12
654	Can long term therapy with oral nucleos(t)ide analogs influence the prognosis of chronic hepatitis B-related complications?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1541-1543.	1.4	2
655	Tenofovir Disoproxil Fumarate for Prevention of Vertical Transmission of Hepatitis B Virus Infection by Highly Viremic Pregnant Women: A Case Series. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2423-2429.	1.1	106
656	Selection of chronic hepatitis B therapy with high barrier to resistance. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 341-353.	4.6	127

#	ARTICLE	IF	CITATIONS
657	HBsAg Quantification in Clinical Practice. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 75-80.	0.4	8
658	New therapeutic paradigm for patients with cirrhosis. <i>Hepatology</i> , 2012, 56, 1983-1992.	3.6	108
659	Case report: Detection of a hepatitis B surface antigen variant emerging in an elderly patient after an ischemic cerebral vascular accident. <i>Journal of Medical Virology</i> , 2012, 84, 1897-1900.	2.5	2
660	The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. <i>European Journal of Health Economics</i> , 2012, 13, 663-676.	1.4	24
661	Serum markers for predicting significant necroinflammatory activity in patients with chronic hepatitis B. <i>Clinical Biochemistry</i> , 2012, 45, 1564-1567.	0.8	7
662	Quantification de l'antigène HBs et de ses limites dans le suivi des patients infectés par le virus de l'hépatite B. <i>Immuno-Analyse Et Biologie Spécialisée</i> , 2012, 27, 332-338.	0.0	0
663	Epidemiology of hepatitis D virus (HDV) infection in an urban area of Northern Italy. <i>Infection</i> , 2012, 40, 485-491.	2.3	12
665	Role of molecular diagnostics in the management of viral hepatitis B. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 395-406.	1.6	6
666	Peginterferon 2-a na co-infecção VHB e "VH delta" Um caso de duplo sucesso terapêutico. <i>GE Jornal Português De Gastrenterologia</i> , 2012, 19, 151-155.	0.0	0
667	Tenofovir como 1ª opção terapêutica na hepatite B. <i>GE Jornal Português De Gastrenterologia</i> , 2012, 19, 165-166.	0.0	0
668	Identification and treatment of chronic hepatitis B in Chinese migrants: Results of a project offering on-site testing in Rotterdam, The Netherlands. <i>Journal of Hepatology</i> , 2012, 57, 1171-1176.	1.8	37
669	Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 291-296.	2.4	19
670	Real-time elastography as a noninvasive technique for quantification of fibrosis in patients with chronic viral liver disease: Preliminary findings. <i>Journal of Ultrasound</i> , 2012, 15, 220-225.	0.7	7
671	Incidence and Determinants of Spontaneous Seroclearance of Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 527-534.e2.	2.4	31
672	Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. <i>Modern Rheumatology</i> , 2012, 22, 470-473.	0.9	19
673	Adefovir dipivoxil in chronic hepatitis B: history and current uses. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 245-254.	0.9	19
674	Chapter 9: Infection-related glomerulonephritis. <i>Kidney International Supplements</i> , 2012, 2, 200-208.	4.6	26
675	Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. <i>Clinical and Experimental Medicine</i> , 2012, 12, 159-164.	1.9	44

#	ARTICLE	IF	CITATIONS
676	Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy, 2012, 12, 193-207.	1.4	85
678	Clinical and Virological Response to Entecavir in HBV-Related Chronic Hepatitis or Cirrhosis: Data from the Clinical Practice in a Single-Centre Cohort. Antiviral Therapy, 2013, 18, 87-94.	0.6	8
679	Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. Liver International, 2012, 32, 622-628.	1.9	68
680	Foxp3 regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma. Liver International, 2012, 32, 644-655.	1.9	37
681	Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver International, 2012, 32, 656-664.	1.9	32
682	Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?. Liver International, 2012, 32, 544-553.	1.9	54
683	Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers. Liver International, 2012, 32, 796-802.	1.9	32
684	Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients. Liver International, 2012, 32, 928-936.	1.9	40
685	HBsAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver International, 2012, 32, 1415-1425.	1.9	52
686	Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. Clinical Microbiology and Infection, 2012, 18, E404-E411.	2.8	22
687	Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. Journal of Gastroenterology, 2012, 47, 1022-1029.	2.3	24
688	Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. Journal of Hepatology, 2012, 56, 115-122.	1.8	74
689	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. Journal of Hepatology, 2012, 56, 520-526.	1.8	114
690	Entecavir in the treatment of chronic hepatitis B in kidney transplantation. Journal of Hepatology, 2012, 56, 997-998.	1.8	4
691	Reply to: Entecavir in the treatment of chronic hepatitis B in kidney transplantation. Journal of Hepatology, 2012, 56, 999.	1.8	0
692	Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review. Journal of Hepatology, 2012, 57, 196-202.	1.8	152
693	EASL/EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 908-943.	1.8	5,214
694	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. Journal of Hepatology, 2012, 56, 1006-1011.	1.8	155

#	ARTICLE	IF	CITATIONS
695	Peginterferon- α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. <i>Journal of Hepatology</i> , 2012, 56, 1239-1246.	1.8	75
696	HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years. <i>Journal of Hepatology</i> , 2012, 56, 1254-1258.	1.8	29
697	EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2012, 57, 167-185.	1.8	2,784
698	Focus. <i>Journal of Hepatology</i> , 2012, 56, 1219-1220.	1.8	1
699	Chronic hepatitis B in children and adolescents. <i>Journal of Hepatology</i> , 2012, 57, 885-896.	1.8	72
700	Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. <i>Journal of Infection</i> , 2012, 65, 180-183.	1.7	38
701	HBsAg titers in the different phases of hepatitis B infection in Syrian patients. <i>Journal of Clinical Virology</i> , 2012, 53, 60-64.	1.6	9
702	The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation. <i>Journal of Clinical Virology</i> , 2012, 54, 66-72.	1.6	32
703	Genotype impact on long-term virological outcome of chronic hepatitis B virus infection. <i>Journal of Clinical Virology</i> , 2012, 54, 321-326.	1.6	14
704	EASL/EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 599-641.	1.3	406
705	Current practice of chronic hepatitis B treatment in Southern Italy. <i>European Journal of Internal Medicine</i> , 2012, 23, e124-e127.	1.0	13
707	A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women. <i>Vaccine</i> , 2012, 30, 5335-5340.	1.7	57
708	Preventing Perinatal Transmission of HBV: An Australian Perspective. <i>Current Hepatitis Reports</i> , 2012, 11, 206-212.	0.3	2
709	Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. <i>BMC Health Services Research</i> , 2012, 12, 385.	0.9	11
710	Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model. <i>Virology Journal</i> , 2012, 9, 280.	1.4	12
711	The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. <i>Clinical Transplantation</i> , 2012, 26, E561-9.	0.8	18
712	T-cell responses to hepatitis B splice-generated protein of hepatitis B virus and inflammatory cytokines/chemokines in chronic hepatitis B patients. ANRS study: HB EP 02 HBSP-FIBRO. <i>Journal of Viral Hepatitis</i> , 2012, 19, 872-880.	1.0	20
713	Factors associated with access to antiviral treatment in a multicentre cross-sectional study of patients with chronic hepatitis B in Italy. <i>Journal of Viral Hepatitis</i> , 2012, 19, 881-889.	1.0	16

#	ARTICLE	IF	CITATIONS
714	Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. <i>Journal of Viral Hepatitis</i> , 2012, 19, 890-896.	1.0	15
715	Is Hepatitis Virus Resistance to Antiviral Drugs a Threat?. <i>Gastroenterology</i> , 2012, 142, 1369-1372.	0.6	9
716	Effectiveness of Hepatitis B Treatment in Clinical Practice. <i>Gastroenterology</i> , 2012, 142, 1360-1368.e1.	0.6	131
717	High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load. <i>Gastroenterology</i> , 2012, 142, 1140-1149.e3.	0.6	469
718	Viral Hepatitis in Liver Transplantation. <i>Gastroenterology</i> , 2012, 142, 1373-1383.e1.	0.6	176
719	Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C. <i>Gastroenterology</i> , 2012, 142, 1293-1302.e4.	0.6	533
720	New Virologic Tools for Management of Chronic Hepatitis B and C. <i>Gastroenterology</i> , 2012, 142, 1303-1313.e1.	0.6	109
721	Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Na ⁺ -ve Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 143, 619-628.e1.	0.6	137
722	Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir. <i>Gastroenterology</i> , 2012, 143, 629-636.e1.	0.6	286
723	Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1349-1361.	0.6	40
724	Entecavir treatment of children 2-16 years of age with chronic hepatitis B infection. <i>Arab Journal of Gastroenterology</i> , 2012, 13, 41-44.	0.4	11
725	Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients. <i>Antiviral Research</i> , 2012, 96, 108-114.	1.9	17
726	Reactivation of resolved hepatitis B virus infection after immunosuppression: Is it time to adopt pre-emptive therapy?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 84-93.	0.7	18
727	Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, e89-e92.	0.7	15
729	The risky body mass index ranges for significant hepatitis B viral load: A campus-based study. <i>Obesity Research and Clinical Practice</i> , 2012, 6, e31-e38.	0.8	14
731	Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 156-166.	12.5	148
732	Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 413-421.	1.4	10
733	Interferon-based Therapy for e-antigen Negative Chronic Hepatitis B Virus Infection. <i>Current Hepatitis Reports</i> , 2012, 11, 263-271.	0.3	0

#	ARTICLE	IF	CITATIONS
734	Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 696-706.	1.9	7
735	Efficacy of peginterferon $\hat{\pm}$ -2a and predictors of response in HBeAg-negative, genotype D-naive patients. <i>Hepatology International</i> , 2012, 6, 718-726.	1.9	7
736	Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 357-360.	1.0	26
737	New insight in the pathobiology of hepatitis B virus infection. <i>Gut</i> , 2012, 61, i6-117.	6.1	190
738	Rheumatology meets hepatology in 2012: a clinician's guideline for TNF inhibitors in hepatitis B/C virus carriers. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 391-393.	1.4	5
739	Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1362-1367.	0.6	18
740	Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24. <i>BMC Gastroenterology</i> , 2012, 12, 178.	0.8	5
741	A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers. <i>PLoS ONE</i> , 2012, 7, e32605.	1.1	46
742	Ultra-Deep Pyrosequencing Detects Conserved Genomic Sites and Quantifies Linkage of Drug-Resistant Amino Acid Changes in the Hepatitis B Virus Genome. <i>PLoS ONE</i> , 2012, 7, e37874.	1.1	49
743	Significance of the Balance between Regulatory T (Treg) and T Helper 17 (Th17) Cells during Hepatitis B Virus Related Liver Fibrosis. <i>PLoS ONE</i> , 2012, 7, e39307.	1.1	111
744	Reactivation of Hepatitis B Virus Replication Due to Cytotoxic Therapy: A Five-Year Prospective Study. <i>Tumori</i> , 2012, 98, 220-224.	0.6	5
745	Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt. <i>Annals of Hepatology</i> , 2012, 11, 464-470.	0.6	8
746	Current Trends in Liver Biopsy Indications for Chronic Liver Diseases. , 2012, , .		2
747	Prevention of hepatocellular carcinoma: a concise review of contemporary issues. <i>Annals of Hepatology</i> , 2012, 11, 284-293.	0.6	22
748	Genotype/subgenotype distribution of hepatitis B virus among hemodialysis patients with chronic hepatitis B. <i>Annals of Hepatology</i> , 2012, 11, 849-854.	0.6	11
749	Epidemiological, clinical and laboratory features of chronic hepatitis B infection in a cohort of immigrant and Italian patients from Ferrara, Italy. <i>Annals of Hepatology</i> , 2012, 11, 862-869.	0.6	11
751	Naturally Occurring Polymerase and Surface Gene Variants of Hepatitis B Virus in Turkish Hemodialysis Patients with Chronic Hepatitis B. <i>Japanese Journal of Infectious Diseases</i> , 2012, 65, 495-501.	0.5	8
752	Hepadnaviruses. , 2012, , 464-474.		1

#	ARTICLE	IF	CITATIONS
753	Diagnostic incidence of the presence of positive HBsAg: epidemiologic, clinical, and virological characteristics. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 10-15.	0.1	11
754	Custo-efetividade dos anti-logos de nucleosÃdeos/nucleotÃdeos para hepatite crÃnica B. <i>Revista De Saude Publica</i> , 2012, 46, 942-949.	0.7	6
755	HDag-L variants in covert hepatitis D and HBV occult infection among Amerindians of Argentina: new insights. <i>Journal of Clinical Virology</i> , 2012, 54, 223-228.	1.6	20
756	Case report: Management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. <i>Journal of Medical Virology</i> , 2012, 84, 1340-1343.	2.5	7
757	Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2012, 56, 67-75.	3.6	75
758	Hepatitis B surface antigen quantification: Not what it seems on the surface. <i>Hepatology</i> , 2012, 56, 411-414.	3.6	30
759	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , 2012, 6, 531-561.	1.9	874
760	Management of rheumatic disease with comorbid HBV or HCV infection. <i>Nature Reviews Rheumatology</i> , 2012, 8, 348-357.	3.5	67
761	What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2012, 11, 65-69.	0.3	1
762	Update on the Role of Quantitative HBsAg and HBeAg Monitoring during Peginterferon Therapy. <i>Current Hepatitis Reports</i> , 2012, 11, 75-81.	0.3	0
763	Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management. <i>Current Hepatitis Reports</i> , 2012, 11, 90-94.	0.3	5
764	Management of Patients with Chronic Hepatitis B Before and After Liver Transplantation: An Update. <i>Current Hepatitis Reports</i> , 2012, 11, 102-110.	0.3	0
765	Drugs in Development for the Treatment of Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2012, 11, 111-118.	0.3	4
766	Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2012, 11, 55-64.	0.3	1
767	Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. <i>Annals of Hematology</i> , 2012, 91, 1007-1012.	0.8	80
768	HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 571-574.	1.3	12
769	Ultrastructural and Stereological Study of the Liver in Chronic Mixed HCV+HBV Infection. <i>Bulletin of Experimental Biology and Medicine</i> , 2012, 152, 764-767.	0.3	2
770	Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 306-312.	1.4	37

#	ARTICLE	IF	CITATIONS
771	Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 158-164.	1.4	40
772	Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2012, 19, e41-7.	1.0	11
773	A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East. <i>Journal of Viral Hepatitis</i> , 2012, 19, 9-22.	1.0	37
774	Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2012, 19, e58-65.	1.0	111
775	Immunosuppression, liver injury and post-transplant HCV recurrence. <i>Journal of Viral Hepatitis</i> , 2012, 19, 1-8.	1.0	44
776	Early serum <sc>HBsAg</sc> level as a strong predictor of sustained response to peginterferon alfa-2a in <sc>HBeAg</sc>-negative chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 458-468.	1.9	39
778	Abatacept therapy and safety management. <i>Joint Bone Spine</i> , 2012, 79, 3-84.	0.8	49
779	Treatment of human immunodeficiency virus and hepatitis B virus infections. <i>Haemophilia</i> , 2012, 18, 34-37.	1.0	1
780	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2012, 42, 139-149.	1.8	57
781	Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. <i>Hepatology Research</i> , 2012, 42, 627-636.	1.8	68
782	Undetectable <sc>HBV DNA</sc> at month 12 of entecavir treatment predicts maintained viral suppression and <sc>HB</sc>e<sc>A</sc>g<sc> seroconversion in chronic hepatitis <sc>B</sc> patients at 3 years. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1326-1335.	1.9	48
783	Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1482-1482.	1.9	0
784	Safety and efficacy of <i>two-step</i> peginterferon alfa-2a treatment in patients of chronic hepatitis B with acute exacerbation. <i>Journal of Viral Hepatitis</i> , 2012, 19, 161-172.	1.0	13
785	Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. <i>Journal of Viral Hepatitis</i> , 2012, 19, 213-219.	1.0	39
786	Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2012, 19, 220-226.	1.0	28
787	Renal function during treatment with adefovir plus peginterferon alfa-2a <i>vs</i> either drug alone in hepatitis B/D co-infection. <i>Journal of Viral Hepatitis</i> , 2012, 19, 387-395.	1.0	6
788	First-line treatment of chronic hepatitis B with entecavir or tenofovir in <i>real-life</i> settings: from clinical trials to clinical practice. <i>Journal of Viral Hepatitis</i> , 2012, 19, 377-386.	1.0	109
789	Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy. <i>Transplant Infectious Disease</i> , 2012, 14, 95-98.	0.7	18

#	ARTICLE	IF	CITATIONS
790	Potent hepatitis B surface antigen response to treatment of hepatitis B e antigen-positive chronic hepatitis B with ð±â€interferon plus a nucleos(t)ide analog. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 481-486.	1.4	15
791	Transient elastography in real practice: A time for action?. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1134-1135.	1.4	0
792	Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing. Internal Medicine Journal, 2012, 42, 170-175.	0.5	4
793	A mutation in the interferon regulatory element of HBV may influence the response of interferon treatment in chronic hepatitis B patients. Virology Journal, 2012, 9, 10.	1.4	11
794	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology, 2012, 55, 68-76.	3.6	130
795	Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-resistant chronic hepatitis B. Journal of Medical Virology, 2012, 84, 18-25.	2.5	12
796	Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China. Journal of Medical Virology, 2012, 84, 207-216.	2.5	22
797	Characterization of hepatitis B virus genome variability in Iranian patients with chronic infection, a nationwide study. Journal of Medical Virology, 2012, 84, 414-423.	2.5	21
798	Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance. Journal of Medical Virology, 2012, 84, 424-430.	2.5	16
799	Is There Any Value to Hepatitis B Virus Genotype Analysis?. Current Gastroenterology Reports, 2012, 14, 37-46.	1.1	71
800	Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B. Digestive Diseases and Sciences, 2012, 57, 221-231.	1.1	7
801	A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. Archives of Virology, 2012, 157, 285-290.	0.9	40
802	Hepatitis B serological changes following allogeneic bone marrow transplantation. Transplant Infectious Disease, 2013, 15, 98-103.	0.7	7
803	Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study. Virology Journal, 2013, 10, 87.	1.4	8
804	Efficacy of pegylated interferon ð±2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy. Virology Journal, 2013, 10, 21.	1.4	4
805	Occult Hepatitis B Infection in the Immigrant Population of Sicily, Italy. Journal of Immigrant and Minority Health, 2013, 15, 725-731.	0.8	12
806	Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection, 2013, 41, 225-229.	2.3	39
807	Chronic hepatitis B: What should be the goal for new therapies?. Antiviral Research, 2013, 98, 27-34.	1.9	112

#	ARTICLE	IF	CITATIONS
808	Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for <scp>HB</scp>e<scp>A</scp>gâ€positive chronic hepatitis <scp>B</scp> patients with resistance to adefovir dipivoxil. <i>Journal of Viral Hepatitis</i> , 2013, 20, 40-45.	1.0	9
809	Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection. <i>The Cochrane Library</i> , 2013, , CD009004.	1.5	16
810	Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors. <i>Onkologie</i> , 2013, 36, 295-302.	1.1	29
811	How to improve care in outpatients with cirrhosis and ascites: A new model of care coordination by consultant hepatologists. <i>Journal of Hepatology</i> , 2013, 59, 257-264.	1.8	146
812	Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. <i>BMC Infectious Diseases</i> , 2013, 13, 181.	1.3	190
813	Chronic HBV Carrierâ€™s acceptance of regular surveilling program in China. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2013, 33, 288-292.	1.0	5
814	Decrease in hepatitis B prevalence among blood donors in Central-West Brazil. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2013, 19, 7.	0.8	12
815	Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. <i>Hepatology International</i> , 2013, 7, 429-436.	1.9	104
816	Current management and recommendations on hepatitis B therapy in HIV-coinfected patients. <i>Hepatology International</i> , 2013, 7, 437-442.	1.9	3
817	Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. <i>Hepatology International</i> , 2013, 7, 88-97.	1.9	136
818	Entecavir and interferon-Î± sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2013, 48, 397-404.	2.3	20
819	Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. <i>Hepatology International</i> , 2013, 7, 316-326.	1.9	46
820	HBsAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report. <i>Journal of Infection and Chemotherapy</i> , 2013, 19, 1188-1192.	0.8	2
821	Treatment of children with chronic viral hepatitis: what is available and what is in store. <i>World Journal of Pediatrics</i> , 2013, 9, 212-220.	0.8	5
822	A 10-year human hepatitis B virus nucleic test external quality assessment in China: continual improvement. <i>Clinica Chimica Acta</i> , 2013, 425, 139-147.	0.5	5
823	The Natural Course of Chronic Hepatitis B Virus Infection and Its Management. <i>Advances in Pharmacology</i> , 2013, 67, 247-291.	1.2	21
824	Expert recommendations on the application of interferon for chronic hepatitis <scp>B</scp>. <i>Journal of Digestive Diseases</i> , 2013, 14, 626-637.	0.7	4
825	Prevention of recurrent hepatitis B infection after liver transplantation. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2013, 12, 465-472.	0.6	11

#	ARTICLE	IF	CITATIONS
826	Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: An Indian subcontinent perspective. <i>Antiviral Research</i> , 2013, 98, 209-216.	1.9	7
827	Dissecting the divergent effects of interferon-alpha on immune cells: Time to rethink combination therapy in chronic hepatitis B?. <i>Journal of Hepatology</i> , 2013, 58, 205-209.	1.8	100
828	HBsAg Quantification to Predict Natural History and Treatment Outcome in Chronic Hepatitis B Patients. <i>Clinics in Liver Disease</i> , 2013, 17, 399-412.	1.0	19
829	A complete genomic analysis of hepatitis B virus isolated from 516 Chinese patients with different clinical manifestations. <i>Journal of Medical Virology</i> , 2013, 85, 1698-1704.	2.5	15
830	Hepatitis B antivirals and resistance. <i>Current Opinion in Virology</i> , 2013, 3, 495-500.	2.6	30
831	HIV/HBV coinfection: Serological control and therapeutic strategies. <i>Revista Colombiana de Medicina y Salud Pública</i> , 2013, 213, 285-290.	0.3	0
832	Strategic use of lamivudine in the management of chronic hepatitis B. <i>Antiviral Research</i> , 2013, 100, 435-438.	1.9	15
833	Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. <i>Journal of Clinical Virology</i> , 2013, 58, 713-717.	1.6	50
834	Biomarkers of Liver Fibrosis. <i>Advances in Clinical Chemistry</i> , 2013, 62, 33-122.	1.8	6
835	Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. <i>Journal of Viral Hepatitis</i> , 2013, 20, e3-10.	1.0	61
836	Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. <i>Journal of Infection</i> , 2013, 67, 322-328.	1.7	26
837	Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 12-27.	2.0	19
838	Performance evaluation of ExiStation HBV diagnostic system for hepatitis B virus DNA quantitation. <i>Journal of Virological Methods</i> , 2013, 193, 492-497.	1.0	1
839	Health-related quality of life and survival in Chinese patients with chronic liver disease. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 131.	1.0	25
840	Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. <i>BMC Cancer</i> , 2013, 13, 534.	1.1	32
841	Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues. <i>Journal of Viral Hepatitis</i> , 2013, 20, 322-327.	1.0	8
842	Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B. <i>Pharmacoeconomics</i> , 2013, 31, 63-75.	1.7	15
843	Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B. <i>Journal of Clinical Oncology</i> , 2013, 31, 2765-2772.	0.8	292

#	ARTICLE	IF	CITATIONS
844	Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2013, 20, 58-64.	1.0	7
845	Hepatitis B vaccines. , 2013, , 205-234.		13
846	Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B. <i>Hepatology Research</i> , 2013, 43, 219-227.	1.8	8
847	Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters. <i>Hepatology Research</i> , 2013, 43, 441-451.	1.8	22
848	Occult HBV infection. <i>Seminars in Immunopathology</i> , 2013, 35, 39-52.	2.8	190
849	Experimental models and therapeutic approaches for HBV. <i>Seminars in Immunopathology</i> , 2013, 35, 7-21.	2.8	34
851	Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: Clonal evolution during lamivudine plus adefovir therapy. <i>Journal of Medical Virology</i> , 2013, 85, 55-64.	2.5	19
852	Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 46-50.	1.4	25
853	Effect of diammonium glycyrrhizinate on entecavir pharmacokinetics in rats. <i>Chinese Journal of Natural Medicines</i> , 2013, 11, 309-313.	0.7	3
854	Comparison of the Efficacy of Lamivudine Plus Adefovir Versus Entecavir in the Treatment of Lamivudine-Resistant Chronic Hepatitis B: A Systematic Review and Meta-Analysis. <i>Clinical Therapeutics</i> , 2013, 35, 1997-2006.	1.1	17
855	Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy. <i>Journal of Hepatology</i> , 2013, 58, 217-224.	1.8	28
856	Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: A retrospective study. <i>European Journal of Surgical Oncology</i> , 2013, 39, 865-872.	0.5	55
857	Response and seroconversion rates among HBeAg-positive chronic HBV Egyptian patients treated with peginterferon alpha 2a (Pegasys), a single-centre experience. <i>Arab Journal of Gastroenterology</i> , 2013, 14, 73-77.	0.4	1
858	Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis. <i>Journal of Hepatology</i> , 2013, 58, 427-433.	1.8	124
859	Hepatitis B in HIV-Infected Patients. <i>Clinics in Liver Disease</i> , 2013, 17, 489-501.	1.0	24
860	Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. <i>Journal of Hepatology</i> , 2013, 58, 225-233.	1.8	202
861	Treatment of Patients with HBV-related Decompensated Cirrhosis and Liver Transplanted Patients. <i>Clinics in Liver Disease</i> , 2013, 17, 451-473.	1.0	14
862	Peginterferon therapy for chronic hepatitis B: one size fits all?. <i>Gut</i> , 2013, 62, 185-187.	6.1	7

#	ARTICLE	IF	CITATIONS
863	A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. <i>Value in Health Regional Issues</i> , 2013, 2, 48-56.	0.5	10
864	ECCHS1 acts as a novel HBsAg-binding protein enhancing apoptosis through the mitochondrial pathway in HepG2 cells. <i>Cancer Letters</i> , 2013, 330, 67-73.	3.2	33
865	Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants. <i>Antiviral Research</i> , 2013, 97, 312-317.	1.9	16
866	Serum proteomic MRM identify peptide ions of transferrin as new fibrosis markers in chronic hepatitis B. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 561-567.	2.5	8
868	The effect of HLA-DQB1 alleles on virologic breakthroughs during chronic hepatitis B treatment with genetically low barrier drugs. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 359-364.	0.7	5
869	Hepatitis B 360: Transplantation Proceedings, 2013, 45, 982-985.	0.3	16
870	Coinfección por VIH/VHB: estrategias terapéuticas y control serológico. <i>Revista Clínica Española</i> , 2013, 213, 285-290.	0.2	2
871	Treatment Options for Hepatitis Delta Virus Infection. <i>Current Infectious Disease Reports</i> , 2013, 15, 31-38.	1.3	68
872	Precore and basal core promoter mutations in Asian American patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 464-472.	1.9	8
873	Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains. <i>Journal of Viral Hepatitis</i> , 2013, 20, 141-148.	1.0	9
874	Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2013, 33, 180-189.	1.9	28
875	Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?. <i>Liver International</i> , 2013, 33, 151-156.	1.9	15
876	Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. <i>Liver International</i> , 2013, 33, 137-150.	1.9	43
877	A Meta-Analysis of Nucleos(t)ide Analogues in Patients with Decompensated Cirrhosis Due to Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2013, 58, 815-823.	1.1	7
878	Hepatitis B virus: from immunobiology to immunotherapy. <i>Clinical Science</i> , 2013, 124, 77-85.	1.8	25
879	IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. <i>Hepatology</i> , 2013, 57, 890-896.	3.6	153
880	Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2013, 45, 600-605.	0.4	15
881	A comparison of clevudine and entecavir for treatment-naïve patients with chronic hepatitis B: results after 2 years of treatment. <i>Hepatology International</i> , 2013, 7, 106-110.	1.9	4

#	ARTICLE	IF	CITATIONS
882	Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 11-18.	1.3	15
883	Randomised study comparing 48 and 96 weeks peginterferon $\hat{\pm}$ -2a therapy in genotype D HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2013, 62, 290-298.	6.1	105
884	Prediction models of long-term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles. <i>Hepatology</i> , 2013, 58, 546-554.	3.6	271
885	Quantification of hepatitis <scp>B</scp> surface antigen and <scp>E</scp> antigen: correlation between Elecsys and Architect assays. <i>Journal of Viral Hepatitis</i> , 2013, 20, 422-429.	1.0	10
886	Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 167-172.	1.1	16
887	Prescription pattern for antivirals in the treatment of chronic hepatitis B: the EUPTHEA Study. <i>European Journal of Hospital Pharmacy</i> , 2013, 20, 174-179.	0.5	2
888	The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients. <i>BMJ Open</i> , 2013, 3, e001309.	0.8	3
889	Influencing Factors on the Outcome and Prognosis of Patients With HBV Infection: Seven Years Follow-up. <i>Hepatitis Monthly</i> , 2013, 13, e8743.	0.1	10
890	Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study. <i>Hepatitis Monthly</i> , 2013, 13, e7862.	0.1	16
891	Occult Hepatitis B: Clinical Viewpoint and Management. <i>Hepatitis Research and Treatment</i> , 2013, 2013, 1-7.	2.0	21
892	Modeling and Simulating Dynamics of Complete- and Poor-Response Chronic Hepatitis B Chinese Patients for Adefovir and Traditional Chinese Medicine Plus Adefovir Therapy. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-12.	0.5	6
893	Prevalence of Occult Hepatitis B Virus in Plasma and Peripheral Blood Mononuclear Cell Compartments of Patients With Chronic Hepatitis C Infection in Tehran-Iran. <i>Hepatitis Monthly</i> , 2013, 13, e10134.	0.1	19
894	Reactivation of Hepatitis B Virus in Patients Receiving Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 8-16.	0.6	22
895	The Diversity and Management of Chronic Hepatitis B Virus Infections in the United Kingdom: A Wake-up Call. <i>Clinical Infectious Diseases</i> , 2013, 56, 951-960.	2.9	35
896	Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: A clinical study. <i>Journal of International Medical Research</i> , 2013, 41, 1732-1739.	0.4	9
897	Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. <i>World Journal of Gastroenterology</i> , 2013, 19, 7671.	1.4	6
898	Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 745-751.	0.6	7
899	Peginterferon- $\hat{\pm}$ 2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1.	0.8	7

#	ARTICLE	IF	CITATIONS
900	Interferon-α plus adefovir combination therapy versus interferon-α monotherapy for chronic hepatitis B treatment: A meta-analysis. <i>Hepatology Research</i> , 2013, 43, 1040-1051.	1.8	17
901	Two Classifiers Based on Serum Peptide Pattern for Prediction of HBV-Induced Liver Cirrhosis Using MALDI-TOF MS. <i>BioMed Research International</i> , 2013, 2013, 1-7.	0.9	8
902	Costs of Treatment, Follow-Up, and Complications of Chronic Hepatitis B and Hepatitis C Infections. <i>Balkan Medical Journal</i> , 2013, 30, 375-381.	0.3	6
903	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2332-8.	1.3	17
904	HBVdb: a knowledge database for Hepatitis B Virus. <i>Nucleic Acids Research</i> , 2013, 41, D566-D570.	6.5	178
905	Elevation in Serum Concentration of Bone-Specific Alkaline Phosphatase without Elevation in Serum Creatinine Concentration Secondary to Adefovir Dipivoxil Therapy in Chronic Hepatitis B Virus Infection. <i>Hepatitis Research and Treatment</i> , 2013, 2013, 1-9.	2.0	0
906	Molecular Mechanisms of HBV-Associated Hepatocarcinogenesis. <i>Seminars in Liver Disease</i> , 2013, 33, 147-156.	1.8	96
907	Antiviral treatment for hepatitis B virus recurrence following liver transplantation. <i>Clinical Transplantation</i> , 2013, 27, E597-604.	0.8	9
908	Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B eAg negative and genotype D. <i>Liver International</i> , 2013, 33, 580-585.	1.9	40
910	Sequential therapy with entecavir and PEG-IFN in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. <i>Journal of Viral Hepatitis</i> , 2013, 20, e11-9.	1.0	34
911	Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 321-326.	0.7	24
912	Long-term outcome of hepatitis B virus-related chronic hepatitis under protracted nucleos(t)ide analogues. <i>Journal of Viral Hepatitis</i> , 2013, 20, 502-509.	1.0	16
913	Extended treatment with peginterferon α2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion. <i>Journal of Digestive Diseases</i> , 2013, 14, 446-450.	0.7	28
914	Letter: first-line monotherapies for chronic hepatitis B – indirect comparison between entecavir and tenofovir. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 584-585.	1.9	1
915	Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels. <i>Journal of Viral Hepatitis</i> , 2013, 20, 328-335.	1.0	14
916	Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. <i>Liver Transplantation</i> , 2013, 19, 594-601.	1.3	83
917	Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study. <i>Journal of Viral Hepatitis</i> , 2013, 20, 52-57.	1.0	8
918	Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil. <i>Journal of Viral Hepatitis</i> , 2013, 20, 46-51.	1.0	2

#	ARTICLE	IF	CITATIONS
919	The correlation between T helper type 17 cells and clinical characters in Chinese paediatric patients with chronic hepatitis B. <i>Clinical and Experimental Immunology</i> , 2013, 171, 307-312.	1.1	6
920	Targeted case finding for hepatitis B using dry blood spot testing in the British Chinese and South Asian populations of the North East of England. <i>Journal of Viral Hepatitis</i> , 2013, 20, 638-644.	1.0	28
921	Uncovering the Experiences and Needs of Patients With Chronic Hepatitis B Infection at Diagnosis. <i>Asia-Pacific Journal of Public Health</i> , 2013, 25, 32-40.	0.4	36
922	Infliximab and occult Hepatitis B infection: to treat or not to treat?. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 377-378.	0.9	1
923	PWE-144 Score in the Assessment of Bone Mineral Density Changes in Tenofovir Treated Chronic Hepatitis B Patients. <i>Gut</i> , 2013, 62, A190.1-A190.	6.1	0
924	PWE-145 Restrospective Review of Hepatitis B Database. <i>Gut</i> , 2013, 62, A190.2-A190.	6.1	0
925	PWE-146 Relaxin Is a Renal Vasodilator in Experimental Models of Cirrhosis and A Potential Novel Therapy for Hepatorenal Syndrome in Humans. <i>Gut</i> , 2013, 62, A190.3-A191.	6.1	0
926	Chronic Hepatitis B Treatment Initiation and Modification Patterns in Five European Countries: A 2-Year Longitudinal, Non-Interventional Study. <i>Antiviral Therapy</i> , 2014, 19, 235-243.	0.6	8
927	Chronic Hepatitis B Monitoring and Treatment Patterns in Five European Countries with Different Access and Reimbursement Policies. <i>Antiviral Therapy</i> , 2014, 19, 245-257.	0.6	20
928	Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 814-819.	0.8	14
929	Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient. <i>Journal of Medical Virology</i> , 2013, 85, 597-601.	2.5	30
930	Predominance of precore mutations and clinical significance of basal core promoter mutations in chronic hepatitis B virus infection in Indonesia. <i>Biomedical Reports</i> , 2013, 1, 522-528.	0.9	15
931	Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009-2010. <i>Hepatology</i> , 2013, 58, 856-862.	3.6	60
932	Posthepatectomy HBV Reactivation in Hepatitis B-Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA Levels. <i>Annals of Surgery</i> , 2013, 257, 490-505.	2.1	104
933	Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naive Chronic Hepatitis B Patients in Real Life. <i>International Journal of Medical Sciences</i> , 2013, 10, 427-433.	1.1	55
934	Tenofovir-Associated Fanconi Syndrome in Patients with Chronic Hepatitis B Mono-infection. <i>Antiviral Therapy</i> , 2013, 18, 945-948.	0.6	66
935	Tumor necrosis factor- α inhibitors and chronic hepatitis C: A comprehensive literature review. <i>World Journal of Gastroenterology</i> , 2013, 19, 7867.	1.4	90
936	Hepatitis B virus reactivation with rituximab-containing regimen. <i>World Journal of Hepatology</i> , 2013, 5, 612.	0.8	27

#	ARTICLE	IF	CITATIONS
937	Monotherapy versus combinations of nucleos(t)ide in treatment-naive hepatitis B decompensated cirrhotic patients: A nested case-control study. <i>African Journal of Pharmacy and Pharmacology</i> , 2013, 7, 2264-2272.	0.2	0
938	Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. <i>OncoTargets and Therapy</i> , 2013, 6, 1463.	1.0	22
939	Antivirais incorporados no Brasil para hepatite B crônica: análise de custo-efetividade. <i>Revista De Saude Publica</i> , 2013, 47, 769-780.	0.7	4
940	52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBsAg-Positive Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e54279.	1.1	34
941	RDW to Platelet Ratio: A Novel Noninvasive Index for Predicting Hepatic Fibrosis and Cirrhosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e68780.	1.1	125
942	Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-5.	3.3	15
943	Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. <i>Annals of Hepatology</i> , 2013, 12, 205-212.	0.6	27
944	Hepatitis B virus part 2: treatment options and the role of the specialist nurse. <i>Gastrointestinal Nursing</i> , 2013, 11, 33-40.	0.0	0
945	Woodhead Publishing Series in Biomaterials. , 2013, , xvi-xix.		0
946	Role of Anti-Viral Therapy on Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC). , 0, , .		0
947	The Skin and Viral Liver Disease. , 2013, , .		0
948	Treatment of Rheumatoid Arthritis Patients with Chronic Hepatitis B: Analysis of Korean National Health Insurance Claims Data. <i>Journal of Rheumatic Diseases</i> , 2013, 20, 24.	0.4	1
949	Influence of chronic HBV infection on superimposed acute hepatitis E. <i>World Journal of Gastroenterology</i> , 2013, 19, 5904.	1.4	41
950	Clinical utility of hepatitis B surface antigen levels during the natural history and treatment of chronic hepatitis B infection. <i>Przegląd Gastroenterologiczny</i> , 2014, 3, 164-167.	0.3	3
951	Comparison of Efficacy and Safety of Tenofovir and Entecavir in Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e98865.	1.1	56
952	One Year of Hepatitis B Immunoglobulin Plus Tenofovir Therapy is Safe and Effective in Preventing Recurrent Hepatitis B Infection Post-Liver Transplantation. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 41-44.	0.8	29
953	MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: Current status and future prospects. <i>World Journal of Gastroenterology</i> , 2014, 20, 5973.	1.4	11
954	Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. <i>World Journal of Gastroenterology</i> , 2014, 20, 7635.	1.4	96

#	ARTICLE	IF	CITATIONS
955	Management of patients with hepatitis B and C before and after liver and kidney transplantation. <i>World Journal of Hepatology</i> , 2014, 6, 315.	0.8	11
956	Process of instrument sterilization in shops with manicure and pedicure services. <i>ACTA Paulista De Enfermagem</i> , 2014, 27, 18-22.	0.1	2
958	Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. <i>Annals of Hepatology</i> , 2014, 13, 762-770.	0.6	27
959	Entecavir for chronic hepatitis B. <i>The Cochrane Library</i> , 2014, , .	1.5	6
960	Hepatitis B and D. , 2014, , 41-57.		1
962	Use of Anti-Tumor Necrosis Factor Alpha Therapy in Patients with Concurrent Rheumatoid Arthritis and Hepatitis B or Hepatitis C: A Retrospective Analysis of 32 Patients. <i>Drug Development Research</i> , 2014, 75, S42-S45.	1.4	25
963	Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 438.	0.7	29
964	Hepatitis B virus genotype B and mutations in basal core promoter and pre-core/core genes associated with acute-on-chronic liver failure: a multicenter cross-sectional study in China. <i>Hepatology International</i> , 2014, 8, 508-516.	1.9	18
965	Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Infectious Diseases and Therapy</i> , 2014, 3, 191-202.	1.8	7
966	Antiviral efficacy of adefovir dipivoxil in the treatment of chronic hepatitis B subjects from Indian subcontinent. <i>Indian Journal of Medical Microbiology</i> , 2014, 32, 60-63.	0.3	2
967	Impact of HBV therapy on the incidence of hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 139-145.	1.9	31
968	Increased levels of IL-21 responses are associated with the severity of liver injury in patients with chronic active hepatitis B. <i>Journal of Viral Hepatitis</i> , 2014, 21, e78-88.	1.0	10
969	Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 430-438.	1.0	37
970	Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 514-523.	0.9	6
971	Correlation of MR elastography with morphometric quantification of liver fibrosis (Fibro-C-Index) in chronic hepatitis B. <i>Magnetic Resonance in Medicine</i> , 2014, 72, 1123-1129.	1.9	35
972	Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: Analysis of 1301 patients from an endemic area in China. <i>Cancer</i> , 2014, 120, 68-76.	2.0	36
973	A functional polymorphism in ADAR1 gene affects HBsAg seroclearance both spontaneously and interferon induced. <i>Liver International</i> , 2014, 34, 1560-1565.	1.9	14
974	Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B. <i>Journal of Medical Virology</i> , 2014, 86, 1705-1713.	2.5	26

#	ARTICLE	IF	CITATIONS
975	<scp>HB</scp>eAgâ€positive chronic hepatitis B: why do I treat my patients with pegylated interferon?. Liver International, 2014, 34, 112-119.	1.9	43
976	Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT). Infection, 2014, 42, 811-815.	2.3	9
977	A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Modern Rheumatology, 2014, 24, 1-7.	0.9	28
978	Chronic Hepatitis B and Liver Cancer Risks among Asian Immigrants in New York City: Results from a Large, Community-Based Screening, Evaluation, and Treatment Program. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2229-2239.	1.1	41
979	Risk Assessment of Liver-related Events Using Transient Elastography in Patients With Chronic Hepatitis B Receiving Entecavir. Journal of Clinical Gastroenterology, 2014, 48, 272-278.	1.1	24
980	Current Treatment Guidelines for Chronic Hepatitis B and Their Applications. Journal of Clinical Gastroenterology, 2014, 48, 773-783.	1.1	11
981	Comparison of telbivudine efficacy in treatment-naïve patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks. European Journal of Gastroenterology and Hepatology, 2014, 26, 396-403.	0.8	5
982	Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents. Current Opinion in Rheumatology, 2014, 26, 395-403.	2.0	7
983	Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patients. United European Gastroenterology Journal, 2014, 2, 99-107.	1.6	10
984	Telbivudine Versus Entecavir for Nucleos(t)ide-Naïve HBeAg-Positive Chronic Hepatitis B: A Meta-analysis. American Journal of the Medical Sciences, 2014, 347, 131-138.	0.4	11
986	Prior Exposure to Lamivudine Increases Entecavir Resistance Risk in Chronic Hepatitis B Patients without Detectable Lamivudine Resistance. Antimicrobial Agents and Chemotherapy, 2014, 58, 1730-1737.	1.4	28
987	Clinical Implications of Evolutionary Patterns of Homologous, Full-Length Hepatitis B Virus Quasispecies in Different Hosts after Perinatal Infection. Journal of Clinical Microbiology, 2014, 52, 1556-1565.	1.8	11
988	SASLT practice guidelines for the management of hepatitis B virus. Saudi Journal of Gastroenterology, 2014, 20, 5.	0.5	27
989	Correlation between hepatitis B surface antigen titers and HBV DNA levels: What about the parameters affecting this correlation?. Saudi Journal of Gastroenterology, 2014, 20, 74.	0.5	2
990	HBV-Associated Cryoglobulinemic Vasculitis: Remission after Antiviral Therapy with Entecavir. Kidney and Blood Pressure Research, 2014, 39, 65-73.	0.9	23
991	Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiology and Infection, 2014, 142, 270-286.	1.0	161
992	Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology, 2014, 59, 2092-2100.	3.6	235
995	Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Antiviral Research, 2014, 102, 35-43.	1.9	34

#	ARTICLE	IF	CITATIONS
996	Effect and mechanisms of curdlan sulfate on inhibiting HBV infection and acting as an HB vaccine adjuvant. <i>Carbohydrate Polymers</i> , 2014, 110, 446-455.	5.1	42
997	From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 178-186.	0.6	61
998	Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 97-104.	0.3	12
999	Similar Response to Entecavir 0.5 and 1.0 Mg in Treatment-Naïve Chronic Hepatitis B Patients: A Case-Control Study. <i>Digestive Diseases and Sciences</i> , 2014, 59, 168-173.	1.1	7
1000	Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. <i>European Radiology</i> , 2014, 24, 70-78.	2.3	147
1001	Intrahepatic interleukin-17 ⁺ T cells and FoxP3 ⁺ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 851-859.	1.4	38
1002	A review of non-nucleoside anti-hepatitis B virus agents. <i>European Journal of Medicinal Chemistry</i> , 2014, 75, 267-281.	2.6	31
1003	HBsAg quantification: useful for monitoring natural history and treatment outcome. <i>Liver International</i> , 2014, 34, 97-107.	1.9	93
1004	Does Anti-HBV Therapy Benefit the Prognosis of HBV-Related Hepatocellular Carcinoma Following Hepatectomy?. <i>Annals of Surgical Oncology</i> , 2014, 21, 1010-1015.	0.7	15
1005	IFN- alpha blocks IL-17 production by peripheral blood mononuclear cells in patients with chronic active hepatitis B Infection. <i>BMC Infectious Diseases</i> , 2014, 14, 55.	1.3	7
1006	Hepatitis B Reactivation and Rituximab: A New Boxed Warning and Considerations for Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2014, 14, 788-796.	2.6	30
1007	Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B antigen seropositive chronic hepatitis B patients. <i>Hepatology Research</i> , 2014, 44, 1000-1007.	1.8	30
1008	Relationship Between Level of Hepatitis B Virus DNA and Liver Disease: A Population-based Study of Hepatitis B e Antigen-Negative Persons With Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 701-706.e3.	2.4	23
1009	Clinical implications of the titer of serum hepatitis B surface antigen during the natural history of hepatitis B virus infection. <i>Journal of Medical Virology</i> , 2014, 86, 117-123.	2.5	11
1010	Ultradeep Pyrosequencing and Molecular Modeling Identify Key Structural Features of Hepatitis B Virus RNase H, a Putative Target for Antiviral Intervention. <i>Journal of Virology</i> , 2014, 88, 574-582.	1.5	10
1011	Association of serum soluble human leukocyte antigen-G levels with chronic hepatitis B virus infection. <i>Clinical and Experimental Medicine</i> , 2014, 14, 35-43.	1.9	20
1012	Performance of LigAmp Assay for Sensitive Detection of Drug-Resistant Hepatitis B Virus Minor Variants in Comparison with Standard Nucleotide Sequencing. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 655-663.	1.6	0
1013	Management of chronic hepatitis B in children: An unresolved issue. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 912-919.	1.4	32

#	ARTICLE	IF	CITATIONS
1015	Prevention of Hepatitis B Virus Reinfection in Liver Transplant Recipients. <i>Intervirolgy</i> , 2014, 57, 196-201.	1.2	21
1016	Long-Term Efficacy of Entecavir Plus Adefovir Combination Therapy versus Entecavir Monotherapy in Adefovir Refractory Chronic Hepatitis B Patients with Prior Lamivudine Resistance. <i>Intervirolgy</i> , 2014, 57, 8-16.	1.2	8
1017	Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. <i>Liver International</i> , 2014, 34, 1216-1223.	1.9	32
1018	Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients. <i>Journal of Clinical Virology</i> , 2014, 61, 199-203.	1.6	6
1019	Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBsAg loss. <i>Journal of Viral Hepatitis</i> , 2014, 21, 909-916.	1.0	16
1020	A rational study for identification of highly effective siRNAs against hepatitis B virus. <i>Experimental and Molecular Pathology</i> , 2014, 97, 120-127.	0.9	6
1021	A drug safety evaluation of rituximab and risk of hepatitis B. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 977-987.	1.0	16
1022	Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. <i>Hepatology International</i> , 2014, 8, 382-394.	1.9	9
1023	Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B. <i>BMC Gastroenterology</i> , 2014, 14, 145.	0.8	31
1024	Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. <i>BMC Infectious Diseases</i> , 2014, 14, 439.	1.3	40
1025	Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 223-240.	1.4	82
1026	Chinese medicine syndrome distribution of chronic hepatitis b virus carriers in immunotolerant phase. <i>Chinese Journal of Integrative Medicine</i> , 2014, 20, 94-100.	0.7	5
1027	Comparison of hepatitis B surface antigen and e antigen in predicting liver histology in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Hepatology International</i> , 2014, 8, 216-223.	1.9	7
1028	Lamivudine Monotherapy in Chronic Hepatitis B Patients from the Indian Subcontinent: Antiviral Resistance Mutations and Predictive Factors of Treatment Response. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 63-71.	1.6	4
1029	A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. <i>BMC Health Services Research</i> , 2014, 14, 170.	0.9	10
1030	Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. <i>Gut</i> , 2014, 63, 1943-1950.	6.1	149
1031	Could Droplet Digital PCR Be Used Instead of Real-Time PCR for Quantitative Detection of the Hepatitis B Virus Genome in Plasma?. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3497-3498.	1.8	18
1032	Evaluation of hepatitis delta virus (HDV) infection in blood donors in western Turkey. <i>Transfusion and Apheresis Science</i> , 2014, 50, 388-391.	0.5	9

#	ARTICLE	IF	CITATIONS
1033	N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. <i>Journal of Hepatology</i> , 2014, 60, 515-522.	1.8	77
1034	Comparisons of presentations and outcomes of cryptococcal meningitis between patients with and without hepatitis B virus infection. <i>International Journal of Infectious Diseases</i> , 2014, 20, 31-36.	1.5	18
1035	Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1337-1349.	0.9	23
1036	Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study. <i>Arab Journal of Gastroenterology</i> , 2014, 15, 1-5.	0.4	3
1037	Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 786-793.	0.8	10
1038	Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound <i>Phyllanthus Urinaria L.</i> <i>Chinese Journal of Integrative Medicine</i> , 2014, 20, 263-271.	0.7	12
1039	Successful Treatment with Entecavir for Reactivation of Hepatitis B Virus Following Systemic Chemotherapy in a Hepatitis B Surface Antigen-negative Patient with Colorectal Cancer. <i>Internal Medicine</i> , 2014, 53, 1759-1762.	0.3	10
1040	Treatment of pegylated-interferon alfa-2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation. <i>Antiviral Therapy</i> , 2014, 20, 217-224.	0.6	1
1041	Efficacy of tenofovir in adefovir-experienced patients compared to treatment-naive patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2014, 19, 543-550.	0.6	11
1042	Occult hepatitis B virus infection. <i>World Journal of Hepatology</i> , 2014, 6, 860.	0.8	81
1043	Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. <i>World Journal of Hepatology</i> , 2014, 6, 384.	0.8	51
1044	PREGNANCY ASSOCIATED HEPATOBILIARY DYSFUNCTION. <i>Fetal and Maternal Medicine Review</i> , 2014, 25, 318-331.	0.3	0
1045	Correlation between the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in the resistance to interferon treatment. <i>Virology Journal</i> , 2014, 11, 51.	1.4	14
1046	Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti-viral treatment. <i>Molecular Medicine Reports</i> , 2014, 9, 1135-1141.	1.1	8
1048	The Reactivation of Occult HBV Infection Emerging with the Case of Acute Hepatitis B in the Wife of a Subject Treated with Rituximab-Based Chemotherapy. <i>Antiviral Therapy</i> , 2015, 20, 349-352.	0.6	5
1049	Approach and Management of Patients with Chronic Hepatitis B and C During the Course of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2142-2150.	0.9	5
1050	Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: post-treatment 1-year results of three Turkish centres. <i>Journal of Chemotherapy</i> , 2014, 26, 339-341.	0.7	3
1051	Preserved Function of Circulating Invariant Natural Killer T Cells in Patients With Chronic Hepatitis B Virus Infection. <i>Medicine (United States)</i> , 2015, 94, e961.	0.4	6

#	ARTICLE	IF	CITATIONS
1052	Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation. <i>Transplantation</i> , 2015, 99, 1321-1334.	0.5	50
1053	Hepatitis B e Antigen and Hepatitis B Surface Antigen Seroclearance with the Emergence of Lamivudine-associated and Core Mutations Following CD4 Elevation in a Patient with Hepatitis B and HIV. <i>Internal Medicine</i> , 2015, 54, 585-590.	0.3	2
1054	Serum HBsAg and HBeAg levels are associated with liver pathological stages in the immune clearance phase of hepatitis B virus chronic infection. <i>Molecular Medicine Reports</i> , 2015, 11, 3465-3472.	1.1	20
1055	Efficacy of Tenofovir Disoproxil Fumarate to Prevent Vertical Transmission in Mothers with Lamivudine-Resistant HBV. <i>Antiviral Therapy</i> , 2015, 20, 681-687.	0.6	21
1056	Naturally occurring deletions/insertions in HBV core promoter tend to decrease in HBeAg-positive chronic hepatitis B patients during antiviral therapy. <i>Antiviral Therapy</i> , 2015, 20, 623-632.	0.6	14
1057	Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. <i>Advances in Therapy</i> , 2015, 32, 727-741.	1.3	19
1058	Leczenie chorych z chłoniakami i wspólnie istniejącym zakażeniem wirusami HCV, HBV lub HIV. <i>Acta Haematologica Polonica</i> , 2015, 46, 86-93.	0.1	0
1059	Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. <i>Transplant Infectious Disease</i> , 2015, 17, 695-701.	0.7	43
1060	Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 2187-2193.	1.9	2
1061	Evaluation of hepatitis B virus transmission and antiviral therapy among hepatitis B surface antigen-positive pregnant women. <i>Journal of Obstetrics and Gynaecology Research</i> , 2015, 41, 1870-1876.	0.6	9
1062	Screening and treatment of hepatitis B virus to prevent liver cancer in Africa. <i>Hepatic Oncology</i> , 2015, 2, 105-109.	4.2	0
1063	Neutrophil-to-lymphocyte ratio as a predictor of fibrosis in inactive hepatitis B carriers. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 475-476.	0.8	1
1064	Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 877-881.	0.8	31
1065	Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2839.	2.0	4
1066	Evaluation of a Rapid One-step Real-time PCR Method as a High-throughput Screening for Quantification of Hepatitis B Virus DNA in a Resource-limited Setting. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2015, 5, 11-15.	0.1	3
1067	Hepatic necroinflammation and severe liver fibrosis in patients with chronic hepatitis B with undetectable HBV DNA and persistently normal alanine aminotransferase. <i>Bangladesh Medical Research Council Bulletin</i> , 2015, 40, 92-96.	0.1	12
1068	Hepatitis B virus reactivation with a rituximab-containing regimen. <i>World Journal of Hepatology</i> , 2015, 7, 2344.	0.8	63
1069	Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 7869.	1.4	23

#	ARTICLE	IF	CITATIONS
1070	Hepatitis B Virus Genotype Distribution and Genotype-Specific BCP/preCore Substitutions in Acute and Chronic Infections in Argentina. PLoS ONE, 2015, 10, e0121436.	1.1	25
1071	The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis. PLoS ONE, 2015, 10, e0132219.	1.1	13
1072	Complex Genotype Mixtures Analyzed by Deep Sequencing in Two Different Regions of Hepatitis B Virus. PLoS ONE, 2015, 10, e0144816.	1.1	9
1073	The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis. Annals of Hepatology, 2015, 14, 150-160.	0.6	14
1074	Viral hepatitis prevalence in patients with active and latent tuberculosis. World Journal of Gastroenterology, 2015, 21, 8920.	1.4	20
1076	Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression. Molecular Medicine Reports, 2015, 12, 1584-1590.	1.1	30
1077	Safety issues and concerns of new immunomodulators in rheumatology. Expert Opinion on Drug Safety, 2015, 14, 389-399.	1.0	34
1078	High rate of core promoter and precore mutations in patients with chronic hepatitis B. Hepatology International, 2015, 9, 209-217.	1.9	8
1079	Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. Hepatology Research, 2015, 45, 1220-1227.	1.8	14
1080	Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy. International Journal of Surgery, 2015, 15, 1-5.	1.1	15
1081	Clinical course of chronic hepatitis B (<scp>CHB</scp>) presented with normal <scp>ALT</scp> in Asian American patients. Journal of Viral Hepatitis, 2015, 22, 809-816.	1.0	9
1082	Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg?. Hepatology, 2015, 61, 703-711.	3.6	192
1084	Hepatitis B surface antigen in late hepatitis B infection. Journal of Medical Virology, 2015, 87, 380-387.	2.5	3
1085	The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection. Journal of Medical Virology, 2015, 87, 575-582.	2.5	14
1086	Prevention of Post-transplant HBV. Current Hepatology Reports, 2015, 14, 153-163.	0.4	0
1087	Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues. Expert Opinion on Drug Safety, 2015, 14, 1353-1371.	1.0	6
1088	The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks. Indian Journal of Medical Microbiology, 2015, 33, S20-S25.	0.3	3
1089	Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. Antiviral Research, 2015, 121, 47-58.	1.9	216

#	ARTICLE	IF	CITATIONS
1090	Intracellular levels of hepatitis B virus DNA and mutational patterns of the polymerase gene of hepatitis B virus in peripheral blood mononuclear cells of patients with lamivudine or telbivudine resistance. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 885-890.	0.8	1
1091	Trends in the management and burden of alcoholic liver disease. <i>Journal of Hepatology</i> , 2015, 62, S38-S46.	1.8	254
1092	Universal Hepatitis B Virus Screening in Patients Receiving Immunosuppressive Therapy: A Small Step for the Oncologists, a Major Advance for Prevention of Hepatitis B Virus Reactivation. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 976-978.	2.4	3
1093	Transplantation for Hepatitis A and B. , 2015, , 105-119.		0
1094	Hepatitis B and C Infections in Multitransfused Thalassemic Patients. <i>Indian Journal of Pediatrics</i> , 2015, 82, 212-214.	0.3	3
1095	Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1032-1039.	1.4	22
1096	Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations. <i>Gene</i> , 2015, 567, 22-30.	1.0	1
1097	Nationwide large survey on hepatitis B surface antigen quantification use in real-life clinical practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 557-560.	0.8	2
1098	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 46-54.	0.8	4
1099	Hepatogastroenterologists'™ knowledge of inactive carriers and immunotolerant hepatitis B virus patients in France. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 544-549.	0.8	0
1100	Sustained Changes of <i>Treg</i> and <i>Th17</i> Cells During Interferon- α Therapy in Patients with Chronic Hepatitis B. <i>Viral Immunology</i> , 2015, 28, 412-417.	0.6	16
1101	Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 199-208.	1.9	51
1102	HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 928-938.	1.9	12
1103	Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom. <i>Value in Health</i> , 2015, 18, 800-809.	0.1	18
1106	Serum microRNA-210 levels in different groups of chronic hepatitis B patients. <i>Clinica Chimica Acta</i> , 2015, 450, 203-209.	0.5	12
1107	Future therapy for hepatitis B virus infection. <i>Clinical Journal of Gastroenterology</i> , 2015, 8, 167-171.	0.4	3
1108	The use of Chinese herbal medicines associated with reduced mortality in chronic hepatitis B patients receiving lamivudine treatment. <i>Journal of Ethnopharmacology</i> , 2015, 174, 161-167.	2.0	17
1109	Acute hepatitis C infection in HIV-negative men who have sex with men. <i>Journal of Viral Hepatitis</i> , 2015, 22, 535-538.	1.0	55

#	ARTICLE	IF	CITATIONS
1110	Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naïve HBeAg-positive chronic hepatitis B patients with high viral load. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 366-372.	0.7	7
1111	Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBV eAg negative with PEG-interferon. <i>Journal of Viral Hepatitis</i> , 2015, 22, 318-327.	1.0	32
1112	Comparison of two immunoassays for quantification of hepatitis B surface antigen in Chinese patients with concomitant hepatitis B surface antigen and hepatitis B surface antibodies. <i>Archives of Virology</i> , 2015, 160, 191-198.	0.9	4
1113	The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. <i>Journal of Pathology</i> , 2015, 235, 355-367.	2.1	116
1114	Serum microRNA-124 is a novel biomarker for liver necroinflammation in patients with chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2015, 22, 128-136.	1.0	25
1116	KASL clinical practice guidelines: management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 18-75.	4.5	155
1117	ADVANCED LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS B AND VIRAL LOAD BELOW 2,000 IU/mL. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2016, 58, 65.	0.5	5
1118	Hepatitis B Serology in Patients with Rheumatic Diseases. <i>Open Rheumatology Journal</i> , 2016, 10, 39-48.	0.1	15
1119	Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-10.	0.7	11
1120	Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-10.	0.7	2
1121	Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 262.	1.4	96
1122	The Diagnostic Accuracy and Clinical Utility of Three Noninvasive Models for Predicting Liver Fibrosis in Patients with HBV Infection. <i>PLoS ONE</i> , 2016, 11, e0152757.	1.1	23
1123	Continued lamivudine for adults with lamivudine-resistant chronic hepatitis B virus infection. <i>The Cochrane Library</i> , 2016, .	1.5	1
1124	Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naïve Chronic Hepatitis B Patients in a Routine Clinical Practice. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 169-174.	1.1	20
1125	Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 338-344.	1.1	2
1126	Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus-related Cirrhosis Patients Receiving Antivirals. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 676-685.	1.1	1
1127	Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy. <i>Medicine (United States)</i> , 2016, 95, e2985.	0.4	23
1128	Clinical impact of five large-scale screening projects for chronic hepatitis B in Chinese migrants in the Netherlands. <i>Liver International</i> , 2016, 36, 1425-1432.	1.9	11

#	ARTICLE	IF	CITATIONS
1129	Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B. <i>Scientific Reports</i> , 2016, 6, 30853.	1.6	22
1130	Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon- α 2a: 1-year follow-up of the OSST study. <i>Antiviral Therapy</i> , 2016, 21, 337-344.	0.6	37
1131	Clevudine in people with chronic hepatitis B virus infection. <i>The Cochrane Library</i> , 0, , .	1.5	0
1132	Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection. <i>Scientific Reports</i> , 2016, 6, 32875.	1.6	17
1133	Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. <i>Hepatology International</i> , 2016, 10, 574-593.	1.9	18
1134	United Kingdom National Guideline on the Management of the viral hepatitis A, B and C 2015. <i>International Journal of STD and AIDS</i> , 2016, 27, 501-525.	0.5	11
1135	Association between hepatitis B virus basal core promoter/precore region mutations and the risk of hepatitis B-related acute-on-chronic liver failure in the Chinese population: an updated meta-analysis. <i>Hepatology International</i> , 2016, 10, 606-615.	1.9	13
1136	Mechanisms of HBV-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, S84-S101.	1.8	664
1137	The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B. <i>Acta Clinica Belgica</i> , 2016, 71, 244-249.	0.5	4
1138	Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises. <i>Immunotherapy</i> , 2016, 8, 569-581.	1.0	14
1139	Occult HBV infection in the oncohematological setting. <i>Infection</i> , 2016, 44, 575-582.	2.3	12
1140	Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. <i>The Lancet Global Health</i> , 2016, 4, e568-e578.	2.9	91
1141	Hepatobiliary Infections After Solid Organ or Hematopoietic Cell Transplantation. , 2016, , 653-673.		3
1142	Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 421-429.	0.7	6
1143	<i>Cimicifuga foetida</i> L. plus adefovir effectively inhibits the replication of hepatitis B virus in patients with chronic hepatitis B. <i>Biomedical Reports</i> , 2016, 4, 493-497.	0.9	2
1145	Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2016, 23, 154-169.	1.0	26
1146	Virological and serological tools to optimize the management of patients with chronic hepatitis B. <i>Liver International</i> , 2016, 36, 78-84.	1.9	9
1147	Toward Biomarker Development in Large Clinical Cohorts: An Integrated High-Throughput 96-Well-Plate-Based Sample Preparation Workflow for Versatile Downstream Proteomic Analyses. <i>Analytical Chemistry</i> , 2016, 88, 8518-8525.	3.2	9

#	ARTICLE	IF	CITATIONS
1148	Screening and diagnosis of HBV in low-income and middle-income countries. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 643-653.	8.2	56
1149	Requirements for global elimination of hepatitis B: a modelling study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1399-1408.	4.6	279
1150	Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. <i>Journal of Viral Hepatitis</i> , 2016, 23, 545-559.	1.0	43
1151	Factors associated with significant liver necroinflammation in chronic hepatitis B patients with cirrhosis. <i>Scientific Reports</i> , 2016, 6, 33093.	1.6	5
1152	Identification and clinical significance of an elevated level of serum aminoacylase-1 autoantibody in patients with hepatitis B virus-related liver cirrhosis. <i>Molecular Medicine Reports</i> , 2016, 14, 4255-4262.	1.1	15
1154	On-treatment and off-treatment efficacy of entecavir in a real-life cohort of chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1179-1187.	0.8	8
1155	Comparison of droplet digital PCR to real-time PCR for quantification of hepatitis B virus DNA. <i>Bioscience, Biotechnology and Biochemistry</i> , 2016, 80, 2159-2164.	0.6	41
1156	Nomogram for hepatic steatosis: A simple and economical diagnostic tool for massive screening. <i>Digestive and Liver Disease</i> , 2016, 48, 914-920.	0.4	4
1157	Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. <i>Journal of Hepatology</i> , 2016, 65, 683-691.	1.8	84
1158	Tollâ€œIL</scp>1 receptorâ€œmediated innate immune responses vary across <scp>HBV</scp> genotype and predict treatment response to pegylatedâ€œIFN</scp> in <scp>HB</scp>e<scp>A</scp>gâ€œpositive <scp>CHB</scp> patients. <i>Journal of Viral Hepatitis</i> , 2016, 23, 170-179.	1.0	16
1159	Effectiveness of hepatitis B rapid tests toward linkage-to-care: results of a randomized, multicenter study. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 633-639.	0.8	9
1160	Pathobiology of Hepatitis B Virus-Induced Carcinogenesis. <i>Molecular and Translational Medicine</i> , 2016, , 95-121.	0.4	2
1161	Challenges in the management of chronic HBV infection in West Africa: The clinicianâ€™s perspective. <i>Tropical Doctor</i> , 2016, 46, 16-20.	0.2	3
1162	Management of infection and febrile neutropenia in patients with solid cancer. <i>Clinical and Translational Oncology</i> , 2016, 18, 557-570.	1.2	14
1163	Insulin Resistance Predicts Virological Response to Interferon-Î± in Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 506-512.	1.1	2
1164	Three cases of hepatocellular carcinoma in Fontan patients: Review of the literature and suggestions for hepatic screening. <i>International Journal of Cardiology</i> , 2016, 206, 21-26.	0.8	53
1165	Serum microRNA-125b correlates with hepatitis B viral replication and liver necroinflammation. <i>Clinical Microbiology and Infection</i> , 2016, 22, 384.e1-384.e10.	2.8	19
1166	Les vaccinations dans les rhumatismes inflammatoires chroniques de lâ€™adulte: le calendrier vaccinal et les recommandations en cas de traitement de fond classique et biologique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 92-98.	0.0	0

#	ARTICLE	IF	CITATIONS
1167	EASL Clinical Practice Guidelines: Liver transplantation. <i>Journal of Hepatology</i> , 2016, 64, 433-485.	1.8	744
1168	Hepatitis B and cancer: A practical guide for the oncologist. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 137-146.	2.0	29
1169	Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection. <i>Clinical Microbiology and Infection</i> , 2016, 22, 379.e1-379.e8.	2.8	8
1170	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	1.9	1,908
1171	The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. <i>Hepatology International</i> , 2016, 10, 462-469.	1.9	53
1172	The effect of peginterferon alpha-2a vs. interferon alpha-2a on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 304-308.	0.7	6
1173	Vaccinations in adults with chronic inflammatory joint disease: Immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs. <i>Joint Bone Spine</i> , 2016, 83, 135-141.	0.8	42
1174	Screening for viral hepatitis prior to rituximab chemotherapy. <i>Annals of Hematology</i> , 2016, 95, 27-33.	0.8	9
1175	Extended duration versus standard duration of peginterferon alfa-2a in treatment of chronic hepatitis B: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 195-202.	0.7	3
1176	Manejo de la infección y la neutropenia febril en el paciente con cáncer sólido. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 451-460.	0.3	11
1177	The nucleotide changes within HBV core promoter/precore during the first 12 weeks of nucleos(t)ide treatment might be associated with a better virological response. <i>Infection, Genetics and Evolution</i> , 2017, 49, 116-121.	1.0	1
1178	Reactivación del virus de la hepatitis B tras el cese de la profilaxis con entecavir en un paciente con leucemia linfoblástica tipo Burkitt tratado con rituximab. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 470-471.	0.2	1
1179	Association between chronic hepatitis B virus infection and HLA-DP gene polymorphisms in the Turkish population. <i>Virus Research</i> , 2017, 232, 6-12.	1.1	21
1180	Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 479-490.	1.0	9
1181	Epidemiology update for HCV and HBV in ESRD in France: Still a lot to do. <i>Liver International</i> , 2017, 37, 815-816.	1.9	1
1182	The Clinical Efficacy and Adverse Effects of Interferon Combined with Matrine in Chronic hepatitis B: A Systematic Review and Meta-Analysis. <i>Phytotherapy Research</i> , 2017, 31, 849-857.	2.8	27
1183	Discontinuation of Lamivudine Treatment in HBeAg-Negative Chronic Hepatitis B: A Pilot Study with Long-Term follow-up. <i>Antiviral Therapy</i> , 2017, 22, 559-570.	0.6	7
1184	Multidimensional Fatigue Inventory in People With Hepatitis B Infection. <i>Gastroenterology Nursing</i> , 2017, 40, 380-392.	0.2	8

#	ARTICLE	IF	CITATIONS
1185	High value of controlled attenuation parameter predicts a poor antiviral response in patients with chronic hepatitis B. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2017, 16, 370-374.	0.6	12
1186	Diagnostic value of Transient Elastography (Fibroscan) in the evaluation of liver fibrosis in chronic viral hepatitis C: Comparison to liver biopsy. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2017, 48, 329-337.	0.3	6
1187	Hepatitis B virus reactivation after cessation of prophylaxis with entecavir in a patient with Burkitt type acute lymphoblastic leukaemia treated with rituximab. <i>Gastroenterology & Hepatology (English)</i> Tj ETQq0 000rgBT /Overlock 10		
1188	Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 56-60.	0.8	4
1189	Nomogram for cirrhosis in patients with chronic hepatitis B: A simple self-assessed scale for individual risk of cirrhosis. <i>Scientific Reports</i> , 2017, 7, 17493.	1.6	3
1190	The Ultra-Short Virological Dynamics in Response to Entecavir or Lamivudine during Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. <i>Antiviral Therapy</i> , 2018, 23, 77-85.	0.6	2
1191	Management of infection and febrile neutropenia in patients with solid cancer. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2017, 35, 451-460.	0.2	3
1192	<i>Diseases of the Liver.</i> , 2017, , 1167-1180.		1
1193	Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. <i>Current Medical Research and Opinion</i> , 2017, 33, 495-504.	0.9	20
1194	Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir. <i>Hepatitis Research and Treatment</i> , 2017, 2017, 1-7.	2.0	2
1195	Protective Effects of <i>Moringa oleifera</i> on HBV Genotypes C and H Transiently Transfected Huh7 Cells. <i>Journal of Immunology Research</i> , 2017, 2017, 1-9.	0.9	23
1196	Elevated serum α_2 -microglobulin in individuals coinfecting with hepatitis B and hepatitis D virus in a rural settings in Southwest Nigeria. <i>BMC Research Notes</i> , 2017, 10, 719.	0.6	2
1197	Management of Antiviral Resistance in Chronic Hepatitis B. <i>Gut and Liver</i> , 2017, 11, 189-195.	1.4	39
1198	Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 636-646.	0.7	17
1199	Comparison between tenofovir disoproxil fumarate and entecavir treatment in real-world clinical practice. <i>Advances in Digestive Medicine</i> , 2017, 4, 87-93.	0.1	0
1200	An analysis of the predictive value of the HIV Ag/Ab screening assay within the performance characteristics of the DiaSorin LIAISON XL for the detection of blood-borne viruses. <i>Journal of Clinical Virology</i> , 2018, 102, 95-100.	1.6	6
1201	Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients. <i>Antiviral Research</i> , 2018, 149, 174-178.	1.9	4
1202	Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection. <i>Journal of Hepatology</i> , 2018, 68, 655-662.	1.8	36

#	ARTICLE	IF	CITATIONS
1203	A promising non-invasive index for predicting liver inflammation in chronic hepatitis B patients with alanine aminotransferase ≥ 2 upper limit of normal. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 4393-4400.	0.8	0
1204	Adverse events in IBD therapy: the 2018 update. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1183-1191.	1.4	49
1205	Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice. <i>BMC Infectious Diseases</i> , 2018, 18, 568.	1.3	5
1206	Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. <i>Viral Immunology</i> , 2018, 31, 632-638.	0.6	3
1207	Entecavir versus other oral antiviral drugs for chronic hepatitis B. <i>The Cochrane Library</i> , 0, , .	1.5	0
1208	Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. <i>Transplant Infectious Disease</i> , 2018, 20, e12960.	0.7	5
1209	Changes in Liver Tissue Trace Element Concentrations During Hepatitis B Viral Infection Treatment. <i>Biological Trace Element Research</i> , 2019, 188, 245-250.	1.9	8
1210	Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. <i>Cancer Medicine</i> , 2019, 8, 5097-5107.	1.3	7
1211	Efficacy of long-term treatment with tenofovir in Chinese nucleos(t)ide-naïve chronic hepatitis B patients regardless of baseline viral load. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 260-268.	0.8	3
1212	Molecular interactions between PAMAM dendrimer and some medicines that suppress the growth of hepatitis virus (Adefovir, Entecavir, Telbivudine, Lamivudine, Tenofovir): a theoretical study. <i>International Nano Letters</i> , 2019, 9, 231-244.	2.3	3
1213	Antiviral Therapy for AECHB and Severe Hepatitis B (Liver Failure). , 2019, , 371-455.		0
1215	Expression of autophagy-modulating genes in peripheral blood mononuclear cells from familial clustering patients with chronic hepatitis B virus infection. <i>Archives of Virology</i> , 2019, 164, 2005-2013.	0.9	6
1216	Molecular cloning and phenotypic analysis of drug-resistance mutants with relevant S-region variants of HBV for a patient during 189-month anti-HBV treatment. <i>Antiviral Therapy</i> , 2019, 24, 237-246.	0.6	4
1217	Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2187-2198.	1.1	6
1218	Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. <i>World Journal of Clinical Cases</i> , 2019, 7, 1784-1794.	0.3	9
1219	A Comparison Between Community and Academic Practices in the USA in the Management of Chronic Hepatitis B Patients Receiving Entecavir: Results of the ENUMERATE Study. <i>Digestive Diseases and Sciences</i> , 2019, 64, 358-366.	1.1	7
1220	Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. <i>Gut</i> , 2019, 68, 150-157.	6.1	65
1221	Novel predictive models using serum ceruloplasmin levels for hepatic steatosis in patients with chronic hepatitis B infection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 57-65.	0.7	4

#	ARTICLE	IF	CITATIONS
1222	How intrahepatic cholestasis affects liver stiffness in patients with chronic hepatitis B: a study of 1197 patients with liver biopsy. <i>European Radiology</i> , 2020, 30, 1096-1104.	2.3	20
1223	Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats. <i>Pharmaceutical Biology</i> , 2020, 58, 1-7.	1.3	8
1225	Oral PrEP in adolescents in sub-Saharan Africa. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 854-855.	2.7	2
1226	Human resources for emergency care systems in Ethiopia: Challenges and triumphs. <i>African Journal of Emergency Medicine</i> , 2020, 10, S50-S55.	0.4	6
1227	Decades of monitoring have informed the stewardship and ecological understanding of Australia's Great Barrier Reef. <i>Biological Conservation</i> , 2020, 252, 108854.	1.9	17
1228	A Robust Titanium Isophthalate Metal-Organic Framework for Visible-Light Photocatalytic CO ₂ Methanation. <i>CheM</i> , 2020, 6, 3409-3427.	5.8	41
1229	Impact of œovarian stagingœ on operative and long-term outcomes in females affected by primary peritoneal surface malignancies requiring CRS and HIPEC: Final results. <i>European Journal of Surgical Oncology</i> , 2020, 46, e2.	0.5	0
1231	P.080 A translational Homer 1a-based network approach: imaging how haloperidol modulates glutamate system functional connectivity. <i>European Neuropsychopharmacology</i> , 2020, 40, S51-S52.	0.3	0
1234	P.626 The longitudinal analysis of sleep quality and relapse: survey data from the cohort of people with substance use disorders. <i>European Neuropsychopharmacology</i> , 2020, 40, S354.	0.3	1
1236	Optimal endoatmospheric ascent phase guidance with load constraint. <i>IFAC-PapersOnLine</i> , 2020, 53, 266-271.	0.5	0
1237	Acute arterial occlusion of the lower limb as the main clinical manifestation in a patient with Covid-19 œœ Case Report. <i>International Journal of Surgery Case Reports</i> , 2020, 77, 454-458.	0.2	7
1238	Hydrologic impacts of cascade dams in a small headwater watershed under climate variability. <i>Journal of Hydrology</i> , 2020, 590, 125426.	2.3	28
1239	Dual Challenge of Climate Change and Agrobiodiversity Loss in Mountain Food Systems in the Hindu-Kush Himalaya. <i>One Earth</i> , 2020, 3, 539-542.	3.6	14
1243	A bridge too far? The role of natural gas electricity generation in US climate policy. <i>Energy Policy</i> , 2020, 147, 111867.	4.2	17
1244	Investigation on preparation porous titanium through calciothermic reduction of porous TiO precursors. <i>Journal of Materials Research and Technology</i> , 2020, 9, 13137-13146.	2.6	5
1245	Comparative Research on Active Learning of Big Aata based on Mapreduce and Spark. <i>Microprocessors and Microsystems</i> , 2020, , 103425.	1.8	1
1246	Comparison of safety and effectiveness between the right and left radial artery approach in percutaneous coronary intervention. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 75, 119-119.	0.4	3
1247	Characterization and application of antimicrobials produced by <i>Enterococcus faecium</i> S6 isolated from raw camel milk. <i>Journal of Dairy Science</i> , 2020, 103, 11106-11115.	1.4	6

#	ARTICLE	IF	CITATIONS
1248	Mental illnesses among COVID-19 patients: Possible immunological underpinnings. <i>Asian Journal of Psychiatry</i> , 2020, 53, 102376.	0.9	4
1249	Man With Worsening Dyspnea. <i>Annals of Emergency Medicine</i> , 2020, 75, e25-e26.	0.3	0
1250	Effect of β phase morphology on fatigue crack growth behavior of Ti-5Al-5Mo-1Cr-1Fe alloy. <i>Transactions of Nonferrous Metals Society of China</i> , 2020, 30, 2459-2471.	1.7	11
1251	Thermal deformation behavior of β -TiAl based alloy by plasma hydrogenation. <i>International Journal of Hydrogen Energy</i> , 2020, 45, 34214-34226.	3.8	6
1252	Optimal delivery strategies for packing box recycling in online platforms. <i>Journal of Cleaner Production</i> , 2020, 276, 124273.	4.6	11
1253	Aqueous outflow regulation – 21st century concepts. <i>Progress in Retinal and Eye Research</i> , 2021, 83, 100917.	7.3	42
1254	Administration of Bacillus cultures as direct-fed microorganisms improves growth performance and reduces mortality of broilers raised under performance-reducing stress challenge. <i>Journal of Applied Poultry Research</i> , 2020, 29, 798-807.	0.6	1
1255	Cardiovascular events, LDL and HDL subfraction size in a cohort of FH patients. <i>Atherosclerosis</i> , 2020, 315, e151.	0.4	0
1256	The successful management of an infected revision TMJ prosthesis using Stimulan [®] cement impregnated with gentamicin – a case report. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2020, 58, e225.	0.4	0
1257	Arrest and emergency medical services events among participants from one of the first mental health courts. <i>International Journal of Law and Psychiatry</i> , 2020, 73, 101644.	0.5	1
1259	Au@BSA microspheres-luminol and a novel luminescent Zeolitic Imidazolate Framework were used for potential-resolved electrochemiluminescence to detect dual targets. <i>Analytica Chimica Acta</i> , 2020, 1140, 89-98.	2.6	7
1262	Apolipoprotein J ablation triggers atherosclerosis in a chow diet-fed LDLR-KO mice. <i>Atherosclerosis</i> , 2020, 315, e50-e51.	0.4	0
1263	Mechanisms underlying hydroxyapatite deposition in human coronary atherosclerosis using 18F-fluoride. <i>Atherosclerosis</i> , 2020, 315, e62-e63.	0.4	0
1264	A study on the relationship between ergonomic factors, pulse wave velocity, and falling accidents in super-aged people in Okinawa during simulated agricultural operations. <i>Atherosclerosis</i> , 2020, 315, e140.	0.4	0
1265	How lipoprotein (a) intervenes at the level of LDL-C determined by Friedewald's formula. <i>Atherosclerosis</i> , 2020, 315, e143-e144.	0.4	0
1266	1-year follow-up using high-resolution MRI of atherosclerotic stenosis at middle cerebral artery. <i>Atherosclerosis</i> , 2020, 315, e179.	0.4	0
1267	Early complications after coronary artery bypass grafting: Predictors and perioperative therapy. <i>Atherosclerosis</i> , 2020, 315, e251.	0.4	0
1268	Development of standard operating procedures for the management of maxillofacial trauma by air ambulance staff. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2020, 58, e190.	0.4	0

#	ARTICLE	IF	CITATIONS
1269	Programmed cell death-1 rs2227981 polymorphism in patients with autoimmune skin blistering disorders: A pilot study. <i>Meta Gene</i> , 2020, 26, 100793.	0.3	2
1275	GPR18-NAGly system in periaqueductal gray and chronic neuropathic pain. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165974.	1.8	2
1276	NRBCE: points d'actualisation. <i>Medecine De Catastrophe Urgences Collectives</i> , 2020, 4, 317-319.	0.1	0
1277	14173 Sun safety education practices in undergraduate teaching colleges. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB20.	0.6	0
1278	18420 A retrospective multicenter study of fatal pediatric melanoma. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB99.	0.6	1
1279	15485 Evaluating the safety and efficacy of intense pulsed light with radiofrequency in US patients with hidradenitis suppurativa: A split-body study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB154.	0.6	0
1280	16046 Long-term efficacy and safety of daily efinaconazole 10% nail solution for mild to moderate onychomycosis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB169.	0.6	0
1281	17113 Early and maintained response levels in psoriasis patients treated with tildrakizumab. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB192.	0.6	0
1282	Editorial: An analysis of World Patent Information publications from 2014 to 2020. <i>World Patent Information</i> , 2020, 62, 101990.	0.7	0
1283	Effect of transverses abdominis block and subcutaneous wound infiltration on post-operative pain analgesia after cesarean section at Hawassa University, southern Ethiopia : A prospective cohort study. <i>International Journal of Surgery Open</i> , 2020, 26, 108-113.	0.2	1
1284	Outcomes of RestoreX Penile Traction Therapy in Men with Peyronie's Disease: Results from Open Label and Follow-Up Phases. <i>Journal of Sexual Medicine</i> , 2020, 17, 2462-2471.	0.3	12
1286	Voter reaction to legislator dissent across political systems. <i>Electoral Studies</i> , 2020, 68, 102235.	1.0	6
1287	The social-economic impact of COVID-19 pandemic: implications for potential forest degradation. <i>Heliyon</i> , 2020, 6, e05354.	1.4	30
1288	Clinical trials may be unethical in certain instances. <i>International Journal of Cardiology: Hypertension</i> , 2020, 7, 100057.	2.2	2
1289	Analysis of Recovery-assisted discontinuous Galerkin methods for the compressible Navier-Stokes equations. <i>Journal of Computational Physics</i> , 2020, 423, 109813.	1.9	5
1290	Factors affecting pregnancy rates for goat embryos recovered and transferred by transcervical route. <i>Small Ruminant Research</i> , 2020, 192, 106215.	0.6	8
1291	Data of the life cycle impact assessment and cost analysis of prospective direct recycling of end-of-life reverse osmosis membrane at full scale. <i>Data in Brief</i> , 2020, 33, 106487.	0.5	6
1293	Circulating Progenitor Cells in Patients With Coronary Artery Disease and Renal Insufficiency. <i>JACC Basic To Translational Science</i> , 2020, 5, 770-782.	1.9	5

#	ARTICLE	IF	CITATIONS
1294	Multi-stage NMPC using sigma point principles. IFAC-PapersOnLine, 2020, 53, 386-391.	0.5	2
1295	Inflammatory myofibroblastic tumor of the lung: A rare entity. Respiratory Medicine Case Reports, 2020, 31, 101287.	0.2	7
1296	Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins. Heliyon, 2020, 6, e05421.	1.4	21
1298	Differential impact on isolated REM sleep without atonia by varying antidepressant therapies. Journal of Affective Disorders Reports, 2020, 1, 100007.	0.9	0
1299	PND8 NETWORK META-ANALYSIS OF DYSPORT (ABOBOTULINUMTOXINA), BOTOX (ONABOTULINUMTOXINA) AND XEOMIN (INCOBOTULINUMTOXINA) FOR THE TREATMENT OF ADULT LOWER LIMB SPASTICITY (ALLS) IN POST-STROKE POPULATION. Value in Health, 2020, 23, S259.	0.1	0
1300	Winter wheat growth assessment using Temporal Normalized Phenology Index (TNPI) in Bhuj Taluka, Gujarat State, India. Remote Sensing Applications: Society and Environment, 2020, 20, 100422.	0.8	1
1301	Can counter-advertising protect spectators of elite sport against the influence of unhealthy food and beverage sponsorship? A naturalistic trial. Social Science and Medicine, 2020, 266, 113415.	1.8	7
1302	Hygroscopic properties and compositional evolution of internally mixed sodium nitrate-amino acid aerosols. Atmospheric Environment, 2020, 242, 117848.	1.9	8
1303	Multimodal process monitoring based on transition-constrained Gaussian mixture model. Chinese Journal of Chemical Engineering, 2020, 28, 3070-3078.	1.7	6
1304	Economic optimization from fleets of aero-derivative gas turbines utilising flared associated gas. International Journal of Thermofluids, 2020, 7-8, 100049.	4.0	4
1305	PDLIM2 protects articular chondrocytes from lipopolysaccharide-induced apoptosis, degeneration and inflammatory injury through down-regulation of nuclear factor (NF)- κ B signaling. International Immunopharmacology, 2020, 88, 106883.	1.7	5
1306	Reply. Journal of the American College of Cardiology, 2020, 76, 2177-2179.	1.2	0
1308	3D boundary element code (direct BEM) for solid elasticity problems. Developments in Petroleum Science, 2020, 70, 351-370.	0.2	0
1309	Morphological changes in the vertebrae and central canal of rat pups born after exposure to the electromagnetic field of pregnant rats. Acta Histochemica, 2020, 122, 151652.	0.9	2
1311	La historia cl�nica en cirug�a ortop�dica y traumatolog�a: quo vadis?. Revista Espa�ola De Cirug�a Ortop�dica Y Traumatolog�a, 2020, 64, 365-366.	0.1	0
1312	Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment. Frontiers in Cellular and Infection Microbiology, 2020, 10, 335.	1.8	2
1313	P53 expression and micro-vessel density in relation with 5-year survival in patients with colorectal cancer. Annals of Medicine and Surgery, 2020, 57, 311-314.	0.5	5
1314	Institutional review of predictors of in-hospital and 30-day discharge mortality in neurosurgical patients. Clinical Neurology and Neurosurgery, 2020, 198, 106231.	0.6	2

#	ARTICLE	IF	CITATIONS
1316	COVID-19 disparity among racial and ethnic minorities in the US: A cross sectional analysis. <i>Travel Medicine and Infectious Disease</i> , 2020, 38, 101904.	1.5	103
1320	Towards understanding the interaction of (S)-thalidomide with nucleobases. <i>Archives of Biochemistry and Biophysics</i> , 2020, 693, 108566.	1.4	1
1321	Effects of dietary laccase supplementation on growth performance, nutrient digestion, rumen fermentation and microbiota in dairy bulls. <i>Animal Feed Science and Technology</i> , 2020, 269, 114645.	1.1	4
1322	Does Social Inferencing Differ in Men and Women after TBI?. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e14.	0.5	1
1323	Exercise for individuals with bone metastases: Delphi consensus process to develop evidence-informed recommendations for rehabilitation professionals working in oncology settings. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e14-e15.	0.5	0
1324	A Phase II Randomized, Virtual, Clinical Trial of Speech Therapy App for Speech, Language, and Cognitive Intervention in Stroke. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e62.	0.5	5
1325	Emotional, Functional, and Physiological Correlates of Opioid Dose Reduction in a Chronic Pain Population. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e99.	0.5	0
1326	Post-stroke Caregiving Experience Across Different Caregiver Identities in Singapore: A Descriptive Qualitative Study. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e111.	0.5	0
1327	Aptamers used for biosensors and targeted therapy. <i>Biomedicine and Pharmacotherapy</i> , 2020, 132, 110902.	2.5	60
1329	Update in Pediatric Diagnostic Microbiology. <i>Clinics in Laboratory Medicine</i> , 2020, 40, 495-508.	0.7	1
1330	ACR Appropriateness Criteria® Vomiting in Infants. <i>Journal of the American College of Radiology</i> , 2020, 17, S505-S515.	0.9	6
1331	41 - Obesity Prevalence in Pediatric Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Canadian Journal of Diabetes</i> , 2020, 44, S19.	0.4	1
1332	88 - Appropriateness of Clinical Indications for Ordering Thyroid-Stimulating Hormone in Noncritically Ill Adult Inpatients – A Modified Delphi Study. <i>Canadian Journal of Diabetes</i> , 2020, 44, S34.	0.4	0
1333	The Anthropocene and Dogs™ Choices in Soviet and Post-Soviet Futurity Fiction. <i>Russian Literature</i> , 2020, 114-115, 67-83.	0.0	0
1334	Differential inhibition of naringenin on human and rat cytochrome P450 2E1 activity. <i>Toxicology in Vitro</i> , 2020, 69, 105009.	1.1	3
1335	Acceptance of a COVID-19 vaccine: A multifactorial consideration. <i>Vaccine</i> , 2020, 38, 7587.	1.7	33
1336	Review article: preventing hepatitis B graft infection in hepatitis B patients after liver transplantation: immunoglobulin vs anti-virals. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 944-954.	1.9	4
1339	A rare extraocular sebaceous carcinoma mimicking primary ectopic breast cancer. <i>Human Pathology: Case Reports</i> , 2020, 21, 200415.	0.2	0

#	ARTICLE	IF	CITATIONS
1340	Effects of 2-Year Walnut-Supplemented Diet on Inflammatory Biomarkers. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2282-2284.	1.2	23
1341	From dysregulated microRNAs to structural alterations in the striatal region of METH-injected rats. <i>Journal of Chemical Neuroanatomy</i> , 2020, 109, 101854.	1.0	13
1342	The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients. <i>Medical Hypotheses</i> , 2020, 144, 110180.	0.8	20
1343	Applying the Business Model Canvas to Design the E-platform for Sailing Tourism. <i>Procedia Computer Science</i> , 2020, 176, 1643-1651.	1.2	17
1344	The Interneuron Class Struggle. <i>Cell</i> , 2020, 183, 845-847.	13.5	0
1345	Proteolysis of Von Willebrand Factor Influences Inflammatory Endothelial Activation and Vascular Compliance in Atherosclerosis. <i>JACC Basic To Translational Science</i> , 2020, 5, 1017-1028.	1.9	12
1346	59: Dosimetric Evaluation of Chest Wall Superficial Dose with or Without Bolus in Postmastectomy Radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 150, S28-S29.	0.3	0
1347	196: Oligo-Terminologies of Oligometastatic Disease - Consistency of New Consensus Definitions Within Current SABR Trials. <i>Radiotherapy and Oncology</i> , 2020, 150, S83-S84.	0.3	0
1348	209: A Quality Assessment of SBRT for Early Stage Non-Small Cell Lung Cancer. <i>Radiotherapy and Oncology</i> , 2020, 150, S88-S89.	0.3	0
1351	Enhanced blue photoluminescence and new crystallinity of Ag/organic rubrene core-shell nanoparticles through hydrothermal treatment. <i>Current Applied Physics</i> , 2020, 20, 1201-1206.	1.1	2
1352	Modern methods for estimation of dietary adherence and quality of life for patients with coeliac disease. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 519.	0.5	0
1353	Identification and use of weight loss supplements. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 655.	0.5	0
1358	Audit of the diagnosis and treatment of seborrhoeic keratosis and compliance with current guidelines. <i>JPRAS Open</i> , 2020, 26, 76-79.	0.4	0
1359	Interatrial blocks: Diagnosis and clinical significance. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 207-214.	0.1	0
1360	Part alignment network for vehicle re-identification. <i>Neurocomputing</i> , 2020, 418, 114-125.	3.5	8
1361	Registro Español de Trasplante Cardíaco. XXXI Informe Oficial de la Asociación de Insuficiencia Cardíaca de la Sociedad Española de Cardiología. <i>Revista Española De Cardiología</i> , 2020, 73, 919-926.	0.6	14
1364	Combining structure and genomics to understand antimicrobial resistance. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 3377-3394.	1.9	17
1365	A supplement of ultraviolet-B radiation under field conditions increases phenolic and volatile compounds of Tempranillo grape skins and the resulting wines. <i>European Journal of Agronomy</i> , 2020, 121, 126150.	1.9	14

#	ARTICLE	IF	CITATIONS
1366	Multistep evolution of $\beta_2\text{o}$ phase during isothermal annealing of Ti-42Al-5Mn alloy: Formation of Laves phase. <i>Intermetallics</i> , 2020, 126, 106932.	1.8	19
1368	Glioblastoma treatment guidelines: Consensus by the Spanish Society of Neurosurgery Tumor Section. <i>Neurocirug�a (English Edition)</i> , 2020, 31, 289-297.	0.1	2
1369	Generation of induced pluripotent stem cell GZHMCI002-A from peripheral blood mononuclear cells with APOB mutation. <i>Stem Cell Research</i> , 2020, 49, 102054.	0.3	0
1370	Techniques de biologie mol�culaire. , 2020, , 83-114.		0
1371	Thermal stimulation of targeted neural circuits via remotely controlled nano-transducers: A therapy for neurodegenerative disorders. <i>Advances in Heat Transfer</i> , 2020, , 543-581.	0.4	5
1372	Endophthalmitis following combined cataract extraction and placement of an iStent trabecular bypass device. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 20, 100830.	0.4	4
1374	An inverse-designed electrochemical platform for analytical applications. <i>Electrochemistry Communications</i> , 2020, 121, 106862.	2.3	12
1375	Recent reports on electrochemical determination of selected antibiotics in pharmaceutical formulations: A mini review. <i>Electrochemistry Communications</i> , 2020, 121, 106863.	2.3	27
1376	A rare case of a retroperitoneal lymphangioma causing chronic flank pain in an adult. <i>Urology Case Reports</i> , 2020, 33, 101408.	0.1	4
1377	The association of recreational and non-recreational physical activity with mental health: A Canadian cross-sectional analysis.. <i>Journal of Affective Disorders Reports</i> , 2020, 1, 100021.	0.9	5
1380	Slovakia to test all adults for SARS-CoV-2. <i>Lancet, The</i> , 2020, 396, 1386-1387.	6.3	42
1384	DOE invests \$34m to develop small SOFCs. <i>Fuel Cells Bulletin</i> , 2020, 2020, 15.	0.7	1
1385	111EMF Development of a Quality Measurement Framework for Acute Psychiatric Care. <i>Annals of Emergency Medicine</i> , 2020, 76, S43-S44.	0.3	0
1386	285 Deployment of Artificial Intelligence for Radiographic Diagnosis of COVID-19 Pneumonia in the Emergency Department. <i>Annals of Emergency Medicine</i> , 2020, 76, S109-S110.	0.3	0
1387	Article on Off-Label Drug Use Wins 2020 Cowles Award. <i>Caring for the Ages</i> , 2020, 21, 2.	0.0	0
1388	Pushing Back Against Ageism. <i>Caring for the Ages</i> , 2020, 21, 13.	0.0	0
1389	Transcaval TAVR on A LVAD Patient Presenting with Cardiogenic Shock. <i>Journal of Cardiac Failure</i> , 2020, 26, S159.	0.7	0
1390	Texas Alliance for Innovation on Maternal Health Collaborative Bundle Implementation to Reduce Postpartum Hemorrhage. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2020, 49, S16.	0.2	1

#	ARTICLE	IF	CITATIONS
1391	A Perinatal Quality Collaborative's Quality Improvement Strategy Toward Achieving Health Equity. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2020, 49, S19-S20.	0.2	0
1392	Innovative On-Demand Microlearning Versus Traditional Instruction. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2020, 49, S74.	0.2	0
1393	Fibroadenoma of the Breast. Mayo Clinic Proceedings, 2020, 95, 2573-2574.	1.4	2
1400	Nonenzymatic electrochemical sensor based on metal oxide, MO (M= Cu, Ni, Zn, and Fe) nanomaterials for neurotransmitters: An abridged review. Sensors International, 2020, 1, 100047.	4.9	24
1401	The effect of a dexmedetomidine constant rate infusion on cardiopulmonary function and colonic blood flow in anesthetized, experimentally endotoxemic horses. Veterinary Anaesthesia and Analgesia, 2020, 47, 855.e6.	0.3	0
1406	Assessing similarity in handwritten texts. Pattern Recognition Letters, 2020, 138, 447-454.	2.6	2
1407	Toxicity and gas chromatography-mass spectrometry analyses of a polyherbal formulation commonly used in Ibadan metropolis, Nigeria. Toxicology Reports, 2020, 7, 1393-1401.	1.6	1
1408	The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of HBV-Related HCC After Curative Resection. Journal of Gastrointestinal Surgery, 2021, 25, 1419-1429.	0.9	5
1409	Care quality and outcomes among US veterans with chronic hepatitis B in the hepatitis C direct-acting antiviral era. Journal of Viral Hepatitis, 2020, 27, 1082-1092.	1.0	2
1410	Interleukin 22 is related to development and poor prognosis of hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 855-864.	0.7	14
1411	Antiviral activity of a polysaccharide from Radix Isatidis (Isatis indigotica Fortune) against hepatitis B virus (HBV) in vitro via activation of JAK/STAT signal pathway. Journal of Ethnopharmacology, 2020, 257, 112782.	2.0	42
1413	Bronchopulmonary dysplasia is associated with reduced oral nitrate reductase activity in extremely preterm infants. Redox Biology, 2021, 38, 101782.	3.9	5
1414	Evolutionary differentiation between alga- and plant-type plastid terminal oxidase: Study of plastid terminal oxidase PTOX isoforms in Marchantia polymorpha. Biochimica Et Biophysica Acta - Bioenergetics, 2021, 1862, 148309.	0.5	6
1415	Assessing the uncertainty of maize yield without nitrogen fertilization. Field Crops Research, 2021, 260, 107985.	2.3	34
1416	Performance metrics for fueled and unfueled turbulent jet igniters in a rapid compression machine. Applied Thermal Engineering, 2021, 182, 115893.	3.0	19
1417	Stoichiometry-modulated dual epsilon-near-zero characteristics of niobium nitride films. Applied Surface Science, 2021, 537, 147981.	3.1	12
1418	A novel evolutionary method for spine detection in ultrasound samples of spina bifida cases. Computer Methods and Programs in Biomedicine, 2021, 198, 105787.	2.6	3
1419	On Kuiper type theorems for uniform Roe algebras. Linear Algebra and Its Applications, 2021, 608, 387-398.	0.4	1

#	ARTICLE	IF	CITATIONS
1420	Level of clinical reasoning in intermediate nursing students explained by education year and days of internships per healthcare branches: A cross-sectional study. <i>Nurse Education Today</i> , 2021, 96, 104641.	1.4	5
1421	Rotating ring-disk electrode theory and method to correct quasi-four-electron oxygen reduction over Fe/N/C and N/C cathode catalysts. <i>Current Opinion in Electrochemistry</i> , 2021, 25, 100633.	2.5	8
1422	UV fluorescence as a method of high throughput surface cleanliness assessment: A comparison with XPS. <i>International Journal of Adhesion and Adhesives</i> , 2021, 104, 102739.	1.4	1
1423	Compressive complex wave retrieval from a single off-axis digital Fresnel hologram for quantitative phase imaging and microlens characterization. <i>Optics Communications</i> , 2021, 478, 126371.	1.0	9
1424	Al/F codoping effect on the structural, electrical, and optical properties of ZnO films grown via atomic layer deposition. <i>Applied Surface Science</i> , 2021, 535, 147734.	3.1	21
1425	Estimating acute urinary retention risk post prostate high dose-rate (HDR) brachytherapy: A clinical-based recursive partitioning analysis. <i>Radiotherapy and Oncology</i> , 2021, 154, 118-122.	0.3	5
1426	Testing the random walk hypothesis for leading cryptocurrencies. <i>Borsa Istanbul Review</i> , 2021, 21, 256-268.	2.4	24
1427	Corticosteroids and circadian rhythms in the cardiovascular system. <i>Current Opinion in Pharmacology</i> , 2021, 57, 21-27.	1.7	4
1428	Litter sex composition influences competitive performance during first reproduction in male mouse lemurs. <i>Physiology and Behavior</i> , 2021, 228, 113196.	1.0	7
1430	Boron nitride self-assembly cladding structure promoting thermal property and dimensional stability of polymer composites. <i>Composites Science and Technology</i> , 2021, 201, 108536.	3.8	28
1432	Biofilm and cell adhesion strength on dental implant surfaces via the laser spallation technique. <i>Dental Materials</i> , 2021, 37, 48-59.	1.6	14
1433	Investigation research of gasoline direct injection on spray performance and combustion process for free piston linear generator with dual cylinder configuration. <i>Fuel</i> , 2021, 288, 119657.	3.4	5
1434	Do we understand each other? Toward a simulated empathy theory for entrepreneurship. <i>Journal of Business Venturing</i> , 2021, 36, 106076.	4.0	35
1435	Network traffic classification using deep convolutional recurrent autoencoder neural networks for spatial-temporal features extraction. <i>Journal of Network and Computer Applications</i> , 2021, 173, 102890.	5.8	77
1436	3D nanoflower-like layered double hydroxide modified quaternized chitosan/polyvinyl alcohol composite anion conductive membranes for fuel cells. <i>Carbohydrate Polymers</i> , 2021, 256, 117439.	5.1	23
1437	Air pollution from traffic during pregnancy impairs newborn's cord blood immune cells: The NELA cohort. <i>Environmental Research</i> , 2021, 198, 110468.	3.7	12
1438	Response to advances statistical methods and designs for clinical trials for COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106235.	1.1	1
1439	HPA axis responses to acute exercise differ in smokers and non-smokers. <i>Physiology and Behavior</i> , 2021, 229, 113258.	1.0	2

#	ARTICLE	IF	CITATIONS
1440	Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies. <i>Critical Care Clinics</i> , 2021, 37, 47-67.	1.0	5
1441	Cobalt ferrite microspheres as a biocompatible anode for higher power generation in microbial fuel cells. <i>Journal of Power Sources</i> , 2021, 483, 229170.	4.0	38
1442	Critical phase-transition temperature for freezing stress in thermo-sensitive photopolymers used for visualizing stress fields in solids. <i>Optics and Lasers in Engineering</i> , 2021, 139, 106458.	2.0	1
1443	Procuring NGA infrastructure: The performance of EMAT auctions in Italy. <i>Telecommunications Policy</i> , 2021, 45, 102074.	2.6	2
1444	Pathophysiology of COVID-19-associated acute respiratory distress syndrome. <i>Lancet Respiratory Medicine</i> , 2021, 9, e3.	5.2	3
1445	Mixed-integer programming in motion planning. <i>Annual Reviews in Control</i> , 2021, 51, 65-87.	4.4	22
1446	Opioids, stimulants, and depressant drugs in fifteen Mexican Cities: A wastewater-based epidemiological study. <i>International Journal of Drug Policy</i> , 2021, 88, 103027.	1.6	16
1447	Quantitative analysis of contact line behaviors of evaporating binary mixture droplets using surface plasmon resonance imaging. <i>International Journal of Heat and Mass Transfer</i> , 2021, 165, 120690.	2.5	17
1448	Hemorragias intracraneales en pacientes crÃ³nicos COVID-19: reporte de tres casos. <i>Medicina ClÃnica</i> , 2021, 156, 38-39.	0.3	1
1449	Utility-efficient differentially private K-means clustering based on cluster merging. <i>Neurocomputing</i> , 2021, 424, 205-214.	3.5	18
1450	Large volume sample stacking of antiepileptic drugs in counter current electrophoresis performed in PAMAPTAC coated capillary. <i>Talanta</i> , 2021, 221, 121626.	2.9	12
1451	Lithium in drinking water, altitude, and suicide rates in rural areas of Argentinean Andes. <i>Spatial and Spatio-temporal Epidemiology</i> , 2021, 36, 100393.	0.9	8
1452	Quadrature methods for integro-differential equations of Prandtl's type in weighted spaces of continuous functions. <i>Applied Mathematics and Computation</i> , 2021, 393, 125721.	1.4	3
1453	Organizational performance with a broader focus: The case for a stakeholder approach to leadership. <i>Business Horizons</i> , 2021, 64, 401-413.	3.4	22
1455	Catalytic o-methylation of phenols and its application in converting crude phenols in a low-temperature coal tar to mesitol and durenol. <i>Fuel</i> , 2021, 288, 119681.	3.4	5
1456	Spectrum of enteropathogens in cases of traveler's diarrhea that were detected using the FilmArray GI panel: New epidemiology in Japan. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 49-54.	0.8	10
1457	Studies on solid particle erosion by HVOF sprayed 25% (Cr3C2-25 (Ni20Cr)) + 75% NiCrAlY on Ti-31. <i>Materials Today: Proceedings</i> , 2021, 45, 246-253.	0.9	2
1458	A general framework of kernel-driven modeling in the thermal infrared domain. <i>Remote Sensing of Environment</i> , 2021, 252, 112157.	4.6	24

#	ARTICLE	IF	CITATIONS
1459	A new perspective on flux and slope limiting in discontinuous Galerkin methods for hyperbolic conservation laws. <i>Computer Methods in Applied Mechanics and Engineering</i> , 2021, 373, 113569.	3.4	5
1460	Detection and localization of inter-frame forgeries in videos based on macroblock variation and motion vector analysis. <i>Computers and Electrical Engineering</i> , 2021, 89, 106929.	3.0	17
1461	Characterization of abscesses from liver, pancreas and kidney using deep sequencing of the 16S rRNA gene. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115277.	0.8	5
1462	Algorithm for epipolar geometry and correcting monocular stereo vision based on a plane mirror. <i>Optik</i> , 2021, 226, 165890.	1.4	7
1463	Microstructure and properties of dual-scale particulate reinforced copper matrix composites with superior comprehensive properties. <i>Journal of Alloys and Compounds</i> , 2021, 860, 157888.	2.8	9
1464	Tribo-behaviour of nano-structured coatings deposited by various techniques: A review. <i>Materials Today: Proceedings</i> , 2021, 44, 4097-4101.	0.9	1
1465	Correlation between surface topological defects and fracture mechanism of β -graphyne-like boron nitride nanosheets. <i>Computational Materials Science</i> , 2021, 188, 110152.	1.4	13
1466	Language in childhood epilepsy: A systematic review and meta-analysis. <i>Epilepsy and Behavior</i> , 2021, 114, 107621.	0.9	2
1467	Engineering care transitions: Clinician perceptions of barriers to safe medication management during transitions of patient care. <i>Applied Ergonomics</i> , 2021, 91, 103299.	1.7	6
1468	Predication of the in-plane mechanical properties of continuous carbon fibre reinforced 3D printed polymer composites using classical laminated-plate theory. <i>Composite Structures</i> , 2021, 259, 113226.	3.1	58
1469	Development of delivery system based on marine chitosan: Encapsulation and release kinetic study of antioxidant peptides from chitosan microparticle. <i>International Journal of Biological Macromolecules</i> , 2021, 167, 1445-1451.	3.6	21
1470	Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis. <i>Gynecologic Oncology</i> , 2021, 160, 405-412.	0.6	9
1472	Zero-power noise up to 100 kHz in the IPEN/MB-01 research reactor facility. <i>Annals of Nuclear Energy</i> , 2021, 152, 107974.	0.9	1
1473	Autism Spectrum Disorder and Sleep. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2021, 30, 195-208.	1.0	24
1474	Structural and Functional Correlates of Gradient-Area Patterns in Severe Aortic Stenosis and Normal Ejection Fraction. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 525-536.	2.3	6
1475	An age profile perspective on two puzzles in global child health: The Indian Enigma & economic growth. <i>Journal of Development Economics</i> , 2021, 148, 102569.	2.1	11
1476	Visual and haptic responses as measures of word comprehension and speed of processing in toddlers: Relative predictive utility. <i>Journal of Experimental Child Psychology</i> , 2021, 203, 105032.	0.7	5
1478	Non-point source pollution in response to rural transformation development: A comprehensive analysis of China's traditional farming area. <i>Journal of Rural Studies</i> , 2021, 83, 165-176.	2.1	28

#	ARTICLE	IF	CITATIONS
1479	Shear behavior of brick masonry strengthened with jute fiber reinforced composite. <i>Materials Today: Proceedings</i> , 2021, 46, 4746-4751.	0.9	2
1480	Robotic Surgery Training. <i>Urologic Clinics of North America</i> , 2021, 48, 137-146.	0.8	20
1482	Compensating PDE actuator and sensor dynamics using Sylvester equation. <i>Automatica</i> , 2021, 123, 109362.	3.0	16
1483	Why do central states accept holding independence referendums? Analyzing the role of state peripheries. <i>Electoral Studies</i> , 2021, 69, 102248.	1.0	4
1484	Climate Change, Air Pollution, and Biodiversity in Asia Pacific and Impact on Respiratory Allergies. <i>Immunology and Allergy Clinics of North America</i> , 2021, 41, 63-71.	0.7	10
1485	Neural network approach for optimizing machining parameters of aluminium nano composite. <i>Materials Today: Proceedings</i> , 2021, 45, 6134-6141.	0.9	0
1486	Influence of diet shift from bloodworm to formulated feed on growth performance, gut microbiota structure and function in early juvenile stages of hybrid sturgeon (<i>Acipenser baerii</i> × <i>Acipenser</i>) <i>Tj ETQq0 0 0 rgBT, Overlock 10 Tf 50 4</i>	1.0	10
1487	Quantifying internal strains, stresses, and dislocation density in additively manufactured AlSi10Mg during loading-unloading-reloading deformation. <i>Materials and Design</i> , 2021, 198, 109339.	3.3	46
1488	DNET presenting with bleed: An infrequent event â€œ Histopatho-radio-surgical report. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2021, 23, 100890.	0.2	1
1489	Impact of axial ligation on photophysical and photodynamic antimicrobial properties of indium (III) methylsulfanylphenyl porphyrin complexes linked to silver-capped copper ferrite magnetic nanoparticles. <i>Polyhedron</i> , 2021, 193, 114882.	1.0	4
1490	Direct versus indirect effects of human activities on dissolved organic matter in highly impacted lakes. <i>Science of the Total Environment</i> , 2021, 752, 141839.	3.9	50
1491	Wheat breeding highlights drought tolerance while ignores the advantages of drought avoidance: A meta-analysis. <i>European Journal of Agronomy</i> , 2021, 122, 126196.	1.9	27
1492	â€œWhy villagers stay put â€œ A structural equation model on staying intentionsâ€œ. <i>Journal of Rural Studies</i> , 2021, 81, 345-357.	2.1	9
1493	Citizen science data predict high potential for macrofungal refugia outside protected riparian areas. <i>Fungal Ecology</i> , 2021, 49, 100981.	0.7	3
1494	Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. <i>Molecular Biology Reports</i> , 2021, 48, 843-854.	1.0	11
1495	Simulated deficit irrigation and climate change effects on sunflower production in Eastern Colorado with CSM-CROPGRO-Sunflower in RZWQM2. <i>Agricultural Water Management</i> , 2021, 246, 106672.	2.4	9
1496	The carboxylation status of osteocalcin has important consequences for its structure and dynamics. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129809.	1.1	5
1497	Effect of the temperature on the mechanical properties and translucency of lithium silicate dental glass-ceramic. <i>Ceramics International</i> , 2021, 47, 9933-9940.	2.3	13

#	ARTICLE	IF	CITATIONS
1498	2G waste lignin to fuel and high value-added chemicals: Approaches, challenges and future outlook for sustainable development. <i>Chemosphere</i> , 2021, 268, 129326.	4.2	44
1499	Slow rotation of a spherical particle in an eccentric spherical cavity with slip surfaces. <i>European Journal of Mechanics, B/Fluids</i> , 2021, 86, 150-156.	1.2	11
1500	Expression, distribution and regulation of RIG-1 in duck bursa of Fabricius during innate immune development. <i>Gene</i> , 2021, 771, 145342.	1.0	0
1501	Expression of ERV3-1 in leukocytes of acute myelogenous leukemia patients. <i>Gene</i> , 2021, 773, 145363.	1.0	5
1505	Addressing Patient to Patient Variability for Autologous CAR T Therapies. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1871-1876.	1.6	12
1507	Microcirculation alterations in severe COVID-19 pneumonia. <i>Journal of Critical Care</i> , 2021, 61, 73-75.	1.0	42
1508	Improving the accuracy of electricity carbon footprint: Estimation of hydroelectric reservoir greenhouse gas emissions. <i>Renewable and Sustainable Energy Reviews</i> , 2021, 136, 110433.	8.2	47
1509	Kronik Hepatit B Tedavisinde HBSAG VE M30 Antijen Titre Takibinin Klinik Yararlılığı. <i>Pamukkale Medical Journal</i> , 0, , .	0.2	0
1510	Chronic Carriage of Hepatitis B Virus at the University Teaching Hospital Yalgado Ouedraogo: Therapeutic Aspects and Outcome in a Cohort of HBeAg+ Outpatients. <i>Open Journal of Epidemiology</i> , 2021, 11, 245-255.	0.2	0
1511	Fibrosis and hepatic regeneration mechanism. <i>Translational Gastroenterology and Hepatology</i> , 2022, 7, 9-9.	1.5	8
1512	Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. <i>Journal of Gastroenterology</i> , 2021, 56, 479-488.	2.3	31
1513	A qualitative exploration of enablers for hepatitis B clinical management among ethnic Chinese in Australia. <i>Journal of Viral Hepatitis</i> , 2021, 28, 925-933.	1.0	1
1514	Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021, 15, 611-620.	1.9	7
1515	A non-invasive model for predicting liver fibrosis in HBeAg-positive patients with normal or slightly elevated alanine aminotransferase. <i>Medicine (United States)</i> , 2021, 100, e25581.	0.4	0
1516	HEPATİT B PREVALANSINDAKİ GÖZEM: HEPATİT B ve GEBELİK. İzmir Democracy University Health Sciences Journal, 0, , .	0.4	0
1517	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429.	1.4	11
1518	Assessing health-related quality of life and health utilities in patients with chronic hepatitis B-related diseases in China: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e047475.	0.8	5
1519	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	2.6	782

#	ARTICLE	IF	CITATIONS
1520	Interferon alpha for chronic hepatitis B. The Cochrane Library, 0, , .	1.5	1
1521	Current Status of Treatment of Hepatitis B in Children. <i>Advances in Experimental Medicine and Biology</i> , 2010, 659, 121-128.	0.8	2
1522	Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. <i>Modern Rheumatology</i> , 2012, 22, 470-473.	0.9	17
1523	Chronic Viral Hepatitis. , 2010, , 1593-1617.		9
1525	Chronic viral hepatitis. , 2012, , 53-69.		2
1526	Treatment for hepatitis B. <i>BMJ: British Medical Journal</i> , 2010, 340, b5429-b5429.	2.4	24
1527	Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab. <i>BMJ Open</i> , 2020, 10, e043672.	0.8	6
1528	Entecavir as specific antiviral therapy in selected cases of severe acute hepatitis B. <i>Germs</i> , 2012, 2, 18-22.	0.5	8
1529	IFN- λ inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. <i>Journal of Clinical Investigation</i> , 2012, 122, 529-537.	3.9	492
1530	Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver. <i>Medical Science Monitor</i> , 2012, 18, CR698-CR705.	0.5	13
1531	Association between Hepatic Steatosis and Entecavir Treatment Failure in Chinese Patients with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e34198.	1.1	70
1532	Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2012, 7, e47648.	1.1	235
1533	Impact of a New Reimbursement Program on Hepatitis B Antiviral Medication Cost and Utilization in Beijing, China. <i>PLoS ONE</i> , 2014, 9, e109652.	1.1	10
1534	Lower Mutation Frequency of BCP/Precore Regions in e Antigen-Negative Chronic HBV-Infected Children instead of Adults Patients. <i>PLoS ONE</i> , 2015, 10, e0120733.	1.1	4
1535	Risk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral Prophylaxis. <i>PLoS ONE</i> , 2015, 10, e0132426.	1.1	28
1536	Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. <i>PLoS ONE</i> , 2015, 10, e0139876.	1.1	22
1537	Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia. <i>PLoS ONE</i> , 2016, 11, e0152043.	1.1	25
1538	Hepatitis B Virus Stimulated Fibronectin Facilitates Viral Maintenance and Replication through Two Distinct Mechanisms. <i>PLoS ONE</i> , 2016, 11, e0152721.	1.1	9

#	ARTICLE	IF	CITATIONS
1539	Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues. <i>PLoS ONE</i> , 2017, 12, e0188303.	1.1	12
1540	Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte. <i>Journal of Clinical and Translational Hepatology</i> , 2015, 3, 220-229.	0.7	32
1542	A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 51.	4.5	31
1543	Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 323-330.	4.5	11
1544	Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 384-391.	4.5	11
1545	Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 312-314.	4.5	2
1547	Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. <i>The Korean Journal of Hepatology</i> , 2011, 17, 261.	1.5	11
1548	Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. <i>The Korean Journal of Hepatology</i> , 2011, 17, 268.	1.5	10
1549	Controversies about occult hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2009, 15, 4986.	1.4	11
1550	Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. <i>World Journal of Gastroenterology</i> , 2009, 15, 753.	1.4	33
1551	Precise prediction model and simplified scoring system for sustained combined response to interferon- α . <i>World Journal of Gastroenterology</i> , 2010, 16, 3465.	1.4	9
1552	Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. <i>World Journal of Gastroenterology</i> , 2010, 16, 4095.	1.4	13
1553	Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 5447.	1.4	31
1554	Predictors of loss of hepatitis B surface antigen in HIV-infected patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 1093.	1.4	17
1555	Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. <i>World Journal of Gastroenterology</i> , 2011, 17, 1531.	1.4	93
1556	Quantification of HBsAg: Basic virology for clinical practice. <i>World Journal of Gastroenterology</i> , 2011, 17, 283.	1.4	38
1557	Virological response to adefovir monotherapy and the risk of adefovir resistance. <i>World Journal of Gastroenterology</i> , 2011, 17, 3526.	1.4	6
1558	Current trends in management of hepatitis B virus reactivation in the biologic therapy era. <i>World Journal of Gastroenterology</i> , 2011, 17, 3881.	1.4	51

#	ARTICLE	IF	CITATIONS
1559	Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. <i>World Journal of Gastroenterology</i> , 2011, 17, 4987.	1.4	8
1560	Effect of interferon- β and tumor necrosis factor- α on hepatitis B virus following lamivudine treatment. <i>World Journal of Gastroenterology</i> , 2012, 18, 3617.	1.4	11
1561	Management of chronic hepatitis B in pregnancy. <i>World Journal of Gastroenterology</i> , 2012, 18, 4517.	1.4	35
1562	Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. <i>World Journal of Gastroenterology</i> , 2012, 18, 6106.	1.4	10
1563	Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2012, 18, 6277.	1.4	34
1564	Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2012, 18, 6987.	1.4	4
1565	Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. <i>World Journal of Gastroenterology</i> , 2012, 18, 6996.	1.4	26
1566	Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. <i>World Journal of Gastroenterology</i> , 2012, 18, 7149.	1.4	19
1567	Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2013, 19, 3481.	1.4	8
1568	Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2013, 19, 6834.	1.4	7
1569	Antiviral drug resistance increases hepatocellular carcinoma: A prospective decompensated cirrhosis cohort study. <i>World Journal of Gastroenterology</i> , 2013, 19, 8373.	1.4	10
1570	Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2013, 19, 9189.	1.4	25
1571	Hepatitis B and inflammatory bowel disease: Role of antiviral prophylaxis. <i>World Journal of Gastroenterology</i> , 2013, 19, 1342.	1.4	28
1572	Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 3516.	1.4	30
1573	Hepatitis B virus genetic mutations and evolution in liver diseases. <i>World Journal of Gastroenterology</i> , 2014, 20, 5435.	1.4	24
1574	Optimization therapy for the treatment of chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2014, 20, 5730.	1.4	10
1575	Current management of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 10223.	1.4	61
1576	Hepatitis B viral load affects prognosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 12039.	1.4	50

#	ARTICLE	IF	CITATIONS
1577	Clinical characteristics and current management of hepatitis B and C in China. World Journal of Gastroenterology, 2014, 20, 13582.	1.4	19
1578	Management of chronic hepatitis B in severe liver disease. World Journal of Gastroenterology, 2014, 20, 16053.	1.4	16
1579	Precore/basal core promoter mutants quantification throughout phases of hepatitis B virus infection by Simpleprobe. World Journal of Gastroenterology, 2015, 21, 6639.	1.4	3
1580	Early warning and clinical outcome prediction of acute-on-chronic hepatitis B liver failure. World Journal of Gastroenterology, 2015, 21, 11964.	1.4	26
1581	Application of nucleoside analogues to liver transplant recipients with hepatitis B. World Journal of Gastroenterology, 2015, 21, 12091.	1.4	9
1582	Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World Journal of Gastroenterology, 2015, 21, 2746.	1.4	20
1583	Hepatocellular carcinoma and hepatitis B surface protein. World Journal of Gastroenterology, 2016, 22, 1943.	1.4	50
1584	Management of Patients with Hepatitis B Virus Infection Who Receive Immunosuppressive Treatment or Chemotherapy. Korean Journal of Medicine, 2012, 82, 149.	0.1	3
1585	MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESSIVE TREATMENT. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009025.	0.5	9
1586	Overview of the histopathology of chronic hepatitis B infection. Hepatitis B Annual, 2012, 9, 49.	0.0	3
1587	Greater prevalence of comorbidities with increasing age: Cross-sectional analysis of chronic hepatitis B patients in Saudi Arabia. Saudi Journal of Gastroenterology, 2019, 25, 194.	0.5	29
1588	Entecavir for treatment of chronic hepatitis B: A clinical update for the treatment of patients with decompensated cirrhosis. Open Journal of Internal Medicine, 2012, 02, 53-61.	0.1	3
1589	Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World Journal of Gastrointestinal Oncology, 2012, 4, 37.	0.8	7
1590	Management of hepatitis B in developing countries. World Journal of Hepatology, 2011, 3, 292.	0.8	41
1591	Noninvasive assessment of liver damage in chronic hepatitis B. World Journal of Hepatology, 2013, 5, 439.	0.8	25
1592	Management of chronic hepatitis B before and after liver transplantation. World Journal of Hepatology, 2015, 7, 1421.	0.8	17
1593	Liver transplantation in adults: Choosing the appropriate timing. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2012, 3, 49.	0.6	8
1594	Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound. World Journal of Radiology, 2009, 1, 25.	0.5	11

#	ARTICLE	IF	CITATIONS
1595	Management of Chronic Hepatitis B with Nucleoside or Nucleotide Analogues: A Review of Current Guidelines. <i>Gut and Liver</i> , 2010, 4, 15-24.	1.4	15
1596	A Low Viral Load Predicts a Higher Initial Virologic Response to Adefovir in Patients with Lamivudine-Resistant Chronic Hepatitis B. <i>Gut and Liver</i> , 2010, 4, 530-536.	1.4	6
1597	Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. <i>Gut and Liver</i> , 2011, 5, 278-287.	1.4	22
1598	The Clinical and Laboratory Characteristics of Patients with Chronic Hepatitis B Using Current or Past Antiviral Therapy in Korea: A Multi-Center, Nation-Wide, Cross-Sectional Epidemiologic Study. <i>Gut and Liver</i> , 2012, 6, 241-248.	1.4	7
1599	Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Na ⁻ ve Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2012, 6, 486-492.	1.4	8
1600	The Efficacy and Safety of Peginterferon-Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting. <i>Gut and Liver</i> , 2013, 7, 197-205.	1.4	7
1601	Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2013, 7, 329-334.	1.4	12
1602	Continuous Long-Term Entecavir Therapy in Na ⁻ ve Chronic Hepatitis B Patients Showing Partial Virologic Response. <i>Gut and Liver</i> , 2013, 7, 712-718.	1.4	13
1603	Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure. <i>Gut and Liver</i> , 2014, 8, 64-69.	1.4	13
1604	The Correlation between NK Cell and Liver Function in Patients with Primary Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2014, 8, 298-305.	1.4	14
1605	Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay. <i>Gut and Liver</i> , 2015, 9, 657-64.	1.4	8
1606	Entecavir for the treatment of real-life chronic hepatitis B patients: a study from Saudi Arabia. <i>Annals of Saudi Medicine</i> , 2013, 33, 119-123.	0.5	5
1607	Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study). <i>European Journal of Rheumatology</i> , 2015, 2, 149-154.	1.3	5
1608	Molecular epidemiology of hepatitis B virus in Asia. <i>World Journal of Medical Genetics</i> , 2014, 4, 19.	1.0	8
1609	Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. <i>World Journal of Virology</i> , 2012, 1, 174.	1.3	28
1610	Low Serum Hepatitis B Surface Antigen Level Predicts Compensated Cirrhosis Caused by Chronic Hepatitis B in HBeAg Positive Patients in East China. <i>Hepatitis Monthly</i> , 2015, 15, e29183.	0.1	9
1611	Recent Advances in the Management of Chronic Hepatitis B. <i>Hepatitis Monthly</i> , 2011, 11, 601-611.	0.1	11
1612	Clinical outcome of a patient cohort with acute hepatitis B. <i>Clinics</i> , 2013, 68, 718-720.	0.6	4

#	ARTICLE	IF	CITATIONS
1615	Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. The Korean Journal of Hepatology, 2009, 15, 106.	1.5	1
1616	Clinical outcomes and development of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients. The Korean Journal of Hepatology, 2009, 15, 383.	1.5	0
1617	Blood Borne and Sexual Transmission: Hepatitis B and C. Statistics in the Health Sciences, 2009, , 333-356.	0.2	0
1618	Virus de lâ€™hÃ©patite B: qui ne pas traiter?. , 2009, , 130-137.		0
1620	Hepatologie (I). , 2010, , 500-546.		0
1621	Goals of therapy in patients with CHB. Hepatitis B Annual, 2010, 7, 16.	0.0	0
1622	Selection of treatment options in the management of chronic Hepatitis B. Hepatitis B Annual, 2010, 7, 45.	0.0	0
1623	Hepatitis B and D. , 2010, , 1287-1312.e5.		7
1624	Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance. World Journal of Gastroenterology, 2010, 16, 4691.	1.4	0
1625	Indications for treatment: Whom to treat and whom not to treat!. Hepatitis B Annual, 2010, 7, 28.	0.0	0
1626	HBV therapeutic end points. Hepatitis B Annual, 2010, 7, 73.	0.0	0
1628	Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B. Gut and Liver, 2010, 4, 212-218.	1.4	3
1630	Leber-, Gallenwegs- und Pankreaserkrankungen. , 2011, , 445-528.		0
1631	Telbivudine: A valuable treatment option in chronic hepatitis B. Hepatitis B Annual, 2011, 8, 84.	0.0	0
1632	The Complex Management of Viral-Related Autoimmune Diseases. , 2011, , 345-357.		0
1634	Histopathological Assessment of Liver Biopsy Specimen in the Context of HBV DNA and HBeAg in Patients with Chronic Hepatitis B. Euroasian Journal of Hepato-gastroenterology, 2011, 1, 83-88.	0.1	0
1635	Actualizaci3n en el Manejo de Hepatitis B. Medwave, 2011, 11, .	0.2	0
1636	HBV/HCV Co-infection and Mixed Cryoglobulinemia. , 2012, , 227-231.		0

#	ARTICLE	IF	CITATIONS
1638	Frequency and Mutation Patterns of Resistance in Patients with Chronic Hepatitis B Infection Treated with Nucleos(t)ide Analogs in Add-On and Switch Strategies. <i>Hepatitis Monthly</i> , 2011, 11, 835-842.	0.1	7
1640	Factors Predicting the Efficacy of Adefovir Dipivoxil on Treatment-Naïve Chronic Hepatitis B Patients at 48 Weeks. <i>Gut and Liver</i> , 2011, 5, 478-485.	1.4	2
1641	Antivirale Pharmaka. Springer-Lehrbuch, 2012, , 679-700.	0.1	0
1642	A Case of de novo Hepatitis B Complicated due to Lack of Comprehensive Interventional Approach. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2012, 2, 122-125.	0.1	0
1643	Maternal-Fetal Transmission of HBV. , 2012, , 195-222.		0
1644	Long-term Follow-up Study of Asymptomatic HBsAg-Positive Carrier. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2012, 2, 76-78.	0.1	0
1645	Interferon plus ribavirin therapy for coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV). <i>Acta Hepatologica Japonica</i> , 2012, 53, 513-522.	0.0	0
1648	Quel est le risque infectieux viral d'un lupique ?. , 2013, , 173-182.		0
1650	Diagnostic Liver Immunology. , 2014, , 45-53.		0
1651	Prolonged Combination Therapy is More Effective than Monotherapy in Management of Chronic Hepatitis B Patients With Sustained Virological Response: An Experience From a "Real-World" Clinical Setting. <i>Iranian Red Crescent Medical Journal</i> , 2013, 15, e7788.	0.5	2
1653	Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 242.	4.5	5
1654	Impact of Post Hepatitis C Chronic Liver Disease and Hepatocellular Carcinoma on Health Related Quality of Life. <i>Advances in Aging Research</i> , 2015, 04, 177-186.	0.3	0
1655	Diseases of the Liver. , 2015, , 1-15.		0
1656	Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. <i>World Journal of Gastroenterology</i> , 2015, 21, 12421.	1.4	2
1657	Entzündliche Lebererkrankungen. , 2015, , 303-349.		0
1658	Hepatitis B Recurrence: Major Milestones and Current Status. , 2016, , 13-34.		0
1659	Antivirale Pharmaka. Springer-Lehrbuch, 2016, , 729-760.	0.1	0
1660	Hepatitis B Virus Infection in B-Cell Non-Hodgkin's Lymphoma, and Effect of Entecavir in Prophylactic Antiviral Therapy. <i>Health</i> , 2016, 08, 495-503.	0.1	0

#	ARTICLE	IF	CITATIONS
1662	Traitement des hépatites virales. , 2018, , 939-963.e1.		0
1663	Les vaccinations dans les rhumatismes inflammatoires chroniques de l'adulte. , 2018, , 601-608.		0
1664	INFLUENCE OF AUTOLEUKOCYTE VACCINATION ON ACTIVITY LEVEL OF TUMOR NECROSIS FACTOR ALPHA IN PATIENTS WITH CHRONIC HEPATITIS B. Wiadomości Lekarskie, 2019, 72, 31-34.	0.1	3
1665	Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B. Terapevticheskii Arkhiv, 2019, 91, 40-47.	0.2	2
1666	Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients. World Journal of Gastroenterology, 2020, 26, 3948-3958.	1.4	0
1667	A STUDY TO DETERMINE FOLLOW-UP STRATEGY FOR DIFFERENTIATING A TRUE INACTIVE CARRIERS FROM CHRONIC HEPATITIS PATIENTS WITH HBEAG NEGATIVE BY THE HBV DNA CUTOFF VALUE. , 2020, , 1-2.		0
1668	Acute B Virus Hepatitis with Fulminant Hepatic Failure Precipitating Crisis in Sickle Cell Disease. Journal of Evolution of Medical and Dental Sciences, 2020, 9, 173-175.	0.1	0
1669	Antivirale Pharmaka. , 2020, , 771-809.		0
1670	Tenofovir plus entecavir combination therapy for chronic hepatitis B with nucleos(t)ide analogue failure. The European Research Journal, 2020, 6, 270-275.	0.1	0
1671	Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients. World Journal of Gastroenterology, 2020, 26, 3952-3962.	1.4	7
1672	Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. Clinical and Molecular Hepatology, 2020, 26, 352-363.	4.5	4
1673	High lymphocyte-to-monocyte ratio is associated with low α -fetoprotein expression in patients with hepatitis B virus-associated hepatocellular carcinoma. Molecular Medicine Reports, 2020, 22, 2673-2684.	1.1	1
1674	Management of chronic hepatitis B patients: efficacy & limitation of nucleos(t)ide analogues. Indian Journal of Medical Research, 2011, 133, 11-3.	0.4	3
1675	A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study: Adefovir versus Entecavir for Chronic Hepatitis B. Hepatitis Monthly, 2011, 11, 27-31.	0.1	10
1676	The HBV DNA cutoff value for discriminating patients with HBeAg-negative chronic hepatitis B from inactive carriers. Hepatitis Monthly, 2011, 11, 351-7.	0.1	2
1677	Molecular diagnosis of entecavir resistance. Hepatitis Monthly, 2010, 10, 42-7.	0.1	6
1678	Multidrug-resistant hepatitis B virus strain in a chronic Turkish patient. Hepatitis Monthly, 2010, 10, 141-6.	0.1	9
1679	Genotype A2/adw2 Strain of Hepatitis B Virus in Turkey. Hepatitis Monthly, 2010, 10, 302-5.	0.1	4

#	ARTICLE	IF	CITATIONS
1680	HIV and Hepatitis B Virus Coinfection: Approach to Management: Case Study and Commentary. <i>Journal of Clinical Outcomes Management</i> , 2010, 17, 273-286.	1.7	2
1681	Virologic response and resistance to lamivudine in patients with chronic hepatitis B: a ten-year retrospective analysis. <i>Hippokratia</i> , 2012, 16, 342-6.	0.3	2
1682	The clinical significance of occult HBV infection. <i>Annals of Gastroenterology</i> , 2014, 27, 15-19.	0.4	40
1683	The utility of thrombopoietin in predicting liver fibrosis in chronic hepatitis B. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 1430-4.	1.3	5
1684	Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. <i>Annals of Gastroenterology</i> , 2014, 27, 380-386.	0.4	4
1685	Hepatitis B and C prophylaxis in patients receiving chemotherapy. <i>Viral Hepatitis in Practice</i> , 2014, 6, 10-13.	0.0	3
1686	Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 21062-70.	1.3	8
1687	An update on hepatitis B, D, and E viruses. <i>Topics in Antiviral Medicine</i> , 2014, 21, 157-63.	0.1	21
1688	Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 726213.	1.3	18
1689	A long-term study of liver-related events in Caucasian hepatitis B patients with normal ALT values and high viremia. <i>Acta Gastro-Enterologica Belgica</i> , 2022, 85, 56-61.	0.4	5
1690	Bushen Jianpi Formula Combined with Entecavir for the Treatment of HBeAg-Negative Chronic Hepatitis B: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-10.	0.5	0
1695	Rethinking the Inactive Carrier State: Management of Patients with Low-Replicative HBeAg-Negative Chronic Hepatitis B and Normal Liver Enzymes. , 0, , 129-134.		0
1696	HBeAg-Negative Chronic Hepatitis B Infection with Abnormal Transaminases and Minimal Changes on Liver Biopsy. , 0, , 135-137.		0
1698	Hepatitis B and Hepatitis C Co-Infection. , 0, , 192-195.		0
1699	Is Interferon a Valuable First-Line Therapy for HBeAg-Positive HBV?. , 0, , 239-245.		0
1700	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , 2009, 14, 489-499.	0.6	34
1701	ĐŸŃ€Đ¼ Đ-Đ°Ń...Đ²Đ¼Ń€ŃŹĐ²Đ°Đ½Ń-ŃŃ,Ń€ Đ½Đ° Đ;Đ°Ń€ĐµĐ½Ń,ĐµŃ€Đ°Đ»Ń€Đ½Ń- Đ³ĐµĐ;Đ°Ń,ĐŃ,Đ,Đ² Đ”Đ¼Đ½ĐµŃ†		
1702	Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7

#	ARTICLE	IF	CITATIONS
1703	Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4253-4270.	2.9	10